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Abstract 
Although chronic lymphocytic leukaemia (CLL) is a B-cell malignancy, T-cells from CLL 
patients often display abnormal characteristics when compared to age-matched healthy 
donors. One example is the preferential expansion of CD8+ T-cells within a subgroup of 
CLL patients resulting in an inverted CD4:CD8 ratio (CLLIR). This thesis describes a 
detailed analysis of the T-cell compartment with an emphasis on CD8+ T-cells. It 
confirms that CLL patients have abnormal memory T-cell subset distributions, with 
skewing to more differentiated memory subsets (EM/EMRA CD8+ T-cells) and an 
increase in a replicative senescent phenotype (CD57+). Furthermore, CLLIR patients 
demonstrated significantly inferior prognosis compared to their normal ratio 
counterparts (CLLNR). The aim of this thesis was to further characterise the expanded 
CD8+ T-cells within the CLLIR subgroup to define more precise prognostic markers and 
to understand the role of these T-cells in CLL disease. 
 
Polychromatic phenotyping of CLL patients (n = 99) was carried out using 8-colour 
flow cytometry, testing for markers associated with senescence (CD57/KLRG-1), 
exhaustion (PD-1) and activation (HLA-DR/CD38). This allowed the identification of 
multiple discrete subsets of T-cells, with a greater complexity of subsets seen in CLL 
patients compared to healthy donors. There was also an increase in senescent 
phenotypes within CLLIR patients, confirming previous results. However, the use of 
additional markers identified increased frequencies of an ‘activated senescent’ 
phenotype (CD8+CD57+HLA-DR+) within CLLIR patients. This phenotype was shown to 
have a prognostic effect on progression-free survival in both multivariate and univariate 
analysis, with higher frequencies conferring inferior prognosis. 
 
Multivariate analyses also revealed CD4+ subsets, including those with a 
CD4+HLA-DR+PD-1+ phenotype, to be of prognostic value. This prompted a phenotypic 
assessment of the CD4+ T-cell compartment. Like the CD8+ population, CD4+ T-cells 
showed increased frequencies of senescent phenotypes within CLLIR patients. There was 
also an exacerbation of CD57+HLA-DR+ and HLA-DR+PD-1+ phenotypes within the 
CLLIR subgroup, the latter being the strongest prognostic phenotype identified by 
multivariate analysis within the entire study.  
 
Abstract 
 
To further evaluate the prognostic potential and stability of the CD4:CD8 ratio in CLL, 
preliminary phenotypic analysis was performed on a small cohort of treated and 
untreated patients. These results showed a disproportionate number of patients with 
inverted ratio in the treated patient group. Furthermore, the prognostic phenotypes 
CD8+CD57+HLA-DR+ and CD4+HLA-DR+PD-1+ were over represented within the 
treated subgroup. 
 
Finally, single telomere length analysis (STELA) of CD8+ T-cells in CLL was performed 
to explore potential changes in the replicative history between CLLNR and CLLIR patients. 
Overall, the mean telomere lengths of T-cells from CLLIR patients was similar to that of 
CLLNR patients, suggesting that the expanded CD8+ compartment does not necessarily 
arise from a long-lived population that has undergone multiple rounds of division. The 
STELA did reveal two additional subgroups of CLL patients that had either “short” or 
“long” telomeres within their T-cell memory subsets. This observation may provide an 
additional molecular marker that could be investigated either in combination or alone 
for prognostic relevance.  
 
Overall the results from the phenotypic analysis and STELA suggest that there is an 
active ongoing T-cell response in CLL, but the nature of the stimulus is unclear. The 
expanded T-cells in CLL are unusual and do not follow the patterns of T-cell exhaustion 
and senescence seen in chronic viral diseases and other cancers. Importantly, this study 
has defined two phenotypes (CD8+CD57+HLA-DR+ and CD4+HLA-DR+PD-1+) that have 
greater prognostic power than the inverted CD4:CD8 ratio. These may be useful in 
identifying patients who are likely to develop more aggressive clinical disease.  
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Chapter 1 
Introduction 
1 .1  The immune sys tem 
The immune system is a complex system of proteins, cells and organs that defend the 
host against pathogens. This primarily targets foreign pathogens such as viruses, 
bacteria and parasites, but the immune system can also play a role in non-infectious 
diseases such as cancer (Wood 2006; Dunn et al. 2004; Dranoff 2004). The immune 
system’s response is usually categorised into two types: the innate immune response and 
the adaptive immune response (Figure 1.1). The innate response refers to pre-existing 
immunological mechanisms that are present in the host system prior to infection that 
can recognise common components that belong to pathogens. The adaptive response 
follows on from the innate and specifically targets pathogens to resolve infection (Kindt 
et al. 2007; Janeway et al. 2001; Dranoff 2004). 
 
1 .1 .1  Innate  immunity  
A human host’s primary defence against external pathogens are the physical barriers of 
the body, such as the skin epithelium, cilia and mucosal membranes (Kindt et al. 2007). 
There are also biochemical immune barriers: hydrochloric acid is secreted by the 
stomach; lysozyme, an enzyme found in bodily secretions such as sweat and tears and 
can break down bacterial walls; skin and mucosa secretions contain antimicrobial 
peptides e.g. defensins (Wood 2006; Kindt et al. 2007; Schauber and Gallo 2009). 
 
If physical and biochemical barriers are unsuccessful, invading foreign pathogens or 
damaged/infected host cells are recognised by specialised immune cells. Specialised 
innate immune cells can recognise foreign pathogen associated molecules that are 
conserved across many pathogens, known as pathogen-associated molecular patterns 
(PAMPs). Innate immune cells recognise these PAMPs via pattern recognition receptors 
(PRRs), such as Toll-like receptors (TLRs)(Kindt et al. 2007; Wood 2006; Iwasaki and 
Medzhitov 2015). Various TLRs have been defined that can recognise pathogen 
products, one example being the Toll-like receptor 4 (TLR4), which recognises the 
lipopolysaccharides (LPS) found in gram-negative bacterial cell walls (Pålsson-
McDermott and O'Neill 2004; Chow et al. 1999). Recognition leads these innate 
immune cells to initiate various downstream immunological processes, including: 
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phagocytosis of foreign/damaged bodies, induction of the complement system, 
production of immunological products such as chemokines and cytokines, mediated 
activation of the innate inflammatory response and, if the innate immune response fails 
to resolve the infection, recruitment of the adaptive immune response (Wood 2006; 
Kindt et al. 2007; Iwasaki and Medzhitov 2015). Examples of innate immune cells are 
discussed further below. 
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Figure 1.1. The components of the innate and adaptive immune response. The 
immune response can be divided into two main components. The innate response acts as the 
non-specific first line of defence against pathogens. The adaptive response is a later response 
following lack of pathogen clearance by the innate system; adaptive components are more 
antigen-specific and form the basis of immunological memory (adapted from Dranoff (2004)). 
 
 
 
Humoral(response(
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1 .1 .1 .1  Neutrophi l s  and other  granulocytes  
Neutrophils are bone marrow-derived granulocytic cells that circulate in the blood 
stream for approximately 5.4 days before migrating into tissue sites following 
extravasation (Pillay et al. 2010). Neutrophils are the first innate cells to be recruited to 
the site of infection via the secretion of chemoattractants including the cytokine IL-8 
(Hammond et al. 1995). During extravasation, the neutrophil ‘rolls’ along and adheres 
to the vascular endothelium, before transmigrating between the endothelial cells and 
basement membrane and into the tissue towards the site of infection (Kindt et al. 2007; 
Wood 2006; Kolaczkowska and Kubes 2013; Janeway et al. 2001). 
 
The predominant function of the neutrophil is the ingestion (phagocytosis) and killing 
of pathogens, particularly bacteria and viruses. Direct recognition of the pathogen (e.g. 
with TLRs) leads to extensions of the neutrophil cell membrane (pseudopodia) that 
surround and engulf the microorganism into a phagosome (Kindt et al. 2007; Wood 
2006). Once engulfed, the neutrophils kill the pathogen by releasing anti-bacterial 
proteins and lytic enzymes from neutrophil granules into the lysosome. Alternatively, 
neutrophils kill phagocytosed microbes by producing reactive oxygen and reactive 
nitrogen species and/or antibacterial proteins (Wood 2006; Kolaczkowska and Kubes 
2013).  
 
In addition to phagocytosis, neutrophils can also aid the elimination of pathogens by 
degranulation, whereby the granular products that are used to kill phagocytosed 
pathogens are released into the extracellular environment to tackle extracellular 
pathogens (Kolaczkowska and Kubes 2013). A third, more recently described method is 
the employment of Neutrophil Extracellular Traps (NETs) by activated neutrophils: 
nuclear products with granular and cytoplasmic proteins are released by neutrophils to 
bind and kill extracellular pathogens (Wartha et al. 2007). Therefore, neutrophils play a 
key role in limiting the spread of infection. 
 
1 .1 .1 .2  Macrophages  
Monocytes are derived from the haematopoietic lineage and are produced in the bone 
marrow. Upon migration from the blood stream into various tissues monocytes develop 
into either tissue-specific macrophages or dendritic cells (DCs) (Murray and Wynn 
2011; Kindt et al. 2007). Once primed, macrophages have increased phagocytic activity 
in a similar way to neutrophils (Kindt et al. 2007). However, where neutrophils are 
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limited to ingesting smaller pathogens such as bacteria and viruses, macrophages can 
phagocytose much larger products, including dead cells and tissue debris. They are 
therefore not only able to aid in the elimination of the pathogen, but also play a role in 
removing the dead/dying cells and maintaining healthy tissue environments (Wood 
2006; Murray and Wynn 2011).  
 
Macrophages can also secrete complement proteins and Fc receptors that bind to 
pathogens and act as opsinins to enhance phagocytic activity (Murray and Wynn 2011). 
Opsinisation of the pathogen, where complement proteins or antibodies are attached to 
the pathogen to enhance recognition and binding, can boost the phagocytic activity of 
neutrophils, macrophage and other phagocytes, in addition to the B- and T-cells of the 
adaptive response (Carroll 2004): when the opsinin is an antibody this is known as 
antibody-dependent cell-mediated cytotoxicity (ADCC) (Wood 2006). 
 
Activated macrophages at the site of an infection can also secrete various inflammatory 
factors that initiate the inflammatory response, such as the cytokines IL-1, tumour 
necrosis factor-α (TNF-α) and IL-6 (Nackiewicz et al. 2014; Murray and Wynn 2011). 
This leads to increased vascular permeability and activation of endothelial cells that 
upregulate adhesion molecules, leading to recruitment of more phagocytic cells to the 
site of infection, such as neutrophils. Vascular permeability also allows entry of further 
immune factors such as complement serum proteins. Furthermore, activated 
macrophages can bridge the innate and adaptive immune responses by presenting 
ingested antigenic peptides to T-cells (Kindt et al. 2007; Murray and Wynn 2011; Wood 
2006).  
 
Depending on tissue locality, microenvironment stimuli and phenotypic function, 
macrophages can be split into distinct subpopulations (Gordon and Taylor 2005; Shi 
and Pamer 2011; Martinez and Gordon 2014). Further to this, they are divided into 
subsets based on their polarisation upon activation. M1 macrophages are considered to 
be ‘classically’ activated by PAMPs and/or interferon-γ (IFN-γ) and play an 
immunological role against pathogens, as well as demonstrating anti-tumour immunity 
(Murray and Wynn 2011; Mantovani et al. 2004). M2 macrophages are ‘alternatively’ 
activated and play a role in immune regulation and tumour promotion. The current 
literature now suggests M2 can be subdivided further based on their inducible factors 
and functional properties (Martinez and Gordon 2014; Mantovani et al. 2004). 
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1 .1 .1 .3  Natura l  K i l le r  (NK)  ce l l s  
The innate natural killer (NK) cells were first identified as lymphocytes displaying 
cytotoxicity to tumour cells (Wood 2006; Vivier et al. 2008). They play an important 
role in the non-specific recognition and destruction of infected host cells and are 
considered the first-line of defence against viral infections (Kindt et al. 2007). NK cells 
display various inhibitory and activating receptors that allow them to distinguish 
between target and non-target cells (Cerwenka and Lanier 2001). Additionally, NK cells 
can recognise target cells through ADCC with their CD16 receptor (Vivier et al. 2008). 
When recruited to inflammatory sites, NK cells are stimulated by other immune cells 
including macrophages and T-cells via IFNs, IL-12, IL-18, IL-15 and IL-2 (Vivier et al. 
2008). NK-mediated killing can occur via Fas ligand (FasL) induced cell death, or by 
degranulation of cytotoxic proteins upon binding to the target cell to trigger apoptosis 
(Wallin et al. 2003; Kindt et al. 2007). Activated NK cells produce important cytokines 
including IFN-γ and TNF-α: as IFN-γ is an activating cytokine for M1 macrophages, this 
enables NK cells and macrophages to establish a constant activation loop during the 
inflammatory immune response (Wood 2006). Furthermore, both IFN-γ and TNF-α can 
stimulate maturation of DCs. 
 
1 .1 .1 .4  Dendr i t ic  ce l l s  (DCs)  
DCs bridge the innate and adaptive immune responses due to their phagocytic activity 
during the innate stage and priming of T-cells in the adaptive response. DCs 
phagocytose pathogens, but they do not demonstrate the killing and digestive functions 
observed in macrophage and neutrophils (Steinman and Hemmi 2006). DCs instead 
process and present antigenic fragments on MHC class-I and MHC class-II complexes to 
T-cells. In this way, they act as innate sentinels within the body. DCs are also able to 
promote innate and adaptive cells by the production of various cytokines, including 
IL-12, an NK cell enhancing cytokine (Steinman and Hemmi 2006; Ferlazzo et al. 
2004).  
 
1 .1 .1 .5  Eos inophi l s ,  basophi l s  and mast  ce l l s  
Like neutrophils, eosinophils and basophils are granulocytic cells. Eosinophils are also 
phagocytes, although their phagocytic activity is less prominent than that of neutrophils, 
whereas basophils are non-phagocytic (Kindt et al. 2007). Mast cells have similar 
properties and possess granules containing immunological factors. Upon activation, 
mast cells undergo degranulation and release histamine, heparin and proteolytic 
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enzymes, as well as produce various prostaglandins and leukotrienes (Marshall 2004). 
All these factors increase vasodilation and vascular permeability, as well as initiate 
recruitment of other cells such as neutrophils (Wood 2006). Where mast cells are 
located in either mucosal or connective tissues, eosinophils and basophils circulate in 
the blood and are recruited to specific locations upon infection (Medzhitov 2007).  
 
These innate cells are all thought to play key roles in the resolution of parasitic 
infections (Medzhitov 2007; Meeusen and Balic 2000). Eosinophils have demonstrated 
anti-parasitic action in vivo via ADCC killing of helminth worms (Wood 2006; Kindt et 
al. 2007). Mast cells, eosinophils and basophils have also been considered prominent 
players in the allergic reaction (Wardlaw et al. 2000; Kindt et al. 2007). 
 
1 .1 .2  The br idge  between innate  and adapt ive  immunity  
If the innate response is unable to resolve pathogenic infection/tissue damage, the more 
specific adaptive immune response is launched. The innate and adaptive responses are 
highly interlinked. Innate recognition of a pathogen allows for a more effective adaptive 
immune response, as the innate immune response produces many immunological 
molecules that aid in the recruitment and activation of adaptive immune cells (Kindt et 
al. 2007).  
 
As mentioned in Section 1.1.1.4, DCs bridge the innate and adaptive responses via their 
ability to ingest pathogens, migrate to the peripheral lymph nodes and present antigenic 
peptides alongside co-stimulatory molecules to activate naive T-cells (Steinman and 
Hemmi 2006). Furthermore, many DC subpopulations have been identified with 
different immunological properties that help determine the type of adaptive response 
(Iwasaki and Medzhitov 2015). In humans, the major CD1c+ DC population express a 
wide variety of PRRs, including TLRs and lectins. CD1c+ DCs play a key role in the 
promoting the T helper type 1 response against intracellular pathogens via the secretion 
of TNF-α, IL-8, IL-10, and IL-12 (Collin et al. 2013; Mittag et al. 2011). They have also 
been shown to produce IL-23, a key Th17 cytokine (Dillon et al. 2010). This implies 
CD1c+ DCs help direct the adaptive immune response against intracellular pathogens 
(Th1 response) and extracellular pathogens such as fungi (Th17 response); 
interestingly, despite promoting CD4+ Th1 cells, CD1c+ DCs show poor cross-
presentation to CD8+ T-cells compared to other DC subsets (Collin et al. 2013). 
Alternatively, a second, smaller CD141+ DC population possess enhanced phagocytosis 
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of dead cells, recognition of viral nucleic acids (via TLR3 and TLR8 receptors) and 
superior cross-presentation to CD8+ T-cells (Joffre et al. 2012; Sancho et al. 2009). 
Langerhans cells, located in the epidermis, have been shown to secrete cytokines 
associated with the T helper type 2 response, thereby directing a humoral adaptive 
response (Iwasaki and Medzhitov 2015). 
 
Similar to DCs, macrophages are also able to present antigen to adaptive immune cells 
(Murray and Wynn 2011), and the aforementioned M1 and M2 subsets promote certain 
adaptive responses. M1 macrophages promote the Th1 response and cellular immunity, 
whereas M2 macrophages help promote the Th2/humoral response (Mills 2015). In the 
same sense, adaptive immune cells such as T-cells can produce cytokines to promote 
further innate cell activation, such as macrophage activation, completing an innate-
adaptive immune response loop.  
 
1 .1 .3  Adapt ive  immunity  
Where the innate system distinguishes between ‘self’ and ‘non-self’ to instigate 
immediate non-specific responses against foreign bodies, the adaptive immune response 
is the generation of highly specific lymphocytes generated against the pathogenic 
antigens (Kindt et al. 2007). The primary cells of the adaptive response are B-cells, 
which play a central role in the humoral immune response, and T-cells that initiate cell-
mediated immunity, in addition to aiding the activation of the B-cell humoral response. 
 
1 .1 .3 .1  B-ce l l s  and humoral  immunity  
B-cell progenitors (pro-B-cells) arise in the bone marrow by commitment of the 
common lymphoid progenitor to the B-cell lineage via expression of the transcription 
factor Pax5 (Cobaleda et al. 2007). Consequently, pro-B-cells undergo multiple 
proliferation and differentiation steps within the bone marrow microenvironment to 
develop into precursor B-cells (pre-B-cells) and then the immature B-cell (Hoffman et 
al. 2016; Thomas et al. 2006). Immature B-cells are then released from the bone 
marrow into the periphery and home to the spleen to undergo further maturation steps 
and differentiate into marginal zone B-cells and follicular B-cells (Hoffman et al. 2016; 
Pillai and Cariappa 2009). Marginal zone B-cells remain in the spleen, whereas 
follicular B-cells circulate in peripheral lymphoid tissues. 
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During the development from pro-B-cell to immature B-cell, multiple immunoglobulin 
heavy- and light- chain gene rearrangements occur that are essential for B-cell 
development, resulting in the presentation of a mature IgM B-cell receptor (BCR), a 
membrane-bound antibody molecule on the B-cell surface for antigen recognition 
(Hoffman et al. 2016; Thomas et al. 2006) (Figure 1.2A). This rearrangement process 
allows for the random generation of a varied BCR repertoire that can recognise a large 
range of antigens, including self-antigens; therefore, to prevent self-reactive B-cells 
leaving the bone marrow, immature B-cells undergo negative selection for self-antigen 
and clonal deletion. Upon entering the periphery and maturing, B-cells express both 
IgM and IgD on their cell surface (Hoffman et al. 2016). 
 
Activation and differentiation of B-cells are dependent upon the antigen type recognised 
by the BCR (signal 1) followed by co-stimulation (signal 2) and the cytokine 
microenvironment (Figure 1.2B). Canonical activation for the majority of BCR antigens 
requires the presence of helper T-cell (Th cell) co-stimulation (T-dependant) through 
receptor/ligand stimulus such as the CD40/CD40L axis, and stimulatory cytokines such 
as IL-4, IFN-γ and IL-21. Upon antigen recognition the B-cell ingests and processes 
antigenic material for MHC-II presentation to CD4+ T-cells, and in this way acts as an 
APC similar to DCs and macrophages (Hoffman et al. 2016; Nutt et al. 2015). Activated 
B-cells upregulate MHC-II alongside co-stimulatory molecules CD80 and CD86, 
enhancing B-cell promotion of Th cell activation by the formation of the T-B link, the so-
called immune synapse (Hoffman et al. 2016; Suvas et al. 2002). This in turn triggers 
upregulation of co-stimulatory CD40L on Th cells, as well as the production of Th 
cytokines to promote further B-cell activation, proliferation and differentiation. 
 
Following BCR engagement, B-cells migrate to the germinal centres of secondary 
lymphoid organs to form the T-B link and undergo rapid proliferation and 
differentiation. During this time, further genetic rearrangements of the Ig heavy- and 
light chains occur to allow for affinity maturation of the antibody. Somatic 
hypermutation (SHM) of the heavy- and light-variable region rapidly generates a wide 
variety of high affinity antigen binding sites, and class switch recombination (CSR) 
generates other antibody isotypes (IgG, IgE, IgA) that can initiate different 
immunological responses. In combination, SHM and CSR produce high affinity antigen-
specific antibodies with a range of specificities and isotypes to trigger various 
immunological reactions (Z. Li et al. 2004; Hoffman et al. 2016).  
Chapter 1: Introduction 
 10 
 
Following affinity-based positive selection, B-cells differentiate into memory B-cells or 
plasma cells (effector B-cells). Plasma cells have low levels of membrane bound 
antibody and secrete high volumes of unbound antibodies that play a vital role in the 
humoral effector responses, including complement activation, ADCC and opsonisation 
(Hoffman et al. 2016). Memory B-cells persist following the resolution of an infection 
and present the same BCRs as their naïve precursor, but with a much higher affinity and 
varying isotypes (IgD, IgE, IgA) due to SHM and CSR (LeBien and Tedder 2008). 
Memory B-cells and long-lived serum antibodies from plasma cells can mount an 
effective, rapid response to secondary antigenic challenge (Hoffman et al. 2016). 
 
Non-canonical activation has also been identified with some antigens that are able to 
induce B-cell activation independently of Th cell involvement (T-independent), such as 
LPS/polysaccharide antigens (Figure 1.2B). T-independent co-stimulatory signals 
include TLRs presented by both B1 and marginal zone B-cells, such as TLR4 recognition 
of LPS (Hoffman et al. 2016). NKT cells, neutrophils and DCs have also demonstrated 
non-canonical stimulation both directly (CD40L) and indirectly (cytokines) with 
marginal zone B-cells (Cerutti et al. 2012). 
 
The majority of B-cells are bone-marrow derived (B2 B-cells), but a subset of self-
renewing B-cells have also been identified that originate from the foetal liver and persist 
past neonatal development (B1 B-cells) (Hoffman et al. 2016). The majority of evidence 
supporting B1 B-cells comes from mouse studies, and the significance of B1 B-cells in 
humans is less understood. They are thought to make up a small proportion of the 
human B-cell compartment and can be distinguished from B2 B-cells by the expression 
of marker CD5, normally found on T-cells. They are a self-renewing population, unlike 
other B-cells that are continuously generated from the bone marrow, and have a short 
life span of a few weeks unless introduced to antigen. Mature B1 B-cells present 
multi-specific IgM as their BCRs, recognise carbohydrate or phospholipid based antigens 
rather than protein antigens and activate independently of T-cells (Hoffman et al. 2016; 
Kindt et al. 2007; Baumgarth 2011). Therefore, the B1 B-cell subset demonstrates lower 
affinity for antigen and little class switching. 
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Figure 1.2. BCR structure and B-cell activation. (A) BCRs are membrane bound Ig 
presented B-cells. Ig molecules comprise two heavy- and two light-chains, both of which contain 
variable (V) and constant (C) regions. The upper region forms the antigen binding site, whereas 
the lower regions confer for the downstream biological activity (e.g. ADCC) (B) B-cell activation 
occurs via BCR signalling (Signal 1) and co-stimulation (Signal 2), which can occur in both a 
T-independent and T-dependant manner. T-independent involves recognition of PAMPs such 
LPS/polysaccharides by both BCR and PRRs. T-independent activation requires BCR recognition 
of antigen combined with costimulation from Th cells, such as CD40/CD40L engagement 
(Figures adapted from Kindt et al. (2007); Villadangos and Schnorrer (2007)). 
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1 .1 .3 .2  T-ce l l s  and ce l l -mediated  immunity  
B-cells and the humoral response hold some limitations for immune defence: antibodies 
are not able to interact with intracellular pathogens, and the humoral response to an 
initial infection takes time, with a lag of 5-7 days before antibody levels increase 
(although the lag is greatly reduced in secondary infections, with a larger, prolonged 
humoral response). The cell-mediated arm of the adaptive immune response involves 
the activation of lymphocytes known as CD4+ and CD8+ T-cells. These recognise peptide 
antigens bound to MHC on APCs using T-cell receptors (TCRs). This recognition and 
activation leads to the generation of Th cells and cytotoxic T-cells (CTLs) that perform 
various effector functions, including killing infected/damaged cells and promoting other 
arms of the immune response (Kindt et al. 2007; Wood 2006). 
 
CD4+ T-cells 
CD4+ T-cells form a vast repertoire of different cellular subtypes that engage in different 
immunological functions within the immune response (Figure 1.3). Development into 
these subtypes depends greatly on the stimulus within the microenvironment during the 
time of activation and differentiation, e.g. cytokines, and can be distinguished by the 
cellular receptors they express and the cytokines they produce (Zhu et al. 2010).  
 
The first CD4+ subsets to be identified were the Th1 and Th2 groups. Th1 cells help the 
cell-mediated immune response by promoting the growth of CD8+ CTLs against 
intracellular pathogens (Wood 2006). The Th1 cell subset development is promoted by 
cytokines produced during the innate phase of the immune response. IL-12, secreted by 
macrophages and DCs, is the main cytokine that can drive Th1 differentiation (Murray 
and Wynn 2011): IL-12 also stimulates IFN-γ production by NK cells that can promote 
Th1 (Martín-Fontecha et al. 2004; Morandi et al. 2006). Th1 cells also produce IFN-γ 
that then further stimulates a Th1 environment and also initiates additional 
macrophage activation, completing an innate-adaptive immune activation loop to fight 
against intracellular pathogens (Medzhitov 2007). B-cells can also stimulate Th1 
differentiation via IFN-γ production (Hoffman et al. 2016). 
 
Th2 cells help mediate responses against extracellular pathogens and promote the 
humoral response. Th2 development is driven by the cytokine IL-4, produced by mast 
cells (Wood 2006; Swain et al. 1990). DCs are also thought to play a role in the 
polarisation to the Th2 subset in an IL-4 environment, although how is unclear (Moser 
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and Murphy 2000; Banchereau and Steinman 1998). Th2 cells drive humoral responses 
via the secretion of IL-4, IL-5 and IL-13 cytokines, which promote eosinophil, basophil 
and mucosal epithelia functions. IL-4 production also encourages B-cell synthesis of IgE 
antibodies, which further promotes mast cell and basophil activation (Medzhitov 2007).  
 
Th17 is a third subset of T helper cells that has been defined more recently (Zhu et al. 
2010). Th17 cells help in the resolution of extracellular bacteria and fungi and are vital 
for inflammatory reactions in tissues (Park et al. 2005; Medzhitov 2007). Activated 
macrophages produce IL-23 and IL-1, cytokines that drive polarisation to the Th17 
subset during infection and stimulates Th17-cell production of pro-inflammatory 
cytokines including IL-17, IL-6 and TNF-α (Murray and Wynn 2011). IL-17 has pro-
inflammatory properties and recruits neutrophils to the site of infection and stimulates 
cytokine production in tissue cells (Park et al. 2005). However, the cytokines known to 
drive early Th17 polarisation in mice are IL-6 and TGF-β, with IL-23 as essential to 
mount a successful Th17-cell response (Weaver et al. 2006). 
 
Follicular helper cells (Tfh) are another T helper cell type, identified by expression of 
homing receptor CXCR5 that aids localisation to the germinal centre. Here Tfh cells 
perform a critical role in T-B cell interactions by promoting B-cell proliferation and 
differentiation (C. S. Ma et al. 2012; C. S. Ma et al. 2009). Early human Tfh cell 
differentiation has been reported to be driven by IL-12 (C. S. Ma et al. 2009), but 
whether Tfh-cells are a distinct subset or linked to the another Th lineage 
(Th1/Th2/Th17) is still uncertain (Zhu et al. 2010; Iwasaki and Medzhitov 2015). Tfh 
cells are distinguished by distinct expression of IL-21, BCL-6 and surface receptors such 
as ICOS and PD-1 (C. S. Ma et al. 2009).  
 
Regulatory T-cells (Tregs) are a subpopulation of CD4+CD25+ T-cells that play an 
important role in the negative regulation of the immune response and peripheral 
tolerance of T-cells (Sakaguchi et al. 1995). Tregs are further characterised by the 
expression of transcription factor Foxp3, which is essential for Treg differentiation (Hori 
et al. 2003; Josefowicz et al. 2012). Tregs can be further subdivided into natural Tregs 
(nTregs) and inducible Tregs (iTregs) (X. Lin et al. 2013). nTregs are developed in the 
thymus via high affinity MHC-II self-selection, similar to other CD4+ T-cells, with the 
exception that Foxp3+ cells with a strong affinity for self-antigens receive survival 
signals, whereas self-reactive Foxp3− cells are deleted (X. Lin et al. 2013; Josefowicz et 
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al. 2012; de Lafaille and Lafaille 2009). On the other hand, iTregs are thymus-derived 
CD4+ Th cells that are converted to Tregs upon peripheral antigenic stimulation (de 
Lafaille and Lafaille 2009), such as gut microbiota or environmental pathogens (e.g. 
food). It has therefore been hypothesised that nTregs play more of a role in the 
tolerance of ‘self’ and the prevention of autoimmune diseases, whereas iTregs are more 
involved in the tolerance of commensal organisms and foreign antigens that are 
commonly found in the environment. This division of function has not been fully 
established and research to fully understand the immune-regulatory mechanisms 
employed by Tregs is still ongoing (Josefowicz et al. 2012; T. T. Lin et al. 2014). 
CTLA-4 is an important molecule on the Treg cell surface that binds with CD80 and 
CD86 molecules on activated CD4+ T-cells and DCs to suppress T-cells (Boehmer 2005). 
Tregs have also been shown to produce immune-regulatory products including IL-10, 
IL-35, IL-9, perforin and granzyme A, and TGF-β that are thought to directly suppress 
activated T-cells (Josefowicz et al. 2012; Boehmer 2005).  
 
Although Foxp3 upregulation appears to play a key role in the immune-regulatory 
ability of Tregs (Josefowicz et al. 2012), two Foxp3− iTregs have also been reported: 
IL-10 producing type 1 regulatory (Tr1) cells and TGF-β producing Th3-cells (X. Lin et 
al. 2013).  
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Figure 1.3. CD4+ T-cell subsets. Following antigenic recognition and activation, naïve 
CD4+ T-cells (Th0) can differentiate into various CD4+ subsets depending upon the cytokine 
microenvironment. Th1 and Th2 were the first helper cell subsets to be identified, followed by 
additional helper subsets including Th17, Th9 and Tfh. CD4+ T-cells can also differentiate to 
Tregs, which play a role in the regulation/suppression of host immunity (Figure taken from Russ 
et al. (2013)). 
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CD8+ T-cells 
The large majority of CD8+ T-cells differentiate into cytotoxic T-cells (CTLs) that can 
directly kill pathogen infected or malignant target cells. CD8+ T-cell activation and 
proliferation is stimulated by IL-2 produced by CD4+ Th cells, thereby activating CD8+ 
T-cells through a Th-dependent manner (N. Zhang and Bevan 2011). Stimulation with 
IL-2 along with cytokines IFN-γ, IL-4 and IL-10 promote differentiation CD8+ 
differentiation into CTLs. CD8+ T-cells can also be activated without CD4+ help when 
activated APCs upregulate co-stimulatory molecules (Wood 2006). 
 
Upon recognition of an infected or malignant target cell, CTLs release granules, 
polarised to the target cell, containing the cytotoxic effector molecules granzyme A, 
granzyme B, and perforin (Bossi and Griffiths 1999; Sanin and Pearce 2016). Perforin 
monomers insert into the target cell membrane to form polymeric pores, with the 
potential to cause cell death by osmotic lysis. Granzymes can enter the target cell 
through perforin pores, lyse cytosolic proteins and initiate programmed cell death 
(Wood 2006). Granzyme A and granzyme B are the most prevalent effector molecules 
within CTLs: one study reported 4.9 x 106 and 2.2 x 107 copies per cell, respectively, 
with granzyme B being one of the most common proteins produced in these cells overall 
(Hukelmann et al. 2016). This allows for rapid cytolytic function upon CTL activation. 
CTLs also secrete cytokines including IFN-γ and TNF-α that indirectly kill the target cell 
by initiating the effector functions of other immune cells (Sanin and Pearce 2016). 
 
CTLs are also able to trigger target cell death by promoting Fas-mediated apoptosis. Fas 
(CD95) is widely expressed across all cell types, and upon activation CTLs synthesise 
Fas ligand (FasL) and transport FasL to the cell surface via secretory molecules during 
CTL degranulation (Bossi and Griffiths 1999). On the CTL surface, FasL then engages 
Fas on the target cell to initiate apoptosis. 
 
CD8+ T-cells have also demonstrated immune-regulatory function by producing IL-10. 
During the peak of the adaptive response, CD8+ T-cells are the largest producers of 
IL-10 in peripheral infection sites, which are dramatically reduced following resolution. 
Interestingly, IL-10+CD8+ T-cells still demonstrate high cytotoxicity (granzyme B, IFN-γ, 
TNF-α)(N. Zhang and Bevan 2011). 
 
Chapter 1: Introduction 
 17 
T-cell development 
Like B-cells, T-cell precursors arise from lymphoid progenitors within the bone marrow, 
which then commit to T-cell development. These progenitors exit the bone marrow and 
migrate to the thymus as double negative (DN) cells, i.e. expressing neither CD4 nor 
CD8 molecules on their surface (CD4−CD8−) (Germain 2002). DN cells undergo 
extensive division in the thymus cortex developing through four DN sub stages (DN1-
DN4)(Germain 2002; Wood 2006). At the DN3 stage cells begin to express the pre-TCR 
α-chain on their surface and undergo genetic rearrangement of the β-chain, which then 
binds with the pre-α-chain to form a pre-TCR. Successful β-chain rearrangement 
resulting in pre-TCR expression, alongside CD3 and other cell surface proteins, is 
essential for further T-cell development. DN3 cells that fail to present pre-TCR enter 
developmental arrest and die by apoptosis. However, the mechanism behind the 
selection process is not completely understood (Wood 2006; Germain 2002). Late 
DN3/DN4 T-cells undergo additional rounds of cell division followed by genetic 
rearrangements of the pre-α-chain and low-level expression of the fully formed α/β TCR 
with CD3, gradually upregulating CD8 and then CD4 to become double positive (DP; 
CD4+CD8+). 
 
DP thymocytes undergo rounds of both positive and negative selection to ensure that 
the T-cells that develop are specific for the host’s own MHC molecules (self-MHC) and 
foreign antigens. Cortical epithelial cells within the cortex present both MHC-I and 
MHC-II on their cell surface: DP T-cells with TCRs specific for the self-MHC complexes 
are positively selected to receive survival signals. If DP T-cells fail to recognise self-MHC 
they die by apoptosis. At the cortico-medullary junction DP T-cells encounter DCs 
presenting self-peptides on MHC complexes. If a DP T-cell recognises self-antigen (via 
TCR) they are negatively selected to undergo apoptosis. Surviving DP cells then 
differentiate to mature single positive (SP) CD8+ or CD4+ T-cells, depending on 
whether they recognised MHC-I or MHC-II during the selection process, and migrate 
into the peripheral circulation (Germain 2002). 
 
A third T-cell type has also been reported; γ/δ T-cells. These make up a small 
proportion of the total T-cell pool (1-5%) but are present in larger proportions 
(20-50%) within specific tissues, including the intestine, dermis, lung and womb (Silva-
Santos et al. 2015; Vantourout and Hayday 2013). DN cells can mature into either α/β 
or γ/δ T-cells, and the γ/δ TCR is generated by genetic rearrangements of γ- and 
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δ-chains in a similar fashion to α/β TCRs (Germain 2002), although there are fewer 
variable genes at the γ or δ locus so the variation in antigen recognition is limited (Born 
et al. 2012). The functional role of γ/δ T-cells within the immune response is still poorly 
defined, although they have demonstrated recognition and cytotoxic function against 
tumour antigens such as phosphoantigens (Tanaka et al. 1995; Morita et al. 1995), 
normally produced by bacteria and parasites but also accumulated in stressed or 
transformed cells (Silva-Santos et al. 2015). 
 
APC-mediated activation of T-cells 
The MHC/antigen complex is recognised by the TCR on a T-cell specific for that MHC 
class and antigen and is an essential factor in T-cell activation. There are two classes of 
MHC molecules on APCs: MHC class I and MHC class II (Figure 1.4A). Although they 
perform similar roles for T-cell activation, they are recognised by different T-cells (CD8+ 
and CD4+, respectively) and the pathways in antigen processing differ (Figure 1.4B) 
(Wood 2006; Germain 2002). 
 
MHC I molecules interact with TCRs of the CD8+ T-cell and present endogenous 
antigens from within an infected/damaged cell. Viral infection and ‘hijacking’ of a host 
cell’s intracellular processes leads to the generation of new viral proteins within the 
cytoplasm that are not accessible to external immune recognition. These viral antigens 
are degraded by the proteasome, along with other cytosolic proteins, into shorter 
peptide fragments. Antigenic peptides are translocated into the rough endoplasmic 
reticulum (RER) by transporter proteins, to bind with newly synthesised MHC I 
molecules. Once the MHC/antigen complex is formed it is transported to the surface of 
the cells where it can be presented to CD8+ T-cells (Wood 2006; Villadangos and 
Schnorrer 2007). 
 
MHC II differs in that it presents extracellular antigens to CD4+ T-cells. Extracellular 
proteins are taken up by APCs into endosomes using endocytic pathways such as 
phagocytosis. Endosome/lysosome fusion exposes the ingested proteins to lower pH 
levels and proteolytic enzymes that activate in the acidic environment, resulting in 
degradation of the antigen into smaller peptide fragments. Both MHC I and MHC II 
molecules are synthesised within the RER, but formation of the MHC II/antigen 
complex occurs elsewhere, in a vesicle called the compartment for peptide loading 
(CPL). During synthesis the invariant chain binds the antigen-binding site of immature 
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MHC II, preventing MHC II from associating with any intracellular peptides (including 
self-peptides) within the RER. The invariant chain also regulates the movement of MHC 
II to the CPL, which then fuses with the endolysosome containing antigenic peptides. 
Here the invariant chain disassociates from MHC II, allowing antigenic peptides to bind, 
before transporting to the cell surface and presenting to CD4+ T-cells (Wood 2006; 
Villadangos and Schnorrer 2007). 
 
Most cell types can present antigen via MHC I to alert CD8+ T-cells to intracellular 
damage or infection and initiate the cytotoxic response, but only APCs can present 
antigen and prime CD8+ T-cells to differentiate into effector T-cells via co-stimulatory 
factors. Phagocytic APCs can ingest and present exogenous antigens to CD8+ T-cells. 
However, the term APC normally refers to cells that can also present MHC II (Kindt et 
al. 2007). The main three cell types that can do this are DCs, macrophages and B-cells, 
and are known as professional APCs (Steinman and Hemmi 2006; Hoffman et al. 2016; 
Murray and Wynn 2011), although MHC II is also expressed by cortical epithelial cells 
(Germain 2002). DCs are the primary APCs that constitutively express MHC II and co-
stimulatory receptors. Upon phagocytosis of antigen material, macrophages begin 
upregulation of MHC II and costimulatory receptors on their cell surface. B-cells, like 
DCs, constitutively express MHC II, but only upregulate co-stimulatory receptors when 
activated (Kindt et al. 2007). Under certain inflammatory conditions, nonprofessional 
APCs, such as fibroblasts or epithelial cells in the thymus, are also able to temporarily 
present MHC II. 
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Figure 1.4. MHC structure and presentation. (A) MHC molecules are presented on APCs 
with antigenic peptides to be recognised by T-cell receptors (TCRs) and initiate T-cell activation. 
MHC I is recognised by CD8+ T-cells, whereas MHC II is recognised by CD4+ T-cells. (B) MHC I 
molecules mainly present endogenous antigen degraded in the cytosol via proteasomes, whereas 
MHC II presents predominantly exogenous antigen ingested by the APC, although presentation 
of internalised endogenous antigen can also occur. MHC I has also demonstrated exogenous 
presentation, although the mechanism is still unknown (Figures adapted from Kindt et al. 
(2007); Villadangos and Schnorrer (2007)). 
 
MHC-Class I MHC-Class II 
A 
B 
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T-cell memory 
Following primary antigenic stimulation the majority of naïve T-cells differentiate into a 
heterogeneous population of short-lived effector cells (SLECs) that work to resolve the 
infection before undergoing apoptosis (Sarkar et al. 2008; N. Zhang and Bevan 2011). A 
smaller population (5-10%) develop into memory precursor effector cells (MPECs) that 
survive the contraction and develop into a long-lived pool of memory T-cells (Figure 
1.5)(Yuzefpolskiy et al. 2015; N. Zhang and Bevan 2011). The memory pool is then able 
to rapidly and efficiently respond to a repeat infection (Sallusto et al. 2004).  
 
T-cells can be initially divided into two functionally different subsets: central memory 
(CM) and effector memory (EM) T-cells. CM T-cells are CD45RO+ and present homing 
receptors CCR7 and CD62L on the cell surface that aid CM homing to the lymph nodes, 
spleen and blood (Sallusto et al. 2004). CM T-cells have a more efficient response to 
antigen than naïve cells but have a slower effector response upon secondary antigen 
stimulation when compared to EM T-cells (Sallusto et al. 2004). CCR7−CD45RO+ EM 
T-cells are located in the blood, spleen and non-lymphoid tissues (Seder and Ahmed 
2003), and upregulate adhesion molecules that initiate homing to inflamed tissues 
(Sallusto et al. 2004). EM T-cells contain large amounts of perforin and have a rapid 
effector function and cytokine secretion upon antigenic challenge (Sallusto et al. 2004; 
Seder and Ahmed 2003). However, compared to CM T-cells, EM T-cells have reduced 
proliferative capacity and shorter telomeres, along with a poorer response to 
homeostatic cytokines and reduced survival (Klebanoff et al. 2006). Normal memory 
subset distribution differs between CD4+ and CD8+ T-cells: CM T-cells are the primary 
memory subset in the CD4+ T-cell compartment, whereas EM T-cells form a higher 
proportion of the CD8+ T-cells (Sallusto et al. 2004).  
 
Persistent antigen, from chronic infection or tumours, can lead to conversion of memory 
T-cells to a more highly differentiated memory subset (EMRA) (Klebanoff et al. 2006; 
Angelosanto et al. 2012). EMRA T-cells are considered ‘terminally differentiated’ and 
‘exhausted’ cells with impaired effector function, poor proliferative capacity and 
reduced ability for cytokine production (Klebanoff et al. 2006; Nunes et al. 2012). 
When antigen-specific T-cells are removed from an established chronic infection they do 
not recover memory potential and function (Angelosanto et al. 2012), although EMRA 
T-cells do appear to have the potential to overcome senescence under certain stimuli (Di 
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Mitri et al. 2011; Chong et al. 2008), or when removed from the earlier stages of 
chronic stimulation (Angelosanto et al. 2012). 
 
Due to their greater homeostatic potential, CM T-cells were thought to perform the 
main role of T-cell memory pool maintenance. Recent studies have now identified 
human CD8+ and CD4+ T-cells with stem cell-like properties (Tscm cells) that form 
approximately 2-3% of the circulating CD8+ and CD4+ lymphocytes of healthy donors 
(Gattinoni et al. 2011). Tscm-cells present similar cell surface markers as the naïve 
T-cell population, including memory markers CCR7 and CD45RA (and lack of 
CD45RO), but can be further distinguished from naïve cells by the expression of 
additional markers CD95 and CD122 (IL2Rβ). The functional profile of Tscm-cells 
differs from naïve T-cells and is more in-line with CM and EM memory subsets; they 
have a more rapid response to antigenic stimulation and production of effector 
cytokines (IFN-γ, IL-2 and TNF-α), and a proliferative capacity when stimulated by 
homeostatic cytokines IL-15 and IL-7. Tscm-cells appear to present the least 
differentiated memory subset, thereby adding to the linear model as 
Tscm>CM>EM>EMRA. 
 
Gattioni et al. (2011) demonstrated superior engraftment potential of Tscm cells via 
adoptive transfer compared to other memory subsets: Tscm cells engrafted with 10- to 
100- fold more progeny compared to naïve and CM T-cells. In addition, adoptive 
transfer of CD8+ Tscm, CM or EM-cells (co-transferred with CD4+ T-cells) into a 
humanised murine tumour model demonstrated that mice with Tscm cells experienced 
tumour regression and cure, whereas all mice with CM cells died within 40 days of 
transfer. EM cells did not significantly extend survival versus application of CD4+ T-cells 
alone. This anti-tumour potential, along with the enhanced proliferative ability and 
longer-lived survival of Tscm cells, suggests they could be prime candidates for adoptive 
T-cell based cancer immunotherapy. However, the relatively low numbers of Tscm cells 
within the T-cell pool limits the successful application of this population in therapy.  
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1 .1 .3 .3  T-ce l l  markers  for  ac t ivat ion ,  senescence  and exhaust ion  
Several cell surface markers have been defined that aid the characterisation of T-cells 
and their differentiation status, some of which have demonstrated functional roles. The 
following markers are discussed due to their relevance in this study. 
 
CD38 
CD38 is a transmembrane glycoprotein expressed on many immune cells, including 
T-cells and B-cells (Malavasi et al. 2008; Dianzani et al. 1994). Ligation of CD38 on 
T-cells leads to the expression of additional activation markers and proliferation 
(Funaro et al. 1990). CD38 also appears to interact and form complexes with cell 
surface receptors including TCRs and BCRs (Funaro et al. 1993; Dianzani et al. 1994). 
This lends strength to CD38 having a functional role in cell activation, and it is now a 
widely accepted marker for activation (Buggert et al. 2014). 
 
As well as being highly upregulated on activated T-cells, CD38 expression is also 
reported on DP thymocytes, naïve CD4+ T-cells and CD4+ Tregs (Tenca et al. 2003; 
Dianzani et al. 1994; Read et al. 1998). There is normally little or no CD38 found on 
memory T-cells (Malavasi et al. 2008). CD8+ T-cells with high CD38 have been reported 
in chronic infections, although the importance of this is uncertain (Malavasi et al. 
2008). CD38 expression on CD4+ and CD8+ T-cells is employed as a prognostic marker 
in HIV patients for AIDS progression (Malavasi et al. 2008). 
 
HLA-DR 
HLA-DR is a MHC class II molecule, usually expressed on APCs, that presents antigen to 
CD4+ T-cells. Upregulation of MHC class II, including human HLA-DR, is also reported 
on activated T-cells. Cytokine stimulation with interleukins and IFNγ has been shown to 
promote HLA-DR upregulation on both CD4+ and CD8+ T-cells (Salgado et al. 2002; 
Basham and Merigan 1983), but the regulation and functional mechanisms behind 
T-cell MHC II presentation are still poorly understood (Holling et al. 2002). 
 
As with CD38, HLA-DR is a commonly used marker for activated T-cells (Buggert et al. 
2014). Co-expression of HLA-DR and CD38 has been reported on early effector T-cells 
at the peak of the primary immune response (Anichini et al. 2010). Similar to CD38, 
increased HLA-DR expression correlates with loss of CD4+ and progression to AIDS in 
HIV patients (Buggert et al. 2014). 
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CD57 
CD57 was first described as an NK glycoprotein receptor, but is also expressed by highly 
differentiated T-cells that have poor proliferative capacity (Koch et al. 2008; Focosi et 
al. 2010). Expression of CD57 on CD4+ and CD8+ T-cells has been shown to be directly 
associated with the number of cellular divisions, and inversely linked to telomere length 
(Focosi et al. 2010; Brenchley et al. 2003). 
 
CD57+ T-cells accumulate during the persistent antigenic stimulation of chronic 
infections, such as CMV and HIV, and increase with age (Focosi et al. 2010; Strioga et 
al. 2011; Brenchley et al. 2003). Increased frequencies of CD57+ T-cells are also 
reported in both solid cancers and haematological malignancies (Akagi and Baba 2008; 
Characiejus et al. 2008; Van den Hove et al. 1998). Expansion of CMV-specific 
CD8+CD57+ T-cells with a more differentiated memory phenotype is often observed in 
the elderly (Focosi et al. 2010). However, CD57+ T-cells still have the ability to produce 
cytokines upon activation, and have demonstrated rapid proliferation under certain 
stimuli (Focosi et al. 2010; Chong et al. 2008). Interestingly, CD8+CD57+ T-cells have 
also shown more cytotoxic potential than CD8+CD57− T-cells, which strongly correlates 
with granzyme A, granzyme B and perforin expression (Chattopadhyay et al. 2008). 
 
Programmed cell death 1 receptor (PD-1) 
PD-1 is a transmembrane receptor containing an Ig superfamily domain, an 
immune-receptor tyrosine-based inhibitory motif (ITIM) and an immune-receptor 
tyrosine-based switch motif (ITSM). Various immune cells can express PD-1, including 
T-cells, B-cells and DCs. For T-cells, upregulation of PD-1 occurs following activation, 
with the immunosuppressive effects of PD-1 ligation to PD-L1/PD-L2 observed as little 
as a few hours following activation (Keir et al. 2008).  
 
Ligation of PD-1 leads to the direct inhibition of the downstream signalling pathways of 
the TCR costimulatory molecule CD28, leading to the dampening of TCR activation and 
inhibition of cytokine induction (Keir et al. 2008). CD8+ T-cells specific for CMV, EBV, 
HIV and vaccinia-virus all demonstrated varying levels of PD-1 expression thought to be 
related to length of antigenic exposure (Day et al. 2006). Furthermore, PD-1 
upregulation on both CD4+ and CD8+ T-cells is associated with progressive HIV 
(increased viral load, reduced CD4+ count), and blocking PD-1/PD-L1 ligation has been 
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shown to reverse immune dysfunction within the disease (Day et al. 2006; Trautmann 
et al. 2006). Therefore, PD-1 is one of the best described immunosuppressive markers 
and is commonly used to distinguish T-cells undergoing differentiation to exhaustion 
following chronic antigenic stimulation (Buggert et al. 2014; Anichini et al. 2010). 
 
Killer cell  lectin-like receptor G1 (KLRG-1) 
KLRG-1 was initially attributed as an NK cell surface receptor, but has since been 
identified on T-cells with poor proliferative potential (Thimme et al. 2005). KLRG-1 is 
also greatly upregulated on the SLEC population during peak response of infection 
(Voehringer et al. 2002; Y. Li et al. 2009), as well as a subset of short-lived terminally 
differentiated KLRG-1+ Tregs with enhanced immune-regulatory capabilities (Cheng et 
al. 2012). KLRG-1 binds to a conserved area on cadherin molecules (including E-, N- 
and R- cadherin), which then inhibits the proliferation of activated T-cells (Y. Li et al. 
2009; Henson et al. 2009). 
 
KLRG-1 is present at very low levels in the naïve T-cell pool, but then KLRG-1+ T-cell 
frequency progressively increases through memory subset differentiation 
(CM<EM<EMRA)(Voehringer et al. 2002). Virus specific T-cells from resolved 
infections demonstrate lower expression of KLRG-1, whereas persistent antigenic 
stimulation leads to increased frequencies of KLRG-1+ T-cells (Bengsch et al. 2007). 
Higher frequencies of KLRG-1+ T-cells have been reported in multiple chronic viral 
infections, including HIV (72-89%), EBV and CMV (>92%) compared to resolved 
influenza (40-73%) (Ibegbu et al. 2005; Thimme et al. 2005). Furthermore, additional 
characterisation with CD57 has identified a ‘terminally differentiated’ CD57+KLRG-1+ 
subset (Ibegbu et al. 2005). KLRG-1 therefore represents a marker to identify more 
differentiated T-cell subsets under conditions of chronic antigen exposure.  
 
Although T-cells expressing KLRG-1 demonstrate poor proliferative capacity, they are 
still able to maintain effector functions similar to that of T-cells with low KLRG-1, such 
as IFN-γ production and degranulation (Ye et al. 2012; Voehringer et al. 2002). 
Interestingly, KLRG-1high T-cells adoptively transferred from mice with influenza 
infection in the lung were able to persist in the absence of antigenic stimulation, and 
demonstrated proliferative potential during antigen re-exposure in new hosts (Ye et al. 
2012), implying some plasticity in response. 
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Interleukin-7 receptor α  (IL-7Rα/CD127) 
Homeostatic cytokines IL-7 and IL-15 maintain naïve and memory T-cell survival and 
population turnover (Seder and Ahmed 2003). Expression of the α-subunit of the IL-7 
receptor, IL-7Rα (CD127), is critical for efficient T-cell memory development and 
survival (Kaech et al. 2003; Hand et al. 2007). Naïve T-cells express CD127 but during 
activation CD127 is downregulated (Hand et al. 2007; Sarkar et al. 2008). At 7 days 
post-infection, a small fraction of T-cells (MPECs) begin to re-express CD127 and the 
frequency of CD127+ cells gradually increases (Bachmann et al. 2005; Sarkar et al. 
2008). Presentation of CD127 could therefore distinguish antigen-specific T-cells with 
memory potential.  
 
CD127 can be used in combination with KLRG-1 to characterise differentiated T-cells. 
Following T-cell contraction CD62high cells are observed within the KLRG-1lowCD127high 
population, implying that that CM T-cells arise from this less differentiated phenotype, 
whereas EM T-cells may be derived from KLRG-1highCD127low T-cells (Kurtulus et al. 
2011). Acute virus-specific T-cells present the KLRG-1lowCD127high phenotype, whereas 
viral-specific T-cells exposed to chronic infection are KLRG-1highCD127low (Bengsch et al. 
2007). Interestingly, IL-7-mediated signalling induces rapid internalisation of IL-7R on 
T-cells and down modulation of CD127 (Ribeiro et al. 2012), thereby losing the ability 
to respond to further IL-7 stimulation. 
 
BCL-2 
BCL-2 is an anti-apoptotic molecule that is induced by IL-7/IL-15 stimulation and 
performs direct interactions with pro-apoptotic molecules, such as Bim or Bax, to 
prevent initiation of cellular apoptosis (Kurtulus et al. 2011; Oltval et al. 1993). 
Formation of Bim/BCL-2 complexes are essential for naïve T-cell survival 
(Wojciechowski et al. 2007). Like CD127, BCL-2 is downregulated during activation. 
MPECs with low KLRG-1 and high CD127 expression were associated with higher 
expression of BCL-2 compared to SLECs, supporting a role for BCL-2 in T-cell memory 
development and survival (Kurtulus et al. 2011; Dunkle et al. 2013). Furthermore, 
BCL-2 is higher in CM T-cells than EM T-cells, suggesting increased homeostatic survival 
within the CM compartment (Kurtulus et al. 2011).  
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1 .2  Cancer  immunology  
The immune system can identify and kill abnormal or damaged host cells. Tumour 
reactive T-cells have been identified in cancer patients, implying that mechanisms to 
recognise and resolve malignant cells are present within the immune response. 
However, tumour resolution is not achieved due to the tumour’s ability to promote 
immune evasion, thereby facilitating tumour progression (Hanahan and Weinberg 
2011). 
 
1 .2 .1  Immune surve i l lance  and immunoedi t ing  
The method by which the immune system regulates response to cancer is known as 
immune surveillance and immunoediting. Immune surveillance was first coined by 
(Burnet 1957), who hypothesised that lymphocytes were responsible for the removal of 
any malignant cells that arise. Immune surveillance is therefore vital for recognition and 
elimination of malignancy. Immunodeficient or immunosuppressed patients 
demonstrate an increased risk of both viral and non-viral malignancies, supporting the 
theory of immune surveillance that prevents cancer progression in normal individuals 
(Hanahan and Weinberg 2011; Dunn et al. 2004). Immune surveillance requires an 
active tumour-specific immune response, and there is evidence for autologous 
tumour-specific antibodies and T-cells in cancer patients. Several tumour antigens have 
been identified that can be recognised by CD4+ and CD8+ T-cells, such as differentiation 
antigens, mutational antigens, overexpressed/amplified antigens, viral antigens and 
cancer-testis antigens (Dunn et al. 2004). Tumour-infiltrating lymphocytes (TILs) within 
the tumour microenvironment have been shown to correlate strongly with patient 
survival in multiple cancers (Dunn et al. 2004; Galon et al. 2006). Specifically, CD3+ 
TILs correlate with better prognoses in epithelial ovarian cancer with a five-year survival 
rate of 38% in patients with CD3+ TILs versus 4.5% survival in patients without TILs (L. 
Zhang et al. 2003). 
 
Research since the original outlining of immune surveillance has evolved the hypothesis 
to include tumour survival and escape from immunological destruction, and it is now 
split into three stages: elimination, equilibrium and escape (Figure 1.6)(Dunn et al. 
2004). Elimination comprises the immune surveillance stage that, if successful, results 
in the recognition and removal of cancerous cells without tumour progression (Dunn et 
al. 2004). The second stage, equilibrium, occurs if the immune system is unable to 
eradicate the cancer completely, but can perform immune functions that prevent the 
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tumour from progressing. However, this form of keeping the tumour cells in check can 
facilitate clonal evolution of immunologically resistant tumour cells that are able to 
escape elimination and suppression due to reduced immunogenicity and the ability to 
induce immune control mechanisms (Smyth et al. 2006; Dunn et al. 2004). 
 
In addition to tumour evasion, tumour-promoting inflammation has been reported as an 
enabling characteristic in cancers. Inflammation within the tumour environment was 
initially thought to be an immune response against the malignancy. However, a pro-
inflammatory environment has since been demonstrated to benefit the tumour in aiding 
tumour promotion and progression. Inflammation provides recruitment of beneficial 
molecules to the tumour site that promote survival and growth, as well as enzymes that 
promote tumour angiogenesis, invasion and metastasis (Hanahan and Weinberg 2011). 
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1 .3  Chronic  lymphocyt ic  leukaemia  
 
1 .3 .1  Epidemiology  
Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in the UK 
and western world, comprising 40% of all leukaemia cases in patients aged 65 years 
and older (Oscier et al. 2004; Motta et al. 2009). Overall, UK incidence is thought to be 
approximately 3 per 100,000 people per year (Oscier et al. 2004), with 3,515 new cases 
of CLL reported in 2014 (CRUK 2016). There is a higher proportion of male CLL 
patients (approximately 2:1, male:female)(Oscier et al. 2004), but why CLL is more 
prominent in males is unclear. Median age at diagnosis is between 64-70 years (Redaelli 
et al. 2004), although 20-30% of patients are identified under 55 years (Oscier et al. 
2004).  
 
CLL is defined by the accumulation of malignant CD5+CD19+ B-cells (Damle 2002) and 
there is evidence that CLL cells could derive from the B1 B-cell subtype (Chiorazzi and 
Ferrarini 2011; Hayakawa et al. 2016; Rosén et al. 2012). However, the driving force 
behind this malignancy is still largely unknown. It is thought that inheritable genetic 
factors play a part, with approximately 17-21% of CLL patients reporting a family 
history of CLL or other lymphoproliferative disorders (Brown 2014). 
 
1 .3 .2  Pathology  
As CLL is an accumulation of malignant monoclonal B-cells, patients are 
immunodeficient in many aspects. 85% of patients have dramatically reduced serum Ig 
(hypogammaglobulinaemia), resulting in impaired humoral responses and antibody 
mediated immunity, and increased susceptibility to bacterial infections. Reactivation of 
dormant viruses are also highly common, including herpes simplex virus, 
cytomegalovirus (CMV) and Epstein-Bar virus (EBV) (Pourgheysari et al. 2010), 
suggesting that cell-mediated responses are also impaired. Therefore, infections are one 
of the main causes of death in CLL, causing mortality in 25-50% of CLL patients (A. D. 
Hamblin and T. J. Hamblin 2008). 
 
Little is known about non-malignant B-cells in CLL, except that they are significantly 
reduced. Due to the low levels of Ig detected, normal B-cell activity is probably 
suppressed, but whether they are directly suppressed by CLL cells or indirectly by other 
modes of immunosuppression is uncertain (A. D. Hamblin and T. J. Hamblin 2008). 
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1 .3 .3  Diagnos is  and s tag ing  
CLL can be either a relatively stable, indolent disease that does not require treatment, or 
a more severe form with poorer prognosis and a shorter life expectancy (Rai et al. 1975; 
A. D. Hamblin and T. J. Hamblin 2008). Therefore, although patients can present with 
symptoms, including lymphadenopathy, tiredness, weight loss, abdominal pain and 
persistent infections, many patients are initially asymptomatic and 70-80% are 
diagnosed following routine blood tests (Oscier et al. 2004). Current diagnosis is based 
on a lymphocyte count of >5 x 109 B-cells/L in peripheral blood with 
immunophenotypic confirmation of B-cell clonality (Hallek et al. 2008). 
 
CLL is normally classified by either Rai (Rai et al. 1975) or Binet (Binet et al. 1981) 
clinical staging systems for prognosis (Oscier et al. 2004; Hallek et al. 2008), with Rai 
being the predominant system in the USA and Binet in Europe (Redaelli et al. 2004). 
Rai staging focuses upon lymphocytosis (Stage 0) leading to lymphadenopathy (Stage 
I), splenomegaly or hepatomegaly (Stage II), anaemia (Stage III) and thrombocytopenia 
(Stage IV); these stages can be considered as low risk (Stages 0-I), intermediate risk 
(Stages II-III) and high risk (Stage IV). The Binet staging system also focuses on 
lymphocyte infiltration but by the number of lymphoid sites: <3 sites (Stage A, 
approximately 60% of patients), ≥3 lymph sites (Stage B, approximately 30% of 
patients) and ≥3 lymph sites plus anaemia or thrombocytopenia (Stage C, 
approximately 10% of patients) (Oscier et al. 2004). Median survival is >10 years for 
Binet stage A patients, <8 years for Binet Stage B patients and 6.5 years for Binet Stage 
C patients (Eichhorst et al. 2011). 
 
1 .3 .4  Prognost ic  markers  
Due to the heterogeneity of the disease, there is a clear clinical need to be able to 
identify whether a patient will have good or bad prognosis. In addition to Binet/Rai 
staging, several other prognostic markers have demonstrated clinical potential for 
grouping patients by prognosis. 
 
1 .3 .4 .1  IGHV  mutat ion  s ta tus  
As previously described in Section 1.1.3.1, activated B-cells undergo major genetic 
rearrangements to produce high affinity Ig (BCR) on their cell surface. Originally, the 
CD5+ B-cells in CLL were thought to be naïve-like. However, it became apparent that 
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CLL patients could by stratified by whether the CLL cells had undergone somatic 
hypermutation of the Immunoglobulin heavy chain variable region (IGHV). 
Approximately 30-40% of CLL patients demonstrated somatic IGHV rearrangement 
(Moreno and Montserrat 2008). Furthermore, patients with unmutated IGHV (≥98% 
homology to the closest germ line sequence) had significantly poorer median survival of 
8 years versus 25 years in the mutated IGHV patients, in addition to poorer response to 
chemotherapy (Damle et al. 1999; T. J. Hamblin et al. 1999). IGHV mutation status is 
therefore considered a powerful prognostic marker in CLL; however, sequencing is still 
one of the more time-consuming and costly methods. Therefore, IGHV mutation status is 
still not used routinely outside of the clinical trials setting (Moreno and Montserrat 
2008). 
 
1 .3 .4 .2  CD38 
Patients with unmutated IGHV also have significantly higher frequencies of CD38+ 
B-cells than their mutated counterparts (63.9% versus 7.3%) and this was suggested as 
a surrogate marker for IGHV mutation status (Damle et al. 1999). Later studies with 
larger patient cohorts demonstrated that CD38 is a prognostic marker of CLL in its own 
right and can be used in combination with IGHV mutation status to identify the poorer 
prognosis patients, i.e. patients with unmutated IGHV and CD38+ (T. J. Hamblin et al. 
2002). CD38+ CLL patients (≥ 20% CD38+) had an inferior prognosis, with more 
advanced pathology, poorer response to chemotherapy, shorter time to first treatment 
and shorter overall survival (Dürig et al. 2002). Ease of phenotypic testing means CD38 
could pose as a beneficial marker, although the optimum value to define CD38 positivity 
is hard to determine as individual studies have opted for different cut off values for 
CD38 expression (5-30%) (Moreno and Montserrat 2008; Oscier et al. 2004). There is 
also longitudinal evidence to suggest that the expression of CD38 is temporal in CLL 
patients (T. J. Hamblin et al. 2002). 
 
1 .3 .4 .3  Zap-70 
70-kDa zeta-associate protein (Zap-70) is a key signalling molecule in T-cells and NK 
cells, but is not usually expressed in B-cells (Schroers et al. 2005). However, analysis 
comparing differential gene expression between mutated and unmutated IGHV in CLL 
revealed that expression of Zap-70 is upregulated in the unmutated IGHV 
subpopulation.  The strong association between Zap-70 and IGHV status and the ability 
to measure Zap-70 by flow cytometry suggests it as a candidate for prognosis in the 
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clinical setting, however, it is not easy to measure since it is an intracellular molecule 
and its levels are highly changeable (Schroers et al. 2005; Moreno and Montserrat 
2008). Median survival in Zap-70+ patients was 9.3 years, versus 24.4 years survival in 
Zap-70− patients (Orchard et al. 2004). Furthermore, Zap-70+CD38+ patients were 
prognostically worse off than Zap-70−CD38− or discordant (Zap-70−CD38+ or 
Zap-70+CD38−) cohorts (Schroers et al. 2005). 
 
1 .3 .4 .4  CD49d 
CD49d is a cell surface adhesion molecule (Zucchetto et al. 2005). Initially studies 
demonstrated that CD49dhigh patients (>30% CD49d expression) had shorter time to 
first treatment, and CD49d expression was strongly associated with CD38 expression, 
IGHV mutation status and Zap-70 expression (Zucchetto et al. 2005; Gattei et al. 2008). 
More recent work lends further support to the prognostic relevance of CD49d, where a 
pooled analysis of 2,972 CLL patients showed CD49d as the strongest phenotypic 
marker in regards to prognosis (Bulian et al. 2014).  
 
1 .3 .4 .5  Genet ic  aberrat ions  
Cytogenic abnormalities have been reported in up to 90% of CLL patients (Moreno and 
Montserrat 2008). The most common genetic aberration is deletion on the long arm of 
chromosome 13 (13q-deletion), found in more than 50% of CLL patients and associated 
with significantly improved prognosis (Redaelli et al. 2004; Puiggros et al. 2014). 
Deletions have also been observed in the long arm of chromosome 11 (11q-deletions, 
10-20% of patients) and short arm of chromosome 17 (17p-deletions, 1.5-7% of 
patients), but both are associated with significantly poorer outcome (Redaelli et al. 
2004; Puiggros et al. 2014). Patients with 17p-deletions are most at risk with the 
shortest overall survival and shortest progression free survival. Elevated CD38 
expression, Zap-70 expression, and unmutated IGHV has been associated with 
17p-deletions, in addition to strong links with aberrations in the TP53 gene (75% of 
cases) that codes for p53 (Puiggros et al. 2014). 
 
Trisomy of chromosome 12 occurs in 10-30% of patients (Redaelli et al. 2004). Often it 
appears as the only genetic aberration in 40-60% of Trisomy 12 cases, but can also 
appear alongside other abnormalities including trisomy (chromosome 18 and 19) and 
deletions (13q, 11q, 14q, or 17p). The prognostic potential of trisomy 12 is unclear as 
studies have identified trisomy 12 patients with varying prognosis: trisomy 12 patients 
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with poor clinical outcome also present other markers including CD38 and unmutated 
IGHV (Puiggros et al. 2014). 
 
Telomere length has also demonstrated strong prognostic potential. A previous study 
demonstrated that Binet A patients had significantly longer telomeres than Binet B/C 
patients, and that shorter telomere length (≤6.0 kb) had significantly poorer survival 
(Bechter et al. 1998). Telomere length has also been suggested as an additional marker 
to IgHV mutational status to further classify patients with poorer prognosis (Grabowski 
et al. 2005). More recently, high resolution single telomere length analysis (STELA) 
showed that Binet A CLL patients could be stratified into subgroups with good (91% 
survival at 10 years) or poor prognosis (13% survival at 10 years) based on mean 
telomere length with telomeric fusion potential (2.26kb) (T. T. Lin et al. 2014). 
Furthermore, telomere length was the strongest prognostic factor when compared 
against Binet stage, IGHV mutation status, CD38, Zap-70 and cytogenetics. 
 
1 .3 .5  Treatment  
With the heterogeneous presentation of the disease, patients who are diagnosed as early 
stage (Rai 0, Binet A) and are asymptomatic are subjected to a ‘wait and see’ approach, 
with therapy induction only if the disease progresses (Hallek et al. 2008). Indications 
for treatment (as defined by the National Cancer Institute) include: progressive marrow 
failure (development or worsening of anaemia/thrombocytopenia); massive/progressive 
lymphadenopathy; massive/progressive splenomegaly; progressive lymphocytosis; 
systemic symptoms; autoimmune cytopenias (Oscier et al. 2004).  
 
Initial first-line treatment is usually the combined chemotherapy of fludarabine and 
cyclophosphamide (FC), or FC and rituximab (FCR). For patients where FCR is 
unsuitable, treatment is chlorambucil or bendamustine in combination with CD20 
antibodies (e.g. obinutuzumab or ofatumumab) (Oscier et al. 2012; NICE 2015a; NICE 
2015b). Rituximab, obinutuzumab and ofatumumab are monoclonal antibodies (mAbs) 
that recognise and bind to the CD20 molecule on the B-cell surface, helping the host 
immune cells to identify and kill CLL cells via ADCC (Coiffier et al. 2008).  
 
Patients with 17p/TP53 deletions do not respond as well to the standard FC or FCR 
treatment (Puiggros et al. 2014) and because of this, current guidance now 
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recommends pre-treatment screening for TP53 loss to allow adequate p53-independent 
treatment (Oscier et al. 2012).  
 
If patients relapse >2 years following initial treatment, they are continued on the same 
treatment (i.e. FCR, chlorambucil or bendamustine) unless it is considered 
inappropriate to do so (Oscier et al. 2012). However, if patients relapse within 2 years, 
treatment with idelalisib is recommended, similar to high-risk patients (TP53 
abnormality). Idelalisib is a small molecule inhibitor of PI3Kδ, a kinase molecule that 
plays a downstream role in many B-cell signalling pathways, including the BCR, CD40, 
CXCR4/CXCR5 and CD49d pathways (Furman et al. 2014). This drug thereby inhibits 
the activation, differentiation, proliferation, migration and survival of CLL cells. 
 
Studies are still ongoing for a further small molecule inhibitor: ibrutinib, which binds to 
Bruton’s tyrosine kinases (BTK). BTK acts downstream of BCR signalling, and BTK 
inhibition leads to downregulated CD20, as well as downregulation of downstream 
pathways including ERK 1/2, PI3K, and NF-κB, leading to loss of cell viability (Herman 
et al. 2014). 
 
1 .3 .6  T-ce l l  dys funct ion  in  CLL  
Although CLL is a B-cell malignancy, T-cell abnormalities have long been observed in 
patients with this condition (Whelan et al. 1982), and their promotion/suppression 
appears to contribute to the pathology of the disease. Low frequencies of CLL-reactive 
T-cells have been identified (Gitelson et al. 2003), however do not appear to 
successfully mount a response against CLL. Direct T-cell interaction with CLL cells 
results in defective TCR recognition and TCR dysfunction (Ramsay et al. 2008). Gene 
expression profiles have revealed that cell-cell contact between CLL cells and T-cells 
induces molecular defects in both CD4+ and CD8+ T-cells (Görgün et al. 2005). Similar 
to the malignant B-cells, CD38 expression on T-cells (≥50%) has been associated with 
poorer prognosis, although in this case the association was seen only in male CLL 
patients (Tinhofer et al. 2006). 
 
T-cell inhibitory cytokines produced by CLL cells include TNF, IL-6, IL-10 and TGF-β 
(DiLillo et al. 2013; Nosari 2012; Garaud et al. 2011). CLL cells (and B-cell lines 
transfected with CD5 cDNA) have been shown to produce IL-10 (Garaud et al. 2011), a 
cytokine not only associated with immunoregulation of T-cells and DCs but also the 
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promotion and survival of B-cells (Garaud et al. 2011; Defrance et al. 1992). CLL 
secretory molecules have also been shown to demonstrate a direct effect on reducing T-
cell CD40L presentation and IL-2 expression (a Th1 cytokine) and promoting 
polarisation to IL-4 Th2-cells (Buggins et al. 2011), the helper subset involved in B-cell 
help. Th-cells specific for CLL antigens that potentially help and maintain the CLL cells 
within the tumour microenvironment have been identified (Os et al. 2013).  
 
Expanded numbers of both CD4+ and CD8+ T-cells have been observed in CLL 
(Pourgheysari et al. 2010). The expansion is markedly greater in the CD8+ T-cell 
compartment of some CLL patients, resulting in a higher number of CD8+ T-cells than 
CD4+ T-cells and an inversion in the CD4:CD8 ratio (Gonzalez-Rodriguez et al. 2010). 
Further analysis of the CD8+ T-cell expansion revealed a decrease in naïve T-cells and 
an expansion in the EM and further differentiated EMRA compartments (Görgün et al. 
2005). Poor prognosis patients (Zap-70+, CD38+) have also demonstrated a similar 
T-cell memory skew (Göthert et al. 2013; Monserrat et al. 2013). 
 
In particular, an extensive study from our group (Nunes et al. 2012) involved the 
immunophenotyping of 110 early-stage untreated patients and demonstrated an 
inverted CD4:CD8 ratio in 47% of patients. Patients were then stratified into normal 
ratio (CLLNR) and inverted ratio (CLLIR) cohorts based on a threshold CD4:CD8 ratio of 
1.0. CLLIR patients demonstrated a significant reduction in both the naïve and CM CD8+ 
T-cell populations and a marked expansion in the EMRA subset when compared with 
CLLNR patients and healthy donors (HDs). Furthermore, Nunes et al. (2012) observed an 
increase in the CD57+CD27−CD28− phenotype within the inverted ratio cohort, 
inferring an increase in a highly differentiated, replicative senescent CD8+ T-cell 
phenotype.  
 
 
1 .4  Hypothes is  and a ims o f  the  current  s tudy  
Previous work has reported an expansion in the CD8+ T-cell compartment in a 
subpopulation of CLL patients, resulting in an inverted CD4:CD8 ratio that is skewed to 
a more differentiated phenotype and linked to poorer prognosis. However, recent 
research has identified several novel human T-cell subsets, and demonstrated that the 
CD4+ and CD8+ compartments are phenotypically complex.  
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We hypothesise that the CD8+ expansion observed in these inverted ratio CLL patients is 
an accumulation of aged T-cells displaying signs of senescence and/or exhaustion. 
Furthermore, the accumulation of these T-cell populations is linked to significantly 
poorer prognosis. Accurate determination of these T-cell populations could 
consequently identify a valuable prognostic marker that may help identify patients with 
inferior prognosis prior to disease progression. Therefore, the overall aim of this thesis 
is to further characterise the expanded CD8+ T-cells in CLL using higher resolution 
techniques to provide more precise definition of T-cell phenotypes associated with poor 
prognosis and to gain an understanding of the role of T-cells in disease pathology.  
 
Firstly, we will explore the phenotypic abnormalities within this inverted T-cell 
compartment to identify T-cell signatures with potential prognostic value.  Markers 
were looked at both individually and in combination to identify T-cell phenotypes of 
interest within the inverted ratio patients; these markers include CD57, KLRG-1 and 
PD-1 (for immune exhaustion/senescence) as well as HLA-DR and CD38 (to indicate 
activation). Further, the marker expression and definition of T-cell subsets were related 
to clinical data of untreated patients, to determine their prognostic value.  
 
Next, any markers of prognostic interest were then applied to the phenotypic analyses 
of treated CLL patients to observe whether treatment affects T-cell populations and 
whether the presence of prognostic phenotypes is indicative of poorer response to 
treatment. 
 
The thesis also aimed to explore the mechanisms behind the expansion of CD8+ T-cells 
in poor prognosis CLL patients. The replicative history of CD8+ T-cells in CLL patients 
will be studied to ascertain whether the expanded CD8+ population arises due to an 
accumulation of ‘aged’ CD8+ T-cells that have undergone multiple rounds of 
proliferation, or because of continual activation and skewed differentiation from the 
naïve T-cell pool. To assess replicative age this study employed single telomere length 
analysis (STELA) to measure telomere length distributions of the CD4+ and CD8+ 
T-cells, in addition to the CD8+ T-cell memory subsets. 
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Chapter 2 
Materials and methods 
 Tissue  cu l ture  bas ics  2.1.
 
 Media  and buf fers  2.1.1.
Freezing mix 
40% Roswell Park Memorial Institute (RPMI) 1640 (Sigma-Aldrich), 10% Dimethyl 
Sulphoxide (DMSO) (Sigma-Aldrich), 50% foetal calf serum (FCS) (Invitrogen). 
 
FACS buffer 
1% FCS was added to Phosphate Buffered Saline (PBS, Invitrogen). 
 
MACS buffer 
0.5% Bovine Serum Albumin (BSA, Sigma) and 2 mM Ethylenediaminetetraacetic acid 
(EDTA, Sigma) was added to 100 ml PBS. The buffer was then sterile filtered using a 
0.2 μm filter (Millipore). 
 
Red blood cell lysis buffer 
1 part red blood cell lysis solution (Miltenyi Biotec) was diluted in 9 parts distilled 
water. 
 
QIAamp DNA extraction buffers 
Qiagen separation kits provided the following buffers: ATL, AL, AW1 and AW2. Before 
initial use 25 ml 100% ethanol was added to 19 ml Buffer AW1 concentrate, and 30 ml 
100% ethanol was added to 13 ml Buffer AW2 concentrate.  
 
1XTEN buffer 
1XTEN buffer was made using a 1:10 dilution of 10xTEN stock (Biorad, Hoechst kit).  
 
Tris-HCl 
Working stock of 10 mM Tris-HCl was prepared by diluting 1 part 1 M Trizma® 
hydrochloride buffer solution (Sigma-Aldrich) with 9 parts ddH20. 
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Taq/PWO (10:1) reagent 
10 μl PWO DNA polymerase (Roche) was added to 100 μl Red Hot DNA polymerase 
(Thermoprime, Fisher). 
 
Telorette 2 (Tel2) primer 
Working stock of Tel2 primer (10 μM) was prepared by diluting 10 μl Tel2 stock with 
90 μl ddH20. Any leftover stock was stored at −20°C and used in subsequent 
experiments. 
 
Teltail  primer 
Teltail primer (5 μM) was made by adding 5 μl Teltail stock and 95 μl ddH20. Any 
leftover stock was stored at −20°C and used in subsequent experiments. 
 
XpYpE2 (Telomere Adjacent) primer 
5 μl of XpYpE2 stock was added to 95 μl ddH2O to make a 5 μM working solution. Any 
leftover stock was stored at −20°C and used in subsequent experiments. 
 
Depurination buffer (0.25 M HCl) 
108 ml of hydrochloric acid was made up to 5 L with ddH2O and mixed thoroughly. 
 
Denaturation buffer (1.5 M NaCl/0.5 M NaOH) 
438.3 g sodium chloride and 100 g sodium hydroxide was solubilised in 5 L ddH2O. 
 
Church buffer 
0.5 M sodium phosphate buffer (pH7.2) was made using 1 M disodium dihydrogen 
phosphate, 1 M disodium hydrogen phosphate, 1% BSA, 1 mM EDTA and 7% SDS 
(Fisher Scientific). 
 
Hybridisation wash buffer 
2.5 ml SSC (sodium chloride sodium citrate) and 2.5 ml SDS (sodium dodecyl sulphate) 
(Fisher Scientific) was made up with ddH2O to make 500 ml. 
 
 Tissue  cu l ture  p las t ics  2.1.2.
Pasteur pipettes and Falcon tubes (15 ml, 50 ml; Corning Incorporated), pipette tips 
(1000, 200, 20 and 2 μl; Star Lab), FACS tubes (BD Biosciences). 
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 Cel l  v iab i l i ty  and count ing  2.1.3.
Cell counts were performed using a Beckman Coulter Vi-cell®. 50µl of sample was 
added to 450μl of PBS (1:10 dilution) in a sample cup and placed into the Vi-cell 
carousel. Cell type (CLL lymphs) dilution (1:10) and sample name were entered into 
the Vi-cell software. Once set to run, the Vi-cell stained the sample with trypan blue, a 
dye that is taken up by dead cells, which allows the Vi-cell to calculate the number of 
viable cells per ml. 
 
 
 Blood donors  and preparat ion  2.2.
 
 Blood donors  2.2.1.
All blood samples were taken with informed consent and appropriate ethical approval. 
Professor Chris Fegan obtained CLL blood samples from patients attending clinics at the 
University Hospital Wales and Llandough Hospital. Samples were also obtained through 
collaboration with Dr Guy Pratt at Birmingham University. Control samples were also 
obtained from healthy, age-matched patients or healthy volunteers within the 
department. 
 
 I so la t ion  o f  PBMC 2.2.2.
Peripheral blood mononuclear cells (PBMC) were isolated via density gradient 
centrifugation using Ficoll-Histopaque (Histopaque-1077, Sigma). Whole blood was 
layered onto histopaque at a 1:1 volume ratio and centrifuged for 20 minutes at 840×g 
with the brake disabled. After centrifugation, PBMC formed a monolayer on top of the 
histopaque and were harvested using sterile Pasteur pipettes. PBMC were then 
transferred to a 15 ml falcon tube and resuspended in fresh PBS. Samples were further 
centrifuged at 470×g for 5 minutes, and supernatant poured off. If the pellet showed 
signs of red blood cell contamination, the pellet was suspended in 1 ml red blood cell 
lysis buffer, incubated for 10 minutes at room temperature and washed with PBS as 
above. The pellet was then resuspended in 1-15 ml of PBS (determined by pellet size) 
and counted using the Vi-Cell (Section 2.1.3). To allow potential use for other 
laboratory projects, samples were also stained for CD19 and CD38 (later also stained for 
CD3 and CD49d; see Table 2.1 for antibody details) and analysed on the BD Accuri 
Flow Cytometer with BD Accuri C6 Software. 
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 T-ce l l  enr ichment  us ing  MACS 2.3.
T-cell enrichment was performed on PBMC in preparation for FACS Aria cell sorting. 
Cells were transferred to a fresh 15 ml falcon tube and centrifuged at 470×g for 
5 minutes to form a pellet before resuspending in 1 ml MACS buffer. 50 μl of anti-
CD19 microbeads (MACS, Miltenyi) per 100 x 106 cells were added and then put onto a 
roller mixer (Bibby Stuart Scientific, SRT2) for 15 minutes at 4°C. Cells were washed 
again and resuspended in a 1 ml fresh MACS buffer before loading onto the MACs 
AutoMACS machine. This passed the cell/microbead suspension through magnetic 
columns, allowing anti-CD19 labelled cells to attach. Unlabelled cells passed through 
the columns and were aliquoted into a fresh 15 ml falcon tube as the negative fraction. 
The CD19+ cells were then released from the columns into a positive fraction 15 ml 
falcon tube. The negative fraction was retained for further T-cell subset isolations via 
FACS sorting. 
 
 
 Fluorescent  ant ibody s ta in ing  and f low cytometr ic  ana lys i s  2.4.
Flow cytometry was undertaken using BD Accuri, BD FACS Canto II and BD FACS Aria 
machines. During data collection Accuri C6 or BD FacsDiva software were used, and 
data was later analysed using Accuri C6 or FlowJo analysis (version 9) software.  
 
 Ant ibodies  used 2.4.1.
Tables 2.1-2.6 below depict the antibody panels used. To determine optimum staining, 
antibodies were titrated by comparing mean fluorescent intensity (MFI) of the full test 
volume as recommended by the manufacturer versus half of the recommended test 
volume. If half the test volume produced similar MFI to the full test, half test volume 
was used for the main experiments; if not, the full recommended test was used. 
 
Table 2.1. Blood sample preparation panel (Accuri C6) 
Antibody Fluorochrome Company (Ref no.) Description 
CD19 APC Invitrogen (MHCD1905) Mouse IgG1, Clone SJ25-C1 
CD38 PE Invitrogen (MHCD3804) Mouse IgG1, Clone HIT2 
CD49d PerCP-Cy5.5 Biolegend (304312) Mouse IgG1, Clone 9F10 
CD3 FITC Biolegend (300440) Mouse IgG1, Clone UCHT1 
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Table 2.2. T-cell memory subsets (Accuri C6) 
Antibody Fluorochrome Company (Ref no.) Description 
CD3 PE-Cy5.5 Invitrogen (MHCD0318) Mouse IgG2a, Clone 7D6 
CD8 APC 
BD Biosciences 
(555369) 
Mouse IgG1, Clone RPA-T8 
CCR7 PE 
R&D Systems 
(FAB197P) 
Mouse IgG2a, Clone 
#150503 
CD45RO FITC Biolegend (304204) Mouse IgG2a, Clone UCHL1 
 
 
 
Table 2.3. T-cell subsets and activation/senescence markers – Panel 1 (Accuri C6) 
Antibody Fluorochrome Company (Ref no.) Description 
CD3 AmCyan BD Biosciences 
(339186) 
Mouse IgG1, Clone SK7 
CD8 APC-Cy7 Biolegend (344714) Mouse IgG1, Clone SK1 
CD4* PE Biolegend (300508) Mouse IgG1, Clone RPA-
T4 
CCR7 PE-Cy7 BD Biosciences 
(557648) 
Rat IgG2a, Clone 3D12 
CD45RO FITC Biolegend (304204) Mouse IgG2a, Clone 
UCHL1 
CD57 APC Biolegend (322314) Mouse IgM, Clone HCD57 
HLA-DR PerCP-Cy5.5 Biolegend (307630)  
PD-1 Brilliant Violet 421 Biolegend (329920) Mouse IgG2a, Clone L243 
*Panel 1 initially included an antibody for BCL-2 (see below): later 
substituted with anti-CD4. 
BCL-2 PE BD Biosciences 
(340576) 
Mouse IgG1, Clone 100 
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Table 2.4. T-cell subsets and activation/senescence markers – Panel 2 (Accuri C6) 
Antibody Fluorochrome Company (Ref no.) Description 
CD3 AmCyan 
BD Biosciences 
(339186) 
Mouse IgG1, Clone SK7 
CD8 APC-Cy7 Biolegend (344714) Mouse IgG1, Clone SK1 
CCR7 PE-Cy7 
BD Biosciences 
(557648) 
Rat IgG2a, Clone 3D12 
CD45RO PE Biolegend (304205) Mouse IgG1, Clone UCHL1 
CD57 APC Biolegend (322314) Mouse IgM, HCD57 
CD38 PerCP-Cy5.5 Biolegend (303522) Mouse IgG1, Clone HIT2 
CD127 
Brilliant Violet 
421 
BD Biosciences 
(562436) 
Mouse IgG1, Clone 
hIL-7R-M21 
KLRG-1 Alexa-Fluor488 Pircher, Germany 
Mouse IgG2a, Clone 
13F12F2 
 
 
 
Table 2.5. T-cell memory sorting (FACS Aria) 
Antibody Fluorochrome Company (Ref no.) Description 
CD3 AmCyan BD Biosciences (339186) Mouse IgG1, Clone SK7 
CD4 PE Biolegend (300508) Mouse IgG1, Clone RPA-T4 
CD8 APC-Cy7 Biolegend (344714) Mouse IgG1, Clone SK1 
CCR7 PE-Cy7 BD Biosciences (557648) Rat IgG2a, Clone 3D12 
CD45RO FITC Biolegend (304204) Mouse IgG2a, Clone UCHL1 
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Table 2.6. T-cell subsets and activation/senescence markers – Treated Patient 
Panel (Accuri C6) 
Antibody Fluorochrome 
Company (Ref 
no.) 
Description 
CD3 PerCP-Cy5.5 Biolegend (317336) Mouse IgG2a, Clone OKT3 
CD8 APC-Cy7 Biolegend (344714) Mouse IgG1, Clone SK1 
CD4 Alexafluor488 Biolegend (300519) Mouse IgG1, Clone RPA-T4 
CCR7 PE-Cy7 Biolegend (353226) Mouse IgG2a, Clone G043H7 
CD45RO Brilliant Violet 510 Biolegend (304246) Mouse IgG2a, Clone UCHL1 
CD57 APC Biolegend (322314) Mouse IgM, Clone HCD57 
HLA-DR PE Biolegend (307606) Mouse IgG2a, Clone L243 
PD-1 Brilliant Violet 421 Biolegend (329920) Mouse IgG1, Clone EH12.2H7 
 
 
 Flow cytometer  and compensat ion  se t -up  2.4.2.
For immunophenotyping on the Accuri cytometer, fluorescence compensation was 
achieved with Accuri C6 software. Initial compensation was applied using 
manufacturer’s recommended compensation values, which were then manually 
optimised for the panel using known positive and negative samples for each marker.  
 
For the BD FACS Canto II or BD FACS Aria, fluorescence compensations were achieved 
automatically using the BD FacsDiva software and positive (anti-mouse Ig and, where 
appropriate, anti-rat Ig) and negative control CompBeads (BD). Three drops of both 
anti-mouse Ig beads and negative control beads were added per 700 μl of FACS buffer; 
100 μl of which was transferred to fresh FACS tubes per each antibody to be 
compensated, plus an unstained control. Each antibody required for that panel (see 
respective tables in Section 2.4.1) was added to a tube containing the beads at the same 
volume that would be added to a cell sample and incubated for 10 minutes at room 
temperature (in the dark). Following incubation, the stained beads (along with one tube 
of unstained beads) were diluted with 900 μl of FACS buffer, ready to run through the 
cytometer machine. 
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The unstained control was run through the flow cytometer to gate on the beads using 
forward and side scatter, as well as to adjust voltages of the appropriate fluorescent 
channels to achieve negatively positioned populations within quadrant gates. Following 
this each single-stained compensation sample was run through the machine and the 
single peak of the positively stained bead population was tightly gated on a histogram. 
If needed, voltages were further adjusted to bring peaks into the parameters of the 
software graphs; if this adjustment was performed all previously run samples would be 
re-analysed to ensure accurate gating. Once all single-stained controls were analysed, 
BD FacsDiva software automatically calculated compensation for the panel. 
Compensation settings could then be checked by eye using a multi-stained cell sample 
for all relevant antibodies to ensure that all the cell populations aligned appropriately 
on the scatter plots.  
 
 Immunof luorescent  s ta in ing  2.4.3.
1 ml FACS buffer was added to 1-2 x 106 cells in a FACS tube and centrifuged at 470×g 
for 5 minutes, and then the supernatant discarded. Antibodies were then added directly 
to the pelleted cells before vortexing briefly and incubating for 30-45 minutes at 4°C in 
the dark. The samples were then washed a further time in FACS buffer and either 
analysed straight away or fixed in 1% paraformaldehyde (PFA) for later analysis. Cells 
for the FACS Canto II panels were always fixed before analysis. Cells destined for the 
FACS Aria were used immediately and were not fixed to allow for further downstream 
DNA (STELA) analyses. 
 
For most immunophenotyping experiments, cells were stained in a single step as above. 
However, initial experiments using Panel 1 for the FACS Canto II (Section 2.4.1, 
Table 2.3) contained an antibody for the intracellular marker BCL-2. In the first 
instance staining was performed as above for all antibodies with the exception of 
anti-BCL-2. Following the second wash 50 μl of Fixation (ThermoFisher) solution was 
added and cells were incubated for 15 minutes at room temperature, in the dark. After 
a further wash, 50 μl Perm solution (ThermoFisher) was then added to the cell pellet 
directly followed by the anti-BCL-2 and incubated for a further 15 minutes at room 
temperature. Cells were then washed a final time with FACS buffer before being 
resuspended in 1% PFA for later analysis. 
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 Fluorescent  minus  ones  (FMOs)  2.4.4.
Negative controls for this study included both unstained cells and fluorescent minus 
ones (FMOs). To achieve an FMO control, 1-2x106 cells were stained with antibodies as 
described above for standard samples, with the exception that the sample was stained 
with all antibodies minus the single antibody that the control is for (see an explanatory 
example of FMOs in Table 2.7). Samples were then incubated for 30-45 minutes at 4°C 
in the dark, as above, before washing and fixing with 1% PFA. 
 
On running and analysing the samples, FMOs were used for constitutively expressed 
markers where there is no clear positive/negative population, e.g. CCR7, HLA-DR, 
CD38, PD-1. FMOs were used to help gauge where the negative population lies, taking 
into account any fluorescent spillover from other antibodies in the panel, thus helping 
to make a more accurate gating of positive populations in the fully stained samples 
(Figure 2.1). 
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Table 2.7. Example matrix for fluorescence minus one (FMO) samples 
FMO 
Antibody 
CD3:AmCyan CD4:PE CD8:APC-Cy7 CCR7:PE-Cy7 CD45RO:FITC 
CD3 − ✔ ✔ ✔ ✔ 
CD4 ✔ − ✔ ✔ ✔ 
CD8 ✔ ✔ − ✔ ✔ 
CCR7 ✔ ✔ ✔ − ✔ 
CD45RO ✔ ✔ ✔ ✔ − 
 
 
 
 
Figure 2.1. Example of fluorescence minus one (FMO) control for flow cytometric 
analysis – CCR7:PE-Cy7. FMO sample was stained with all antibodies, with the exception of 
anti-CCR7. The CCR7 negative population was gated based on the negative population of the 
FMO sample. This gave a more accurate gating strategy than if using an unstained control as it 
accounts for fluorescence spillover from other antibodies used in the staining. 
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 Absolute  counts  2.4.5.
Absolute counts were performed using BD Trucount tubes, containing a freeze-dried 
pellet with a known quantity of fluorescent Trucount beads. To ensure volume accuracy, 
a reverse pipetting technique was employed. 
 
An antibody master mix was made for the number of samples to be stained, using T-cell 
subset Panel 1 antibodies. 2 x 106 PBMC sample was transferred to a FACS tube and 
washed with 1 ml FACS buffer. The sample was centrifuged at 470×g for 5 minutes and 
supernatant poured off. The sample was then resuspended in 50 μl of FACS buffer and 
transferred to the Trucount tube, ejecting the sample just above the metal retainer. The 
appropriate volumes of antibodies were added to the Trucount tube from the antibody 
mastermix. The tube was then vortexed gently to mix, and incubated for 15 minutes at 
room temperature in the dark. 
 
Following incubation 200 μl of FACS buffer was added and the sample was stored 
covered and on ice, until ready to run through the BD FACS Canto II flow cytometer. 
Prior to running samples on the flow cytometer, each sample was vortexed gently and 
PMT voltages were adjusted on the machine in order to visualise the forwards and side 
scatter profile of the beads (SSC-A/FSC-A). 
 
Following data acquisition, the following calculation was performed in Excel to 
determine absolute counts: 
 
 
Where the number of events in the region containing the cell is the count within the 
gated population of interest, and the absolute count bead region is gated in the 
forward/side scatter graph. The number of beads per test was obtained from the 
Trucount packaging (number varies from lot to lot) and the test volume was the final 
volume of PBMC, antibodies and FACS buffer added to the Trucount tube.  
 
 Stat i s t ica l  ana lyses  2.4.6.
Phenotypic data was collated in Excel, and statistics performed in GraphPad Prism. 
Initial column statistics were performed to analyse distribution of immunophenotyping 
data and determined that the majority of columns were non-parametric: therefore, use 
# of events in region containing cell 
# of events in absolute count bead region 
# of beads per test 
test volume X = 
absolute count 
of cell 
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of non-parametric tests were applied. The Mann-Whitney U test was used to analyse 
differences between two independent parameters (HD versus CLL) and the 
Kruskal-Wallis test with post-hoc Dunns was applied for comparisons between three or 
more variables (HD versus CLLNR versus CLLIR). Correlation analyses were performed 
using Spearman’s rank correlation coefficient and Kaplan-Meier curves were used to 
determine survival. For associations between Inverted Ratio and clinical data, Fisher’s 
exact test was used. Pestle (Pestle 1.7) was used to convert data text files into SPICE 
files, and SPICE (SPICE 5.3 software) was used to create pie chart overviews and 
calculate significance between pies and variables. Multivariate analyses were performed 
by Professor Robert Hills (Haematology Clinical Trials Unit, Cardiff University). 
 
 
 Single  te lomere  length  analys i s  (STELA) o f  T -ce l l  subsets  2.5.
 
 Acquis i t ion  o f  samples  2.5.1.
Isolated PMBC were separated via autoMACS as described in Section 2.3. The 
CD19-negative fraction was retained and stained with the T-cell memory sorting 
antibody panel (Section 2.4.1, Table 2.5) and FACS sorted using BD FACS Aria for 
CD4+, CD8+ and CD8+ memory T-cells into 1.5 ml eppendorf tubes. Cells were pelleted 
by spinning at 3400×g for 5 minutes, and the supernatant removed. Cells were then 
washed twice in 1 ml PBS and all but 20 μl of supernatant removed. Samples were 
then stored on ice ready for DNA extraction. 
 
 DNA extract ion  2.5.2.
DNA extraction was performed using QIAamp DNA Micro kits (Qiagen) according to 
manufacturer instructions (Figure 2.2). Briefly, 80 μl of Buffer ATL was added to the 20 
μl samples to make a final volume of 100 μl. Buffer AL (100 μl per sample) was 
aliquoted into a fresh eppendorf tube and 1 μl of carrier RNA added per 100 μl of 
Buffer AL. 10 μl proteinase K and 101 μl of the Buffer AL/carrier RNA mix were then 
added to each sample sequentially and mixed by vortexing for 15 seconds. The samples 
were then transferred to a heating block and incubated at 56°C for 10 minutes. 
 
Following incubation, samples were pulse-centrifuged briefly to remove droplets from 
the lid before adding 50 μl 100% ethanol (stored at −20°C) and pulse-vortexing again 
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for 15 seconds. Samples were incubated for 3 minutes at room temperature and briefly 
centrifuged to remove droplets from the lid.  
 
Cell lysate was carefully transferred to a QIAamp MinElute column (inside a 2 ml 
collection tube), the lid closed and sample centrifuged at 6000×g for 1 minute to allow 
the lysate to pass through the membrane. The collection tube and flow-through was 
then discarded and the MinElute column transferred to a fresh collection tube. 500 μl 
Buffer AW1 was added to the MinElute column and centrifuged as before, discarding 
the collection tube for a fresh one. The same process was then repeated with 500 μl 
Buffer AW2. The column was then centrifuged at full speed for 3 minutes to dry the 
column membrane completely, before transferring the MinElute column into a fresh 
1.5 ml eppendorf tube (lid removed). An appropriate amount of Buffer AE (between 
20-100 μl, depending on the number of cells in the original sample) was added to the 
column and incubated for 5 minutes at room temperature. Tubes were then centrifuged 
at full speed for one minute. To ensure complete elution of the DNA, the flow through 
was then transferred back into the MinElute column and incubated for a further 
5 minutes, then centrifuged. The MinElute column was discarded and DNA sample was 
then quantified or stored at −80°C for future quantification. 
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Figure 2.2. Brief overview of the QIAamp DNA Micro procedure, used to isolate 
DNA from T-cell populations. CD19− PBMC was cell-sorted to obtain whole CD4+ T-cells, 
whole CD8+ T-cells and CD8+ memory T-cell populations. DNA was isolated from these 
populations using the QIAamp DNA micro kits (Qiagen) according to manufacturers instructions. 
Figure obtained from QIAamp® DNA micro handbook (3rd ed., 2014). 
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 DNA quant i f i ca t ion 2.5.3.
DNA was quantified using a fluorometer and Hoechst DNA quantification kit (BioRad). 
The fluorometer was turned on and left to warm up for a minimum of 30 minutes prior 
to DNA quantification. DNA samples were kept on ice at all times and, if frozen, left on 
ice to thaw prior to quantification. An appropriate volume of 1XTEN was made for the 
number of samples, before adding Hoechst for a 1:10,000 dilution (i.e. for 100 ml 
1XTEN, 10 μl Hoechst would be added). Blank and Standard controls were used for 
fluorometer calibration: 2 ml of 1XTEN/Hoechst was transferred to a fresh cuvette for 
the Blank control, and the Standard control was made by adding 10 μl calf thymus DNA 
(100 ng/μl) to a second cuvette with 2 ml 1XTEN/Hoechst.  
 
To quantify the DNA, 2 μl of the DNA sample was added to a fresh cuvette with 2 ml 
1XTEN/Hoechst. The cuvette was placed in the fluorometer and the relative fluorescent 
unit (RFU) value recorded. Each sample was measured in triplicates and the mean RFU 
was used to give the quantity of DNA (ng/μl). 
 
 STELA polymerase  cha in  react ion  (PCR) 2.5.4.
Following quantification of DNA, PCR was performed. If the initial concentration of 
sample DNA was above 10 ng/μl, DNA was further diluted with tris-HCl to a 
concentration of 10 ng/μl in 20 μl total. Telorette 2/DNA mix (Tel2/DNA) was then 
prepared using 1 μl DNA (10 ng/μl), 1 μl Tel2 (10 μM) and 38 μl tris-HCl. If the 
original DNA concentration was <10 ng/μl the dilution step was missed and a sample 
volume equivalent to 10 ng DNA was added to 1 μl Tel2 and the volume of tris-HCl 
adjusted accordingly to give a final volume of 40 μl.  
 
For this study 6 PCR reactions were carried out per DNA sample, but calculations were 
made to allow for 7 reactions to allow for error. PCR reaction mix was made in a 1.5 ml 
eppendorf as described in Table 2.8 for the number of samples needed (e.g. if doing 
PCR for 5 patient samples, with 7 reactions per sample, a PCR mastermix for 35 
reactions is needed). The telomere specific primer used in this study was XpYpE2. The 
reagents were added to a fresh eppendorf with the exception of the Taq/PWO. 7 μl of 
each DNA/Tel2 was added to a fresh 0.5 ml eppendorf. Taq/PWO was transferred from 
a freezer (−20°C) to cold block (also stored at −20°C) and the required volume quickly 
added to the reaction mix. The reaction mix was then mixed briefly by gently inverting 
the tube and 63 μl was added to the 7 μl aliquots of DNA/Tel2 and briefly mixed again. 
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The final PCR mix was then transferred to PCR strips in 10 μl aliquots (6 aliquots for 
each strip). 10 μl mineral oil was then dropped on the surface of each PCR reaction and 
strips transferred to a PCR block and run through a primer-dependant PCR programme.  
For XpYpE2 primers the programme was 22 cycles of: 94°C, 20 seconds; >65°C, 
30 seconds; >68°C, 8 minutes. On completion of the programme samples were kept at 
10°C in the PCR block until ready to use, or transferred to be stored at 4°C. 
 
Table 2.8. Reagents for PCR master mix, with 7 reactions used per DNA sample. 
Reagent 1 reaction (μ l) 7 reactions (μ l) 
H2O 4.98 34.9 
Taq 10xbuffer 1 7.0 
MgCl2 (25mM) 0.8 5.6 
NTPs (100mM total) 0.12 0.84 
Teltail  (5µM) 1 7.0 
Telomere specific primer XpYpE2 (5µM) 1 7.0 
Taq/Pwo (10:1)* 0.1 0.7 
Total volume 9.0 63.0 
*Taq/Pwo to be added directly before aliquoting to DNA/Tel2 
 
 Gel  e lec trophores is  2.5.5.
Forty well 0.5% agarose gels were prepared in a 40 cm submarine gel tank: 2 g agarose 
MP (Roche) was completely dissolved in 400 ml 1xTAE by heating in a microwave. 
Once the agarose had cooled to hand hot temperature 40 μl ethidium bromide 
(10 mg/ml) solution was added and mixed in gently. The agarose was then poured into 
the 40 cm submarine containing a 40 well comb and left for a minimum of 30 minutes 
to set. Once set the gel was submerged in 1xTAE, which was left to cool for a minimum 
of 30 minutes via buffer circulation through a cooling incubator before sample loading. 
 
PCR samples were prepared for loading by adding 2 μl 6x Ficoll loading dye to each 
reaction. DNA ladders were prepared using 0.5 μl 1 kb ladder (Stratagene), 0.5 μl 
2.5 kb ladder (Bio-Rad), 1 μl 6xFicoll and 4 μl of ddH2O per ladder lane needed. 5 μl 
of sample (or ladder) were then loaded per lane and the gel was run overnight with 
chilled buffer recirculation at 120v (approximately 60mA). 
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 Southern  b lo t t ing  2.5.6.
Once removed from the tank, gels were visualised using a UV transilluminator and, 
using the DNA ladder as a guide, was cut above the largest fraction and below the 
smallest fraction. Gels were then transferred to a shallow tray and washed twice in 
depurination buffer (0.25 M HCl) for 6 minutes on a shaker. Following each 
depurination wash, the gel was briefly washed in milli-Q water. Following depurination 
gels were then washed for 15 minutes with denaturation buffer (1.5 M NaCl, 500 mM 
NaOH). Gels were then transferred to a Southern Blot system, as outlined in Figure 2.3. 
Briefly, Whatman paper was placed over a glass plate in a deep tray and wetted with 
denaturation buffer until buffer filled the tray to a depth of approximately 5 cm and the 
sides of the Whatman paper dipped into the buffer. A second piece of Whatman paper, 
cut to the size of the glass plate, was then placed on top of the first and wetted. The gel 
was then transferred on top of the Whatman paper and Hybond-XL GE membrane  (cut 
to the size of the gel) placed directly on top. Clingfilm was placed around the gel to 
prevent the buffer short-circuiting. The gel was then covered by a third Whatman paper 
pre-wet with denaturation buffer (cut to the size of the gel) and paper towels. Pressure 
was applied by placing another (dry) glass plate with a 500ml glass bottle filled with 
water on top of the blot. This was then left to blot for a minimum of 4 hours, 
occasionally replacing the wet paper towels as needed. After blotting the membrane was 
removed ready for hybridisation, or dried and stored until needed. 
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Figure 2.3. Southern blot system for STELA. 
 
 
!
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 Radioact ive  labe l l ing  o f  STELA membranes .  2.5.7.
1 μl of telomere probe DNA (25 ng/μl) was diluted with 44 μl TE buffer and denatured 
by incubating at 96°C for 5 minutes, followed by snap cooling on ice for 5 minutes. 
After briefly centrifuging, the DNA was then transferred to a 1.5 ml tube containing a 
DNA labelling bead or rediprime II labelling system (Amersham/GE Biosciences) and 
gently pipetted until the bead/mix had dissolved. 4 μl of 33P isotope was then added 
and the mix was incubated for a minimum of 1 hour in a water bath set to 37°C. Once 
incubation was complete the tube was once again briefly centrifuged and 1 μl of pre-
labelled 1 Kb/2.5 Kb ladder marker was added. The probe was then diluted with 50 μl 
ddH2O (giving a total volume of 100 μl). The probe could then be used straight away or 
stored at 4°C until needed.  
 
STELA southern blots were briefly washed in ddH2O before transferring to a clean 
hybridisation bottle (ensuring the side with DNA was facing inwards) with 15 ml church 
buffer (hybridisation buffer). Bottles were then placed in the hybridisation oven and 
incubated at 56°C until ready to add the probe. The radioactive probe was denatured by 
incubating at 96°C for 5 minutes, then used immediately. Bottles were removed from 
the oven and 25 μl of the denatured probe was added to each bottle before being 
returned to the oven. Bottles were left to incubate for at least overnight.  
 
Following sufficient incubation, the hybridisation solution was then carefully disposed 
of down the designated sink. The membrane then underwent three brief washes with 
50 ml pre-warmed wash buffer, allowing the membrane to roll and unroll. The bottle 
was then returned to the oven with 50 ml wash buffer and incubated twice for 
30 minutes, replacing the wash buffer between incubations. The membranes were 
briefly washed a further 3 times before removing the membrane and placing DNA side 
up on 3MM folded paper, patted dry with a piece of blue roll and placed in an oven to 
dry. Once completely dry, membranes were transferred to storage cassettes with a 
phosphoimager screen (Amersham) that had been ‘blanked’ using a 15 minute exposure 
to visible light and left for a minimum of 24 hours. The screen was then visualised by 
scanning with Typhoon 9410 or Typhoon 9500 biomolecular imager (GE Healthcare). 
 
 Stat i s t ica l  ana lys i s  2.5.8.
Gel images were analysed using ImageQuant. The telomeres visualised on the blot were 
identified and molecular weights calculated using Phoretix 1D software. Microsoft Excel 
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was used to obtain actual telomere lengths (by subtracting the STELA primer) and 
calculate mean, standard deviation, standard error and 95% confidence intervals. 
General statistical analyses of telomere lengths were performed in GraphPad Prism. 
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Chapter 3 
Immunophenotyping of CD8+ T-cells in CLL 
Although a B-cell malignancy, altered immunological function has long been observed 
within the T-cell compartment of CLL patients (Whelan et al. 1982; Rossmann et al. 
2002; Riches et al. 2013). These T-cell abnormalities may reduce any immunological 
response against the disease, and may thereby contribute to the CLL pathology. Recent 
studies exploring the CLL T-cell compartment have revealed a sub-group of patients 
with a preferential expansion within the CD8+ T-cell subset, leading to an inverted 
CD4:CD8 T-cell ratio (Nunes et al. 2012; Gonzalez-Rodriguez et al. 2010). Nunes et al. 
(2012) demonstrated that patients showing this inverted phenotype had shorter time to 
first treatment and a poorer prognosis. Therefore, immunophenotypic characterisation 
of CD8+ T-cells, particularly within the inverted ratio cohort, may help further 
understanding of the role of T-cells within CLL pathology. 
 
The main aim of this chapter was to further explore the CD8+ T-cell phenotypes in CLL 
using multi-colour flow cytometry. This study used the peripheral blood mononuclear 
cells (PBMC) from 99 CLL patients and 14 age-matched healthy donors. 25 of the 99 
CLL patients were analysed using a 4-colour T-cell memory panel (see Chapter 2, 
Table 2.2) and the full phenotypic analysis was performed on the remaining 74 patients 
(see Chapter 2, Tables 2.3 and 2.4). The majority of CLL patients tested (63/74 [85%]) 
were Binet Stage A. These patients were analysed as a complete cohort, and also 
stratified into subgroups according to their CD4:CD8 ratio; patients with a ratio <1.0 
were considered to have an inverted ratio (CLLIR) whereas patients with a ratio >1.0 
were assigned a normal ratio (CLLNR) (Nunes et al. 2012).  
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Figure 3.1. Gating strategy used for phenotypic analysis of CD8+ T-cells derived 
from CLL patients and healthy donors. (A) Cells were labelled with an 8-colour panel of 
antibodies (see Chapter 2 Materials and methods, Tables 2.3 and 2.4 for complete antibody list) 
prior to data acquisition using flow cytometry (FACS CantoII, BD FACSDiva) and analysed with 
FlowJo (v.9). Lymphocytes were gated based on forward and side scatter profile; single cells 
were gated by forward scatter area and height. CD8+ T-cells were identified by gating on CD3+ 
and then CD8+ populations. Memory T-cell subsets were defined using CCR7 and CD45RO 
memory markers: naïve (CCR7+CD45RO−), central memory (CM, CCR7+CD45RO+), effector 
memory (EM, CCR7−CD45RO+) and EMRA (CCR7−CD45RO−). (B) Gating strategy for activation 
and senescence/exhaustion markers within the CD8+ T-cell compartments and memory subsets. 
The boundary of the gating was determined by using fluorescence-minus-one (FMO) controls 
where necessary. 
0 50K 100K 150K 200K 250K
FSC-A
0
50K
100K
150K
200K
250K
SS
C
-A
66.4
0 50K 100K 150K 200K 250K
FSC-A
0
50K
100K
150K
200K
250K
FS
C
-H
99.8
0 102 103 104 105
<AmCyan-A>: CD3
0
2000
4000
6000
# 
C
el
ls
2.86
Lymphocytes Single Cells CD3+ T-cells 
0 103 104 105
<APC-Cy7-A>: CD8
0
102
103
104
105
<P
E-
A
>:
 C
D
4
56.2 0.4171.84
315.93 3.35
CD4+/CD8+ T-cells 
0 102 103 104 105
<FITC-A>: CD45RO
0
103
104
105
<P
E-
C
y7
-A
>:
 C
C
R
7
9.49 0.774
28.761
CD8+ Memory Subsets 
Gating Strategy for CD8+ T-cells 
A 
Pa
ne
l 1
 
0 102 103 104 105
<FITC-A>: KLRG1
0
102
103
104
105
<A
m
C
ya
n-
A
>:
 C
D
3
72.5
0 102 103 104 105
<Pacific Blue-A>: CD127
0
102
103
104
105
<A
m
C
ya
n-
A
>:
 C
D
3
64.6
0 103 104 105
<PerCP-Cy5-5-A>: CD38
0
102
103
104
105
<A
m
C
ya
n-
A
>:
 C
D
3
3.3
Pa
ne
l 2
 
CD57 
0 103 104 105
<APC-A>: CD57
0
102
103
104
105
<A
m
C
ya
n-
A
>:
 C
D
3
29.9
0 102 103 104 105
<Pacific Blue-A>: PD-1
0
102
103
104
105
<A
m
C
ya
n-
A
>:
 C
D
3
24.7
0 103 104 105
<PerCP-Cy5-5-A>: HLA-DR
0
102
103
104
105
<A
m
C
ya
n-
A
>:
 C
D
3
8.1
PD-1 HLA-DR 
KLRG-1 CD127 CD38 
B 
Chapter 3: Results 
61 
 Memory subsets  3.1.
The T-cell compartment can be divided into functionally different subsets: naïve, 
Central Memory (CM), Effector Memory (EM) and EMRA (Sprent and Surh 2002; 
Sallusto et al. 2004; Harty and Badovinac 2008). These subsets can be phenotypically 
defined based on the co-expression of different cell-surface markers; in this study CCR7 
and CD45RO were used (for gating strategy see Figure 3.1A).  
 
Distinct differences in CD8+ memory subset distribution were observed between the CLL 
cohort and the healthy donors (Figure 3.2). Specifically, the CLL cohort showed a 
significant 3-fold reduction within the naïve subset (p <0.001) as well as a reduction in 
the CM compartment (p = 0.0013). On the other hand the EM subset was significantly 
increased in CLL patients (p = 0.0087); the EMRA subset was also increased in 
frequency in CLL patients but this did not reach significance. The CD8+ population 
therefore demonstrated a marked shift towards a differentiated memory phenotype 
when compared with age-matched healthy donors. 
 
To determine whether the shift towards a memory phenotype contributed to the 
different CD4:CD8 ratios found in CLL patients, the cohort was stratified into inverted 
and normal ratio subgroups (Figure 3.3). Patients with an inverted ratio (CLLIR, 
CD4:CD8 ratio <1.0) had a more significant decrease in the naïve subset when 
compared with both the healthy donors and CLL patients with a normal ratio (CLLNR) 
(p ≤0.001 for both).  A stepwise increasing trend (CLLIR>CLLNR>HD) was seen in both 
the EM and EMRA subsets, with the CLLIR EM subset showing a significantly increased 
frequency when compared with healthy donors (p ≤0.01). 
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Figure 3.2. Comparison of CD8+ T-cell memory subsets in CLL patients (n = 99) 
and age-matched healthy donors (HD, n = 14). Cells were collected using flow 
cytometry (FACS CantoII, BD FACSDiva) and analysed with FlowJo (v.9) using gating as 
described in Figure 3.1. Pairwise statistical analysis (HD vs CLL) was performed using the 
non-parametric Mann-Whitney test. Significant results were included on the graph 
(* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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Figure 3.3. Comparison of CD8+ T-cell memory subsets in healthy donors (HD, 
n = 14) and CLL patients with a normal (CLLNR, n = 63) and inverted (CLLIR, 
n = 36) CD4:CD8 T-cell ratio. Cells were collected using flow cytometry (FACS CantoII, 
BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 3.1. CLL 
patients with a CD4:CD8 ratio <1.0 were considered inverted. Three-way ANOVA statistical 
analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data 
assessed using the Dunn’s post-test.  Significant results were included on the graph 
(* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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 Phenotyp ic  overv iew 3.2.
Previous work has shown a preferential expansion within the CD8+ population of some 
CLL patients that is linked with a more differentiated, potentially senescent phenotype 
(Nunes et al. 2012). Consequently, the phenotypic composition of the CD8+ 
compartment was further explored in this study using additional markers for senescence 
(KLRG-1), activation (HLA-DR, CD38), and differentiation (CD127), across two 
multi-colour flow cytometry panels (for gating strategy see Figure 3.1B). 
 
Pie charts were generated using SPICE version 5.3 (Roederer et al. 2011) to provide an 
expansive overview of the relationships between the different markers. This 
demonstrated the phenotypic complexity within the CD8+ T-cell compartment of CLL 
patients (Figure 3.4). SPICE also performed statistical analysis to compare the 
differences in pies (permutation analyses, Table 3.1 and 3.2) and marker combinations 
(two-tailed t-tests: see Appendix I for t-test tables). Overall, there were significant 
phenotypic differences between the CLL patients and healthy age-matched donors 
(Table 3.1). The pie charts clearly show that the CLL patients possessed a greater 
proportion of CD8+ T-cells that were positive for one or more of the phenotypic markers 
used in both panels; co-expressing 2 or 3 markers in particular. For example, by looking 
at the arcs above the Panel 1 pie charts it can be seen that there were greater numbers 
of CD8+ T-cells co-expressing CD57 and HLA-DR in CLL patients versus healthy donors 
(p = 0.0012), as well as CD57+PD-1+ (p = 0.0003) and HLA-DR+PD-1+ (p <0.0001). 
An expansion of triple-positive CD57+HLA-DR+PD-1+ cells in CLL was also observed 
(p <0.0001). Similarly, the Panel 2 pie charts demonstrated that CLL patients had a 
higher proportion of triple positive CD57+CD38+CD127+ (p = 0.0002), 
CD57+KLRG-1+CD38+ (p = 0.0012), CD57+CD127+KLRG-1+ (p = 0.0001) CD8+ 
T-cells than healthy donors. Overall, there appeared to be a greater complexity of T-cell 
subsets in the CLL patients as more phenotypically distinct groups of T-cells could be 
defined based on differential expression of the markers studied.  
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Furthermore, distinct phenotypic differences between the stratified CLLNR and CLLIR 
cohorts were also seen in both panels (Figure 3.5, Table 3.2). Compared to the healthy 
donors, the proportion of CD8+ T-cells expressing one or more of the markers was 
higher in the CLLNR sub-group and even higher in the CLLIR sub-group. For Panel 1, 
CD57+HLA-DR+ expressing T-cells were increased in the CLLIR cohort compared to both 
CLLNR (p = 0.0010) and healthy donors (p <0.001). The population of the triple 
positive (CD57+HLA-DR+PD-1+) cells was also higher in CLLIR, but only significant 
against healthy donors (p <0.0001). Testing with Panel 2 revealed that 
CD57+KLRG-1+CD38+ T-cells made up a higher proportion of the CLLIR subgroup 
compared to both CLLNR and healthy donors (p = 0.0026 and p 0.0002, respectively). 
 
These pie charts clearly present overall phenotypic differences in the CD8+ T-cells of 
CLL patients and healthy donors. They also show that certain phenotypes are 
exacerbated within the CLLIR subgroup. In the following sections, the distribution of 
single and co-expressed markers will be compared between CLL and healthy donors in 
more detail.  
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Table 3.1 Overall CD8+ phenotypic pie chart analysis (HD vs CLL) 
 
 
 
 
Table 3.2 Overall CD8+ phenotypic pie chart analysis (HD vs CLLNR vs CLLIR) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Panel HD vs CLL 
Panel 1 <0.0001 
Panel 2 0.0130 
Panel HD vs CLLNR HD vs CLLIR CLLNR vs CLLIR 
Panel 1 0.0006 <0.0001 <0.0001 
Panel 2 0.1342 <0.0001 0.0004 
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 Markers  assoc ia ted  with  senescence  and/or  exhaust ion  3.3.
 
 CD57 and PD-1  3.3.1.
Previous work showed higher levels of CD57+ and PD-1+ cells within the CD8+ T-cell 
compartment of CLL patients when compared with healthy donors (Nunes et al. 2012). 
In keeping with this, the current study also showed that CLL patients had a significantly 
higher frequency of PD-1+ CD8+ T-cells compared with healthy donors (p = 0.0001, 
Figure 3.6A). When subdividing into memory subsets, the increase in PD-1 frequency 
was observed in both the EM and EMRA subsets (p = 0.0013 and p = 0.008, 
respectively). When stratified based on ratio, the CLLNR and CLLIR subgroups 
demonstrated significantly higher PD-1 frequencies than healthy donors in both the EM 
(p ≤0.05 and p ≤0.01) and EMRA (p ≤0.01 and p ≤0.05) subsets (Figure 3.6B): 
however, no difference was seen between the CLLNR and CLLIR subgroups. This implies 
that although PD-1 is a T-cell marker of interest in CLL, its expression is not associated 
with the inverted ratio in this cohort. 
 
The frequency of CD57+ T-cells was also higher in the CLL cohort than healthy donors 
(p = 0.0063, Figure 3.7A). Similar to PD-1, the subsets containing the highest 
frequencies of CD57+ T-cells were the EM and EMRA subsets, although only the EMRA 
subset was significantly increased compared to healthy donors (Figure 3.7A, 
p = 0.0281). CLLIR patients had significantly higher CD57 frequency within the whole 
CD8+ T-cell compartment versus both CLLNR and healthy donors (p ≤0.05 and 
p ≤0.001, Figure 3.7B). Interestingly, CD8+CD57+ did not differ in the EMRA subset of 
CLLNR and CLLIR patients, but the EM population of CLLIR patients demonstrated a 
dramatic increase in this phenotype that was on average 2-fold higher than both the 
CLLNR subgroup and healthy donors (p ≤0.001 and p ≤0.05, respectively). This 
suggests that it is the EM population, not the EMRA population, which predominantly 
contributes to the increase in CD8+CD57+ T-cells in CLLIR patients. 
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Figure 3.6. PD-1 frequency in CD8+ T-cell memory subsets of CLL patients and 
healthy donors. Cells were collected using flow cytometry (FACS CantoII, BD FACSDiva) and 
analysed with FlowJo (v.9) using gating as described in Figure 3.1. (A) CD8+PD-1+ T-cells in the 
whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA memory subsets of CLL patients 
(n = 74) and healthy donors (n = 14).  Pairwise statistical analysis (HD vs CLL) was 
performed using the non-parametric Mann-Whitney test. Patients were stratified based on 
CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a ratio ≥1.0 were 
considered normal ratio patients (CLLNR). (B) Frequency of CD8+PD-1+ T-cells in the whole CD8+ 
T-cell compartment, CD8+ EM and CD8+ EMRA memory subsets of CLLNR (n = 47), CLLIR 
(n = 27) and healthy donors (n = 14). Three-way ANOVA statistical analysis was performed 
using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data assessed using the Dunn’s 
post-test. Significant results were included on the graph (* = p ≤0.05; ** = p ≤0.01; 
*** = p ≤0.001). 
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Figure 3.7. CD57 frequency in CD8+ T-cell memory subsets of CLL patients and 
healthy donors. Cells were collected using flow cytometry (FACS CantoII, BD FACSDiva) and 
analysed with FlowJo (v.9 using gating as described in Figure 3.1. (A) CD8+CD57+ T-cells in the 
whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA memory subsets of CLL patients 
(n = 74) and healthy donors (n = 14). Pairwise statistical analysis (HD vs CLL) was performed 
using the non-parametric Mann-Whitney test. Patients were stratified based on CD4:CD8 ratio: a 
ratio <1.0 was considered inverted (CLLIR). Patients with a ratio ≥1.0 were considered normal 
ratio patients (CLLNR). (B) Frequency of CD8+CD57+ T-cells in the whole CD8+ T-cell 
compartment, CD8+ EM and CD8+ EMRA memory subsets of CLLNR (n = 47), CLLIR (n = 27) 
and healthy donors (n = 14). Three-way ANOVA statistical analysis was performed using 
Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data assessed using the Dunn’s 
post-test. Significant results were included on the graph (* = p ≤0.05; ** = p ≤0.01; 
*** = p ≤0.001). 
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In addition to looking at the PD-1 and CD57 independently, the relationship between 
CD57 and PD-1 was further explored by investigating co-expression of the two 
molecules on the same cell. As seen in Figure 3.8A, CLL patients had significantly higher 
CD57+PD-1+ co-expression in the whole CD8+ T-cell compartment when compared with 
age-matched healthy donors (p = 0.0012). When divided into memory subsets, 
significantly higher CD57+PD-1+ frequency was observed in both the CD8+ EM and 
EMRA subsets (p = 0.0077 and p = 0.0026, respectively). No significant change was 
seen in CD57+PD-1+ frequency in the overall CD8+ compartment or the EM/EMRA 
subsets of CLLIR and CLLNR patients (Figure 3.8B). CD57 co-expression with PD-1 is 
therefore not a factor associated with inverted ratio in this CLL cohort. 
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Figure 3.8. CD57 and PD-1 co-expression in CD8+ T-cell memory subsets of CLL 
patients and healthy donors. Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 3.1. (A) 
CD8+CD57+PD-1+ T-cells in the whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA 
memory subsets of CLL patients (n = 74) and healthy donors (n = 14). Pairwise statistical 
analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney test. Patients were 
stratified based on CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a 
ratio ≥1.0 were considered normal ratio patients (CLLNR). (B) Frequency of CD8+CD57+PD-1+ 
T-cells in the whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA memory subsets of 
CLLNR (n = 47), CLLIR (n = 27) and healthy donors (n = 14). Three-way ANOVA statistical 
analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data 
assessed using the Dunn’s post-test. Significant results were included on the graph 
(* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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 CD57 and KLRG-1 3.3.2.
KLRG-1 is a marker associated with poor proliferative capacity in a more highly 
differentiated memory T-cell type (Göthert et al. 2013; Ibegbu et al. 2005). The CLL 
cohort showed a trend of increase in KLRG-1 frequency within the CD8+ compartment 
and the more differentiated memory subsets (Figure 3.9A), but only the EM subset 
showed a significant increase (p = 0.0096). Subdividing by T-cell ratio showed that 
the CLLIR CD8+ compartment had significantly higher expression of KLRG-1 than both 
the CLLNR patients and healthy donors (p ≤0.05 for both, Figure 3.9B). Sub-dividing 
further into memory subsets demonstrated that the increased expression of KLRG-1 was 
within the EM subset of CLLIR group when compared to healthy donors (p ≤0.05) but 
not CLLNR patients: again the EMRA subset showed an increasing trend, but this was not 
significant (p = 0.1252). 
 
KLRG-1 and CD57 have been associated together as markers of senescence (Ibegbu et 
al. 2005). Therefore this study tested whether the co-expression of the two markers 
associated with CLL disease (Figure 3.10A). CD57+KLRG-1+ cells were present at a 
significantly higher frequency within the total CLL CD8+ T-cell compartment than the 
healthy donors (p = 0.0065). This phenotype was also significantly increased within 
the CD8+ EM subset (p = 0.0104), and the EMRA subsets showed a similar increasing 
trend, though it did not reach statistical significance (p = 0.0646). 
 
Stratification of the CLL cohort into the CLLIR and CLLNR subgroups showed the same 
patterns of increase as seen in KLRG-1 frequency alone; increased frequency of 
CD57+KLRG-1+ was exaggerated in the total CD8+ T-cells of the CLLIR cohort compared 
to CLLNR group (p ≤0.05) and healthy donors (p ≤0.001; Figure 3.10B). The stepwise 
pattern of increased frequency between HD, CLLNR and CLLIR was also reflected within 
the CD8+ EM and EMRA T-cells. However, a significant difference was only seen within 
the EM subset (p ≤0.05) when compared to healthy donors. 
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Figure 3.9. KLRG-1 frequency in CD8+ T-cell memory subsets of CLL patients and 
healthy donors. Cells were collected using flow cytometry (FACS CantoII, BD FACSDiva) and 
analysed with FlowJo (v.9) using gating as described in Figure 3.1. (A) CD8+KLRG-1+ T-cells in 
the whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA memory subsets of CLL patients 
(n = 74) and healthy donors (n = 14). Pairwise statistical analysis (HD vs CLL) was 
performed using the non-parametric Mann-Whitney test. Patients were stratified based on 
CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a ratio ≥1.0 were 
considered normal ratio patients (CLLNR). (B) Frequency of CD8+KLRG-1+ T-cells in the whole 
CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA memory subsets of CLLNR (n = 47), CLLIR 
(n = 27) and healthy donors (n = 14). Three-way ANOVA statistical analysis was performed 
using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data assessed using the Dunn’s 
post-test. Significant results were included on the graph (* = p ≤0.05; ** = p ≤0.01; 
*** = p ≤0.001). 
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Figure 3.10. CD57 and KLRG-1 co-expression in CD8+ T-cell memory subsets of 
CLL patients and healthy donors. Cells were collected using flow cytometry (FACS CantoII, 
BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 3.1. (A) 
CD8+CD57+KLRG-1+ T-cells in the whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA 
memory subsets of CLL patients (n = 74) and healthy donors (n = 14). Pairwise statistical 
analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney test. Patients were 
stratified based on CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a 
ratio ≥1.0 were considered normal ratio patients (CLLNR). (B) Frequency of CD8+CD57+KLRG-1+ 
T-cells in the whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA memory subsets of 
CLLNR (n = 47), CLLIR (n = 27) and healthy donors (n = 14). Three-way ANOVA statistical 
analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data 
assessed using the Dunn’s post-test. Significant results were included on the graph 
(* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001) 
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Although patterns of increased KLRG-1+ and CD57+KLRG-1+ were seen in the CLL 
cohort, and in some cases the increases were exacerbated within the CLLIR subgroup, 
they did not always reach significance. For example, in the case of the CD8+ EM subset 
significance was observed between the inverted group and healthy donors, but not in 
inverted versus normal ratio. Therefore, although a facet of ratio inversion may include 
the accumulation of these ‘phenotypically senescent’ cells, it is not a defining feature of 
the inverted ratio. 
 
 CD127 3.3.3.
IL-7 is a key cytokine for lymphocyte growth and differentiation, including the 
proliferation required to maintain T-cell memory populations (A. Ma et al. 2006). The 
IL-7 receptor (IL-7R) would therefore be a good potential marker for non-senescent 
cells that are still able to undergo activation and divide. This study looked at the 
expression of IL7Rα (CD127), a molecule that forms part of the IL-7R. Reduced IL7Rα 
expression has previously been associated with a more differentiated phenotype 
(Golden-Mason et al. 2006). As a whole, the presentation of this marker in the CLL 
cohort showed significance in only the naïve subset: a 2-fold reduction in CD127 
frequency was seen in CLL versus healthy donors (p = 0.0008; Figure 3.11A). 
 
As shown in Figure 3.11B, CLLIR patients a significant reduction in the frequency of 
CD127+ CD8+ T-cells compared to CLLNR patients and healthy donors (p ≤0.01 and 
p ≤0.05 respectively). This was primarily reflected in the 3-fold decrease in the 
CD8+CD127+ naïve population, (p≤0.001 for both), and appeared to reflect the 3-fold 
reduction of the CLLIR naïve population as a whole (Section 3.1, Figure 3.3). The 
frequency of CD127+ T-cells was also lower in the CD8+ EM and EMRA subsets of CLLIR 
patients compared to the CLLNR subgroup (p ≤0.05 for both). 
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Figure 3.11. CD127 in CD8+ T-cell memory subsets of CLL patients and healthy 
donors. Cells were collected using flow cytometry (FACS CantoII, BD FACSDiva) and analysed 
with FlowJo (v.9) using gating as described in Figure 3.1. (A) CD8+CD127+ naïve T-cells of CLL 
patients (n = 74) and healthy donors (n = 14). Pairwise statistical analysis (HD vs CLL) was 
performed using the non-parametric Mann-Whitney test. Patients were stratified based on 
CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a ratio ≥1.0 were 
considered normal ratio patients (CLLNR). (B) Frequency of CD8+CD127+ T-cells in the whole 
CD8+ T-cell compartment, CD8+ Naïve, CD8+ EM and CD8+ EMRA memory subsets of CLLNR 
(n = 47), CLLIR (n = 27) and healthy donors (n = 14). Three-way ANOVA statistical analysis 
was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data assessed 
using the Dunn’s post-test. Significant results were included on the graph (* = p ≤0.05; 
** = p ≤0.01; *** = p ≤0.001). 
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 CD127 and KLRG-1 3.3.4.
Differential expression of CD127 and KLRG-1 has been shown to be relevant in 
identifying antigen-specific populations (Bengsch et al. 2007; Ibegbu et al. 2005). It has 
previously been postulated that virus-specific CD8+ T-cells in resolved infections are 
predominantly CD127+KLRG-1−, whereas CD127−KLRG-1+ T-cells are associated with 
chronic viral persistence (Bengsch et al. 2007). This study also investigated these 
phenotypes to see whether CD8+ T-cells of CLL patients presented a phenotype 
representative of chronic or acute antigenic stimulation.  
 
Overall CD127+KLRG-1- T-cells were significantly reduced within the CD8+ 
compartment of the CLL cohort (p = 0.0191), but no significant difference was seen in 
the frequency of CD127−KLRG-1+ T-cells (p = 0.0532; Figure 3.12). The majority of 
changes within the CD127/KLRG-1 phenotypes were seen when the CLL cohort was 
stratified based on T-cell CD4:CD8 ratio (Figure 3.13). The CLLIR subgroup showed a 
significant reduction in CD8+CD127+KLRG-1− T-cells compared with both CLLNR and 
healthy donors (p ≤0.001 for both), and a marked increase in the CD127−KLRG-1+ 
phenotype when compared with CLLNR and healthy donors (p ≤0.01 in both cases; 
Figure 3.13A). The CLLIR CD8+ EM subset showed a similar pattern (Figure 3.13B): 
CD127+KLRG-1− frequency was significantly higher in the CLLIR subgroup than the 
CLLNR subgroup (p ≤0.01), and CD127−KLRG-1+ frequency was significantly reduced 
when compared to the healthy donors (p ≤0.01). CD8+ EMRAs also followed this 
pattern with a significant decrease in the CD127+KLRG-1− phenotype compared to both 
the CLLNR and healthy donors (p ≤0.05 and p ≤0.01, respectively; Figure 3.13C). It is 
worth noting that the same relationships were observed between CD57 and CD127 
co-expression (supplementary Appendix II).  
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Figure 3.12. Co-expression of CD127 and KLRG-1 in CD8+ T-cells of total CLL 
cohort (n = 74) and healthy donors (HD; n = 14). Cells were collected using flow 
cytometry (FACS CantoII, BD FACSDiva) and analysed with FlowJo (v.9) using gating as 
described in Figure 3.1.  Frequency of CD127+KLRG-1− and CD127−KLRG-1+ T-cells in the whole 
CD8+ T-cell compartment are shown.  Pairwise statistical analysis (HD vs CLL) was performed 
using the non-parametric Mann-Whitney test. Significant results were included on the graph 
(* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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Figure 3.13. Co-expression of CD127 and KLRG-1 in CD8+ T-cell memory subsets 
of CLLNR (n = 47), CLLIR (n = 27) and healthy donors (HD; n = 14). Cells were 
collected using flow cytometry (FACS CantoII, BD FACSDiva) and analysed with FlowJo (v.9) 
using gating as described in Figure 3.1. Patients were stratified based on CD4:CD8 ratio: a ratio 
<1.0 was considered inverted. Patients with a ratio ≥1.0 were considered normal ratio patients. 
CD127+KLRG-1− and CD127−KLRG-1+ frequency of (A) the whole CD8+ T-cell compartment, (B) 
CD8+ EM, and (C) CD8+ EMRA memory subsets. Three-way ANOVA statistical analysis was 
performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data assessed using 
the Dunn’s post-test. Significant results were included on the graph (* = p ≤0.05; 
** = p ≤0.01; *** = p ≤0.001). 
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To further define these phenotypic subsets of T-cells, CD57, a marker associated with 
differentiation and senescence (Focosi et al. 2010; Nunes et al. 2012; Brenchley et al. 
2003), was studied in conjunction with KLRG-1 and CD127 (Figure 3.14A). The CLL 
cohort showed an increase in CD8+ T-cells with a CD57+KLRG-1+CD127− phenotype 
(p = 0.0269) and reduction in CD57−KLRG-1−CD127+ phenotype (p = 0.0115). 
Greater significance was seen when patients were stratified based on CD4:CD8 ratio 
(Figure 3.14B): the increase in CD57+KLRG-1+CD127− phenotype was exacerbated in 
the CLLIR CD8+ compartment compared to both CLLNR and healthy donors (p ≤0.01 for 
both). Furthermore, a significant reduction in the percentage of cells expressing the 
CD57−KLRG-1−CD127+ phenotype was also observed (p ≤0.001 for both). The CLLIR 
CD8+ EM subset also demonstrated an increase in CD57+KLRG-1+CD127− and a 
reduction in CD57−KLRG-1−CD127+. The CLLIR EMRA population only showed a 
significant reduction in the CD57−KLRG-1−CD127+ (supplementary data, see Appendix 
II). 
 
Overall there appeared to be an increase in T-cell phenotypes consistent with 
senescence associated with persistent infection or chronic antigenic stimulation. This 
was particularly enhanced in the CLLIR patient subgroup, suggesting a preferential 
accumulation of chronically stimulated CD8+ T-cells. 
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Figure 3.14. CD57, KLRG-1, and CD127 co-expression in CD8+ T-cells of CLL 
patients and healthy donors. Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 3.1. (A) 
CD8+CD57+KLRG-1+CD127− T-cells in the whole CD8+ T-cell compartment of CLL patients 
(n = 74) and healthy donors (n = 14). Pairwise statistical analysis (HD vs CLL) was 
performed using the non-parametric Mann-Whitney test. Patients were stratified based on 
CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a ratio ≥1.0 were 
considered normal ratio patients (CLLNR). (B) Frequency of CD8+CD57+KLRG-1+CD127− T-cells 
in the whole CD8+ T-cell compartment of CLLNR (n = 47), CLLIR (n = 27) and healthy donors 
(n = 14). Three-way ANOVA statistical analysis was performed using Kruskal-Wallis test (HD vs 
CLLNR vs CLLIR), with all pairs of data assessed using the Dunn’s post-test. Significant results were 
included on the graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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 BCL-2  3.3.5.
The anti-apoptotic protein BCL-2 plays an important role in T-cell survival and is 
thought to play a role in the regulation of T-cell memory (Dunkle et al. 2013). Initial 
phenotypic analyses included BCL-2 to assess whether the CD8+ memory T-cell 
expansion present in CLLIR was attributable to an accumulation of surviving long-lived 
BCL-2+ memory cells.  However, preliminary results revealed a significantly lower 
percentage of CD8+BCL-2+ in CLL patients compared to the healthy donors 
(p = 0.0048). The subset that most reflected this decrease was the naïve compartment 
(p = 0.0089); no significant change was observed in the CD8+ EM or EMRA subsets. 
When stratified by T-cell ratio, the CD8+ compartment as a whole showed little 
difference between the CLLNR and CLLIR patients. A trend towards decrease in the 
number of BCL-2+ T-cells was observed in the CD8+ naïve subset (HD>CLLNR>CLLIR): a 
mean 4-fold reduction was seen between the CLLNR and CLLIR patients (n.s.), and a 
significant 9-fold reduction was observed between healthy donors and CLLIR patients 
(p ≤0.01). The decrease in BCL-2 aligns with the decrease seen in the naïve CD8+ 
T-cell frequency (Section 3.1, Figure 3.2 and 3.3) and the reduction in CD127 
expression (Section 3.3.3, Figure 3.11). Previous work has shown that BCL-2 is 
regulated by IL-7/IL-7R (Niu and Qin 2013), so it is not surprising that they follow 
similar patterns of presentation here. Overall, with regards to the memory 
compartments, no change in EM/EMRA subsets suggests that there is not an increase in 
long-lived memory T-cells primed for survival. 
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Figure 3.15. BCL-2 frequency in CD8+ T-cell memory subsets of CLL patients and 
healthy donors (HD). Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 3.1. (A) 
CD8+BCL-2+ T-cells in whole CD8+ T-cell compartment and CD8+ naïve subset of CLL patients 
(n = 20) and healthy donors (n = 5). Pairwise statistical analysis (HD vs CLL) was performed 
using the non-parametric Mann-Whitney test. Patients were stratified based on CD4:CD8 ratio: a 
ratio <1.0 was considered inverted (CLLIR). Patients with a ratio ≥1.0 were considered normal 
ratio patients (CLLNR). (B) Frequency of CD8+BCL-2+ T-cells in whole CD8+ T-cell compartment 
and CD8+ naive subset of CLLNR (n = 11), CLLIR (n = 9) and healthy donors (n = 5). Three-
way ANOVA statistical analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), 
with all pairs of data assessed using the Dunn’s post-test. Significant results were included on the 
graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
BCL-2+ in Total CLL Cohort
HD CL
L HD CL
L
0
20
40
60
80
100
CD8+ Total
**
**
CD8+ Naive
%
 o
f C
D
8+
 c
el
ls
BCL-2+ in Stratified CLL Cohort
HD
CL
L
NR
CL
L
IR
HD
CL
L
NR
CL
L
IR
0
20
40
60
80
100
*
*
**
CD8+ Total CD8+ Naive
%
 o
f C
D
8+
 c
el
ls
A 
B 
Chapter 3: Results 
86 
 Markers  assoc ia ted  with  act ivat ion  3.4.
 
 HLA-DR and CD38 3.4.1.
Increases in senescent and exhausted T-cell phenotypes within CLL have been reported 
in the literature (Göthert et al. 2013; Riches et al. 2013; Nunes et al. 2012), but an 
increase in absolute numbers of activated HLA-DR+ T-cells have also been reported 
(Tötterman et al. 1989). T-cells displaying an activated phenotype have been described 
in other cancers; a tumour-reactive “early effector” CD8+ T-cell subset expressing 
activation markers HLA-DR and CD38 has been reported in metastatic melanoma 
(Anichini et al. 2010). Furthermore, expression of CD38 on T-cells has been proposed as 
a potential prognostic marker in CLL (Tinhofer et al. 2006). Therefore, this study 
included HLA-DR (Panel 1) and CD38 (Panel 2) within the phenotypic analysis to 
identify the presence of any potentially activated subgroups of CD8+ T-cells within CLL, 
and specifically the CLLIR subgroup.  
 
CD8+HLA-DR+ T-cells were significantly higher in frequency within the CLL cohort than 
the healthy donors (p = 0.0123), an increase that was reflected within both the CD8+ 
EM and CD8+ EMRA T-cells (p = 0.0257 and p = 0.0277, respectively; Figure 
3.16A). Stratification by ratio revealed that HLA-DR expressing CD8+ T-cells were 
higher in CLLIR patients than either CLLNR patients or healthy donors (p ≤0.05 and 
p ≤0.01, respectively; Figure 3.16B). This was shown predominantly within the CD8+ 
EM subset (p ≤0.001 against both CLLNR and healthy donors). The CD8+ EMRA subset 
of the CLL cohort demonstrated a significantly higher frequency of HLA-DR expressing 
T-cells than the EMRA subset in the healthy donors (p ≤0.05). However, there was no 
difference in the frequency of HLA-DR+ T-cells between the EMRA subsets of the CLLIR 
vs CLLNR patients. These results suggest an activated subgroup of T-cells in CLL, more 
specifically the CLLIR patients. 
 
The maximum frequency of CD38 expressing T-cells was higher in the CLL patients 
(~80%) compared to healthy donors (~40%), and there was a trend towards higher 
frequencies in the CLL cohort, although this was not significant. When looking at the 
CD8+ memory subsets, the frequency of CD38+ T-cells was on average 3-fold higher in 
the EM subset (p = 0.0014) and 2-fold higher in EMRA subset (p = 0.0453) of CLL 
patients (Figure 3.17A). Stratified into CD4:CD8 ratio subgroups, CLLIR patients had a 
significantly higher frequency of CD8+CD38+ T-cells than CLLNR patients and healthy 
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donors (p ≤0.05 for both, Figure 3.17B). Similar to the results seen with HLA-DR, the 
memory subset where this pattern was the most pronounced was the CLLIR EM subset 
(p ≤0.01 versus CLLNR, p ≤0.001 versus healthy donors). These results, along with the 
increase in HLA-DR+ T-cells described earlier in the section, support the presence of an 
activated subgroup of CD8+ memory T-cells within the CLLIR cohort. 
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Figure 3.16. HLA-DR frequency in CD8+ T-cell memory subsets of CLL patients 
and healthy donors (HD). Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 3.1. (A) 
CD8+HLA-DR+ T-cells in the whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA 
memory subsets of CLL patients (n = 74) and healthy donors (n = 14). Pairwise statistical 
analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney test. Patients were 
stratified based on CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a 
ratio ≥1.0 were considered normal ratio patients (CLLNR). (B) Frequency of CD8+HLA-DR+ 
T-cells in the whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA memory subsets of 
CLLNR (n = 47), CLLIR (n = 27) and healthy donors (n = 14). Three-way ANOVA statistical 
analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data 
assessed using the Dunn’s post-test. Significant results were included on the graph 
(* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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Figure 3.17. CD38 frequency in CD8+ T-cell memory subsets of CLL patients and 
healthy donors (HD). Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 3.1. (A) 
CD8+CD38+ T-cells in the whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA memory 
subsets of CLL patients (n = 74) and healthy donors (n = 14). Pairwise statistical analysis 
(HD vs CLL) was performed using the non-parametric Mann-Whitney test. Patients were 
stratified based on CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a 
ratio ≥1.0 were considered normal ratio patients (CLLNR). (B) Frequency of CD8+CD38+ T-cells 
in the whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA memory subsets of CLLNR 
(n = 47), CLLIR (n = 27) and healthy donors (n = 14). Three-way ANOVA statistical analysis 
was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data assessed 
using the Dunn’s post-test. Significant results were included on the graph (* = p ≤0.05; 
** = p ≤0.01; *** = p ≤0.001). 
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 PD-1,  CD57 and HLA-DR 3.4.2.
There is controversy around both PD-1 and CD57 in their usage as markers for 
senescence or exhaustion. PD-1 is often described as a marker for exhaustion due to its 
inhibitory role in T-cell activation and co-expression with other senescence/exhaustion 
markers (Bengsch et al. 2010; Brusa et al. 2013). However, PD-1 is initially 
up-regulated during T-cell activation and the early stages of differentiation, and is then 
down-regulated during the later stages of differentiation (Sauce et al. 2007). 
Furthermore, PD-1 can be co-expressed with activation markers CD38 and HLA-DR 
(Sauce et al. 2007). CD57 is often used as a marker for replicative senescence, but 
studies have demonstrated that CD8+CD57+ T-cells are capable of rapid proliferation 
and cytokine secretion (Chong et al. 2008). This study therefore looked at whether the 
expression of PD-1 and CD57 were associated with markers of activation. As PD-1 and 
CD57 were included together on antibody Panel 1, relationships were investigated with 
HLA-DR. 
 
This study observed that PD-1+HLA-DR+ frequency was increased 3-fold in the CLL 
cohort versus healthy donors (Figure 3.18), both in the whole CD8+ T-cell compartment 
(p = 0.0001) and the EM and EMRA subsets (p = 0.0004 and p = 0.0005, 
respectively). No significant difference was seen between the CLLNR and CLLIR 
subgroups, and therefore PD-1 co-expression with HLA-DR was considered of 
phenotypic interest within CLL, but not the CD4:CD8 ratio. Unfortunately, this study 
was unable to look at the co-expression of PD-1 and CD38 due to the antibodies being 
included on different flow cytometry panels (Panel 1 and Panel 2). 
 
CD57 and HLA-DR co-expression on CD8+ T-cells was significantly higher in the CLL 
patients versus their healthy counterparts (p = 0.0012, Figure 3.19A). CD57+HLA-DR+ 
frequency was increased in the CD8+ EM (p = 0.0144) and the highly differentiated 
CD8+ EMRA memory cells (p = 0.0027). The increased CD57+HLA-DR+ phenotype 
observed in the whole CLL cohort was more marked within the CLLIR subgroup (Figure 
3.19B): CLLIR had significantly higher levels of CD57+HLA-DR+ cells within the CD8+ 
T-cell compartment than either the CLLNR or healthy donors (p ≤0.01 and p ≤0.001, 
respectively). This seemed to be predominantly due to an increase of this phenotype 
within the EM compartment (p ≤0.001 versus both CLLNR and healthy donors). The 
EMRA population of CLLIR patients demonstrated higher CD57+HLA-DR+ frequency 
compared to the healthy donors (p ≤0.01) but not CLLNR patients.  
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Figure 3.18. PD-1 and HLA-DR co-expression in CD8+ T-cell memory subsets of 
CLL patients and healthy donors. Cells were collected using flow cytometry (FACS CantoII, 
BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 3.1. 
CD8+PD-1+HLA-DR+ T-cells in the whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA 
memory subsets of CLL patients (n = 74) and healthy donors (n = 14).  Pairwise statistical 
analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney test. Significant 
results were included on the graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
 
PD-1+HLA-DR+ in Total CLL Cohort
HD CL
L HD CL
L HD CL
L
0
20
40
60
***
CD8+ Total CD8+ EM CD8+ EMRA
***
***
%
 o
f C
D
8+
 c
el
ls
Chapter 3: Results 
92 
 
 
 
Figure 3.19. CD57 and HLA-DR co-expression in CD8+ T-cell memory subsets of 
CLL patients and healthy donors. Cells were collected using flow cytometry (FACS CantoII, 
BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 3.1. (A) 
CD8+CD57+HLA-DR+ T-cells in the whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA 
memory subsets of CLL patients (n = 74) and healthy donors (n = 14). Pairwise statistical 
analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney test. Patients were 
stratified based on CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a 
ratio ≥1.0 were considered normal ratio patients (CLLNR). (B) Frequency of 
CD8+CD57+HLA-DR+ T-cells in the whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA 
memory subsets of CLLNR (n = 47), CLLIR (n = 27) and healthy donors (n = 14). Three-way 
ANOVA statistical analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with 
all pairs of data assessed using the Dunn’s post-test. Significant results were included on the 
graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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As both PD-1+HLA-DR+ and CD57+HLA-DR+ frequencies were higher in the CLL cohort 
than healthy donors, the presence of triple positive cells (CD57+HLA-DR+PD-1+; Figure 
3.20) was investigated. Overall, the CLL cohort showed an increased frequency of 
CD57+HLA-DR+PD-1+ in the CD8+ T-cell compartment when compared to healthy 
donors (p = 0.0004, Figure 3.20A). The triple positive phenotype was also increased 
in the CD8+ EM subset of CLL patients (p = 0.0016) and the EMRA subset 
(p = 0.0070). The CD8+ EMRA subset also showed higher levels of 
CD57+HLA-DR+PD-1- (p = 0.0338). 
 
When stratified into CLLNR and CLLIR subgroups, there was no difference in 
CD57+HLA-DR+PD-1+ frequency based on ratio but the CD8+ EM subset did 
demonstrate a higher frequency of the CD57+HLA-DR+PD-1+ phenotype versus CLLNR 
and healthy donors (p ≤0.05 and p ≤0.001, respectively; Figure 3.20B). However, 
stronger significance was seen in CD57+HLA-DR+ T-cells lacking PD-1 
(CD57+HLA-DR+PD-1−; Figure 3.20C). Compared to CLLNR patients and healthy donors, 
CLLIR patients showed significantly higher CD57+HLA-DR+PD-1− frequency in both the 
CD8+ compartment as a whole (p ≤0.01 and p ≤0.001), as well as the CD8+ EM 
subset (p ≤0.001 and p ≤0.01). This, along with the absence of any significant 
difference in the frequency of CD8+PD-1+ T-cells between CLLIR and CLLNR (Section 
3.3.1, Figure 3.6B) demonstrates that although PD-1 expression is not an independent 
marker of CLLIR, co-expression of PD-1 with other markers may further define 
populations that are significantly different between patient cohorts. However, 
CD57+HLA-DR+ co-expression, without PD-1, is a stronger characteristic within the 
CLLIR subgroup. 
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Figure 3.20. CD57, HLA-DR and PD-1 co-expression in CD8+ T-cell memory 
subsets of CLL patients and healthy donors. Cells were collected using flow cytometry 
(FACS CantoII, BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in 
Figure 3.1. (A) CD8+CD57+HLA-DR+PD-1+ T-cells in the whole CD8+ T-cell compartment, CD8+ 
EM and CD8+ EMRA memory subsets of CLL patients (n = 74) and healthy donors (n = 14). 
Pairwise statistical analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney 
test. Patients were stratified based on CD4:CD8 ratio: a ratio <1.0 was considered inverted 
(CLLIR). Patients with a ratio ≥1.0 were considered normal ratio patients (CLLNR). (B) Frequency 
of CD8+CD57+HLA-DR+PD-1+ T-cells in the whole CD8+ T-cell compartment, CD8+ EM and 
CD8+ EMRA memory subsets of CLLNR (n = 47), CLLIR (n = 27) and healthy donors 
(n = 14). (C) Frequency of CD8+CD57+HLA-DR+PD-1− T-cells in the whole CD8+ T-cell 
compartment, CD8+ EM and CD8+ EMRA memory subsets of CLLNR, CLLIR and healthy donors. 
Three-way ANOVA statistical analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs 
CLLIR), with all pairs of data assessed using the Dunn’s post-test. Significant results were 
included on the graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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 CD57,  KLRG-1 and CD38 3.4.3.
As described in the previous section, senescence markers can be co-expressed with 
activation markers. This study explored associations between senescence markers CD57 
and KLRG-1 with the activation marker CD38 (Panel 2). Co-expression of CD57 and 
CD38 was significantly higher in the total CLL CD8+ T-cell compartment when 
compared with healthy donors (p = 0.0057). This was also observed in the CD8+ EM 
and EMRA memory subsets when compared with healthy donors (p = 0.0031 and 
p = 0.0441, respectively; Figure 3.21A). The higher CD57+CD38+ frequency was 
exacerbated in CLLIR CD8+ T-cells compared to both the CLLNR subgroup and healthy 
donors (p ≤0.01 and p ≤0.001; Figure 3.21B). Again, a similar pattern was observed 
when the CD8 T-cells were sub-divided on the basis of EM (p ≤0.01 versus CLLNR and 
p ≤0.001 versus HD) and EMRA cells (p ≤0.05 versus both CLLNR and HD).  
 
KLRG-1+CD38+ frequency showed the same increasing trends as CD57+CD38+ 
frequency, particularly with regards to the inverted ratio patients (see Appendix III). 
Furthermore, expression of CD57 and KLRG-1 together with CD38 was more prevalent 
in the CD8+ T-cells of the CLL patients than the healthy donors (p = 0.0169; Figure 
3.22A). When patients were stratified based on CD4:CD8 ratio, the CLLIR patients had 
higher frequencies of CD57+KLRG-1+CD38+ T-cells than either the CLLNR cohort or 
healthy donors (p ≤0.001 for both; Figure 3.22B). However, the most prevalent 
CD57/KLRG-1/CD38 combination was the CD57+KLRG-1+CD38− population in both 
CLL patients and healthy donors (see Appendix III). This suggests that the majority of 
T-cells with a highly senescent/differentiated phenotype (CD8+CD57+KLRG1+) are not 
activated. However, there is a smaller subgroup of these T-cells that appear to be 
activated and are enriched in CLLIR patients. 
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Figure 3.21. CD57 and CD38 co-expression in CD8+ T-cell memory subsets of CLL 
patients and healthy donors. Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 3.1. (A) 
CD8+CD57+CD38+ T-cells in the whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA 
memory subsets of CLL patients (n = 74) and healthy donors (n = 14). Pairwise statistical 
analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney test. Patients were 
stratified based on CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a 
ratio ≥1.0 were considered normal ratio patients (CLLNR). (B) Frequency of CD8+CD57+CD38+ 
T-cells in the whole CD8+ T-cell compartment, CD8+ EM and CD8+ EMRA memory subsets of 
CLLNR (n = 47), CLLIR (n = 27) and healthy donors (n = 14). Three-way ANOVA statistical 
analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data 
assessed using the Dunn’s post-test. Significant results were included on the graph 
(* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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Figure 3.22. CD57, KLRG-1 and CD38 co-expression in CD8+ T-cell memory 
subsets of CLL patients and healthy donors. Cells were collected using flow cytometry 
(FACS CantoII, BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in 
Figure 3.1. (A) CD8+CD57+KLRG-1+CD38+ T-cells in the whole CD8+ T-cell compartment, CD8+ 
EM and CD8+ EMRA memory subsets of CLL patients (n = 74) and healthy donors (n = 14). 
Pairwise statistical analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney 
test. Patients were stratified based on CD4:CD8 ratio: a ratio <1.0 was considered inverted 
(CLLIR). Patients with a ratio ≥1.0 were considered normal ratio patients (CLLNR). (B) Frequency 
of CD8+CD57+KLRG-1+CD38+ T-cells in the whole CD8+ T-cell compartment, CD8+ EM and 
CD8+ EMRA memory subsets of CLLNR (n = 47), CLLIR (n = 27) and healthy donors 
(n = 14). Three-way ANOVA statistical analysis was performed using Kruskal-Wallis test (HD vs 
CLLNR vs CLLIR), with all pairs of data assessed using the Dunn’s post-test. Significant results were 
included on the graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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 Inver ted  ra t io  and cytomegalov irus  (CMV) in fect ion  3.5.
Cytomegalovirus (CMV) is a common persistent viral infection in the elderly population 
(Vasto et al. 2007; Pita-Lopez et al. 2009). Previous work has shown that both the CD4+ 
and CD8+ T-cell compartments in CMV-positive patients are skewed towards more 
differentiated memory subsets (Pourgheysari et al. 2010; Khan et al. 2002). This is 
thought to be due to expansions in chronically stimulated CMV-specific T-cells that are 
defined as senescent, although there is evidence that CMV-specific T-cells from CLL 
patients can act in a functional capacity (Raa et al. 2014). Therefore, to assess whether 
CMV was a contributing factor in this study, patient serum from a cohort of CLL patients 
was collected and serotyped by Public Health Wales Microbiology Lab, UHW, Cardiff.  
 
The CMV serostatus was assessed in 63 of the CLL patients used in this study: of those 
tested, over 68% were CMV+ (43 patients). Patients were stratified based on CD4:CD8 
T-cell ratio and CMV seropositivity. In line with previous work by our group (Nunes et 
al. 2012), there were no significant differences between groups (Fisher’s exact test, 
p = 0.0922; Figure 3.23) suggesting that CLL CD4:CD8 T-cell ratio is not driven by 
CMV. Furthermore, SPICE software analysis was used to compare the distribution of 
memory T-cell subsets among CLL patients based on CMV serostatus using pie charts 
(Figure 3.34). This showed that the distribution of CD8+ memory subsets were 
significantly different in CMV+ and CMV− CLL patients (p = 0.0192), and this was due 
to a proportionally larger EMRA subset in CMV+ patients (Figure 3.24). Overall these 
results lend support to CMV infection not being a contributing factor to inversion of the 
CD4:CD8 ratio or phenotypic abnormalities associated with CLL (Nunes et al. 2012). 
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Figure 3.23. CMV serostatus in CLL patients. Plasma samples from CLL patients were 
serotyped for cytomegalovirus. To observe the relationship between CMV and CD4:CD8 ratio, 
patients were stratified into four groups based ratio (CLLNR and CLLIR) and CMV seropositivity:  
CLLNR CMV+ (n = 24), CLLNR CMV− (n = 16), CLLIR CMV+ (n = 19) and CLLIR CMV− 
(n = 4). Fisher’s exact test was used for analysis. 
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Figure 3.24. Distribution of CD8+ memory subsets in CMV seropositive (n = 43) 
and CMV seronegative (n = 20) CLL patients. Cells were collected using flow cytometry 
(FACS CantoII, BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in 
Figure 3.1. Plasma samples from CLL patients were serotyped for cytomegalovirus. Flow 
cytometry data and CMV information were analysed using SPICE software (v5.3). 
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 Assessment  o f  CD4:CD8 rat io  with  prognos is  3.6.
 
 Estab l i shed prognost ic  markers  3.6.1.
There are many documented tumour associated markers in CLL that relate to disease 
prognosis. Where available, the ratio data acquired in this study was collated with 
previously recorded prognostic characteristics, including: Binet stage, lymphocyte 
doubling time (LDT), CD38+ status (of CLL B-cells), and immunoglobulin heavy-chain 
variable region (IGHV) mutational status. Patients were stratified based on CD4:CD8 
ratio and the relevant characteristic (see Figure 3.25). Performance of Fisher’s exact 
tests revealed that there was no association between the established prognostic markers 
and CD4:CD8 ratio.  
 
 Univar ia te  analys i s  3.6.2.
To reaffirm the prognostic value of the inverted ratio reported in previous studies 
(Nunes et al. 2012), Kaplan-Meier curves for progression-free survival (PFS) were 
produced. The CLL cohort was subdivided by CD4:CD8 ratio as before i.e. patients with 
a CD4:CD8 ratio <1.0 were considered inverted and patients with a ratio ≥1.0 were 
considered normal. A ratio of 1.00 was initially considered the best cut-off for this study 
for two reasons. First, it represents the true point of numerical inversion, where there 
are more CD8+ T-cells than CD4+ T-cells. Second, previous work within the group 
analysed a CLL cohort with a median ratio of 1.00 (Nunes et al. 2012).  
 
Figure 3.26A shows the Kaplan-Meier curve comparing the PFS for these ‘traditional’ 
CLLNR and CLLIR subgroups. CLLIR patients have a significantly worse prognosis 
(HR = 5.539, p = 0.0002). Kaplan-Meier curves with CLL patients divide based on 
the ratio median are also shown (Figure 3.26B). The prognostic effect was decreased 
when patients were stratified by the median (HR = 3.200, p = 0.0056). This lends 
further support for 1.0 as the best limit to subdivide based on ratio; therefore, using 1.0 
as the cut-off ratio was continued in this study. 
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Figure 3.25. Prognostic markers in CLLNR and CLLIR patients. (A) Binet disease stage 
in CLL patients with normal (n = 46) and inverted ratio (n = 27). (B) Lymphocyte doubling 
time in CLL patients with normal (n = 36) and inverted (n = 21) ratio. (C) CD38+ status in 
CLL patients with normal (n = 29) and inverted (n = 15) ratio. (D) IGHV mutational status in 
CLL patients with normal (n = 11) and inverted ratio (n = 12). Analysis performed using 
Fisher’s exact test. 
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Figure 3.26. Prognosis of CLL patients stratified by CD4:CD8 ratio. Cells were 
collected using flow cytometry (FACS CantoII, BD FACSDiva) and analysed with FlowJo (v.9) 
using gating as described in Figure 3.1. Multivariate recursive partitioning was performed to 
establish significant ‘cut-off’ ratio values within the study group. Kaplan-Meier curves for 
progression-free survival of CLL patients stratified by a ratio of (A) the ‘traditional’ 1.0, and (B) 
the median ratio 1.33 are shown. Univariate analyses (Kaplan-Meier curves and survival 
statistics) were performed using GraphPad Prism. 
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 Mult ivar ia te  analys i s  3.7.
Multivariate analyses were performed by Professor Robert Hills (Haematology Clinical 
Trials Unit, Cardiff University). Due to the large number of variables generated in this 
phenotypic study, separate data sets were built to include either the single frequency 
and Boolean combination data from either Panel 1 or Panel 2: these data sets contained 
70 and 128 variables respectively. Initial cox-proportional hazard regression with 
forward selection was performed on each data set to establish which variables had the 
greatest effect on PFS within each panel. The results of these analyses were then used to 
compile the variables of importance from both Panels into a single data set for a further 
multivariate analysis to determine the variables that had greatest effect across the two 
panels. A total of 128 variables were considered in the final analysis. In addition to the 
cox-proportional hazard regression, correlation analyses were performed comparing 
CD4:CD8 ratio against all phenotypic variables.  Complete analyses for the final 
multivariate set is provided in Appendix IV, including simple variable statistics, 
correlation statistics and hazard modelling. For the purposes of completeness, 
phenotypic data for the CD4+ T-cell compartment was also included in the analyses. 
  
 Corre la t ions  with  CD4:CD8 rat io  3.7.1.
Correlation analyses were performed for each variable versus the CD4:CD8 ratio. Table 
3.3 summarises the variables that demonstrated the strongest correlation with ratio 
(where r >0.5 or >−0.5, p ≤ 0.05; see Appendix IV for complete correlation 
analysis).  As expected, frequency of total CD4+ and total CD8+ strongly correlated with 
ratio (r = 0.870 and r = −0.850, p <0.0001, respectively). Both the CD4+ and CD8+ 
naïve memory populations positively correlated with ratio (r = 0.575 and r = 0.712, 
respectively; p <0.0001 for both). The variables that had the strongest negative 
relationships with ratio were CD4+ populations: these included EM CD57+HLA-DR+ 
(r = −0.634, p <0.0001), CD57+PD-1+ (r = −0.616, p  = <0.0001), 
CD57+HLA-DR+ (r = −0.612, p <0.0001), and CD57+PD-1+ (r = −0.605, 
p <0.001). The CD8+ phenotypes that demonstrated the strongest correlations were 
CD38+CD57+KLRG-1+ (r = −0.519, p <0.0001) and CD57+ (r = −0.510, 
p <0.0001). These results confirm the phenotypic analysis that demonstrated that both 
CD8+CD57+ and CD8+CD38+CD57+KLRG-1+ frequency were both significantly higher in 
the CLLIR subgroup of patients (Section 3.3.1 an 3.4.3, respectively). Taken together 
these results suggest that these two CD8+ phenotypes appear to be most linked with 
decreasing CD4:CD8 ratio. 
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Table 3.3 Ratio correlations against T-cell phenotypes in CLL. 
 
 
 
                                                
1 A positive correlation indicates that the phenotypic marker(s) are associated with an increase in 
the CD4:CD8 ratio.  
2 A negative correlation indicates that the phenotypic marker(s) are associated with a decrease in 
the CD4:CD8 ratio. 
Variable r p-value 
Positive Correlation1 
  
CD4+ 0.87022 <0.0001 
CD8+ Naïve 0.71172 <0.0001 
CD4+ Naïve 0.57513 <0.0001 
Negative Correlation2 
  
CD8+ −0.85023 <0.0001 
CD4+EM+CD57+HLA-DR+ −0.634 <0.0001 
CD4+CD57+PD-1+ −0.61579 <0.0001 
CD4+CD57+HLA-DR+ −0.61185 <0.0001 
CD4+CD57+PD-1+ −0.60481 <0.0001 
CD4+EM+CD57+HLA-DR+PD-1+ −0.6013 <0.0001 
CD4+CD57+HLA-DR+PD-1+ −0.5868 <0.0001 
CD4+EM+CD57+ −0.57537 <0.0001 
CD4+HLA-DR+PD-1+ −0.5718 <0.0001 
CD4+HLA-DR+PD-1+ −0.55478 <0.0001 
CD4+EM+HLA-DR+ −0.54785 <0.0001 
CD4+HLA-DR+ −0.54439 <0.0001 
CD4+CD57+ −0.52054 <0.0001 
CD8+CD38+CD57+KLRG-1+ −0.51862 <0.0001 
CD8+CD57+ −0.51858 <0.0001 
CD4+CD38+CD57+ −0.51012 <0.0001 
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 Cox-proport ional  hazards  regress ion  3.7.2.
A cox-proportional hazard regression model with forward selection was used to 
determine which phenotypic factors had the strongest effect on CLL patient prognosis 
(progression-free survival: PFS). The aim of this chapter was to investigate the CD8+ 
T-cell population in CLL: interestingly, the most powerful variable given by the 
multivariate analysis was CD4+HLA-DR+PD-1+ (Table 3.4), which initiated subsequent 
phenotypic exploration of the CD4+ compartment in the next chapter (Chapter 4). 
 
There were three CD8+ variables that demonstrated a significant effect (at the 0.05 level 
entry; Table 3.4): CD8+, CD8+CD57+HLA-DR+ and CD8+ EMRA CD57+HLA-DR+PD-1+. 
These variables were then subjected to univariate analysis. For each phenotype, patients 
were initially stratified based on the median value (frequency of CD8+ T-cells); 
however, the median cut-off did not always provide a significant difference in prognosis 
between the two patient subgroups (see Appendix IV). Therefore, using the median 
frequency was not the best cut-off point on which to divide the patient population into 
better/poorer prognosis subgroups. To address this, further multivariate analyses were 
implemented to perform recursive partitioning (using a regression model with forward 
selection) and identify the optimum frequency thresholds that had the greatest effect on 
PFS for each phenotype. Ratio was also included to assess whether the 1.0 boundary 
identified by previous work was the optimum cut-off for this study. The analyses gave 
an output for each variable showing the frequencies that had the strongest effect (at 
0.05 level entry). For each variable, survival analyses (Kaplan-Meier curves and hazard 
ratios) were produced to identify which cut-offs identified the optimum frequency for 
prognostic assessment (Table 3.4). Here the most prognostically relevant results are 
summarised. Comprehensive results tables and Kaplan-Meier curves are shown in 
Appendix IV. 
 
Table 3.4 Summary of Cox-proportional hazard regression model with forward 
selection. 
Variable 
Number 
in 
Chi-
square 
p 
CD4+HLA-DR+PD-1+ 1 23.4347 <0.0001 
CD8+ 2 5.5428 0.0186 
CD8+CD57+HLA-DR+ 3 4.7188 0.0298 
CD8+EMRA+CD57+HLA-DR+PD-1+ 4 5.2623 0.0218 
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Section 3.6.2. showed that the ‘traditional’ ratio cut-off of 1.0 based on prior research by 
(Nunes et al. 2012) held more prognostic value than using the median ratio of this 
study’s patient cohort. In this analysis, recursive partitioning identified the CD4:CD8 
ratios of 0.95, 0.99 and 1.01 as having a great effect on PFS (Figure 3.27A-C), 
supporting the use of 1.0 as a reasonable cut-off point for patient stratification. In 
addition, the greatest effect on prognosis was observed with a ratio of 0.52 or lower 
(Figure 3.27D). This further supports that decreasing ratio leads to an exacerbated 
prognosis, and suggests that a cut-off ratio around 0.5 could be used to identify a 
high-risk inverted ratio group.  
 
The frequency of CD8+ T-cells was also a factor that had a significant effect on 
prognosis, which might be expected given the link between inverted CD4:CD8 ratios 
and inferior prognosis. Both 31% and the median 33.2% CD8+ T-cells were identified as 
prognostic thresholds via recursive partitioning (Figure 3.28A-B). Higher frequencies 
revealed even poorer prognosis for patients with 56.9-58.5% CD8+ T-cells and above, 
with 56.9% given as the strongest cut-off within the multivariate analyses (Figure 
3.28C-D).   
 
 
Chapter 3: Results 
108 
 
 
 
 
 
 
Figure 3.27. Prognosis of CLL patients stratified by CD4:CD8 ratio. Cells were 
collected using flow cytometry (FACS CantoII, BD FACSDiva) and analysed with FlowJo (v.9) 
using gating as described in Figure 3.1. Multivariate recursive partitioning was performed to 
establish significant ‘cut-off’ ratio values within the study group. Kaplan-Meier curves for 
progression-free survival of CLL patients stratified by a ratio of (A) 0.95 (B) 0.99 (C) 1.01 and 
(D) 0.52 are shown. These were the most prognostically relevant thresholds based on the 
combined multivariate and univariate analyses. Multivariate analyses were performed by Dr. 
Robert Hills (Haematology Clinical Trials Unit, Cardiff University). Univariate analyses 
(Kaplan-Meier curves and survival statistics) were performed using GraphPad Prism. 
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Figure 3.28. Prognosis of CLL patients stratified based on CD8+ frequencies. Cells 
were collected using flow cytometry (FACS CantoII, BD FACSDiva) and analysed with FlowJo 
(v.9) using gating as described in Figure 3.1. Lymphocytes were gated based on forward and side 
scatter profile; forward scatter area and height were used for exclusion of doublet cells. CD8+ 
T-cells were identified by gating first on CD3+ then CD8+ cells. Multivariate recursive 
partitioning was performed to establish significant ‘cut-off’ ratio values within the study group. 
Kaplan-Meier curves for progression-free survival of CLL patients stratified by a CD8+ frequency 
of (A) 31%, (B) 33.2% (the median), (C) 56.9% and (D) 58.5% are shown. These were the most 
prognostically relevant thresholds based on the combined multivariate and univariate analyses. 
Multivariate analyses were performed by Dr. Robert Hills (Haematology Clinical Trials Unit, 
Cardiff University). Univariate analyses (Kaplan-Meier curves and survival statistics) were 
performed using GraphPad Prism. 
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The frequency of the CD8+CD57+HLA-DR+ phenotype was also shown to have a 
significant impact on PFS. Recursive partitioning followed by univariate analyses 
revealed that the ideal prognostic cut-off for this cohort was between 24.7-26.2% 
(Figure 3.29A-B). Patients with a CD8+CD57+HLA-DR+ frequency above this threshold 
had significantly poorer prognosis. The phenotypic analysis undertaken earlier in this 
chapter demonstrated that CLL patients had higher frequencies of CD8+CD57+HLA-DR+, 
and this was further accentuated in the CLLIR subgroup (Section 3.4.2, Figure 3.19). As 
CLLIR patients also have poorer prognosis, it is not surprising that some inverted ratio 
patients also have high CD8+CD57+HLA-DR+. However, a strong correlation was not 
observed between these two variables (r = −0.455), implying that although there is 
some relationship between the two, they are not directly linked. 
 
The final CD8+ variable to demonstrate a significant effect on prognosis within the CLL 
cohort was the frequency of CD57+HLA-DR+PD-1+ within the CD8+ EMRA memory 
subset. The potential cut-offs suggested by recursive portioning were 6.45-6.86% 
(Figure 3.29C and D); the seven patients who had this frequency or higher (ranging 
from 6.45 to 19%) had significantly poorer prognosis compared to the remainder of the 
cohort. This phenotype was significantly higher in CLL patients versus healthy donors in 
Section 3.4.2 (Figure 3.20), but not exacerbated in CLLIR patients, indicating that any 
phenotypic effect of increased CD57+HLA-DR+PD-1+ in the CD8+ EMRA compartment 
was independent of CD4:CD8 ratio. 
 
Forward selection was also performed to include additional phenotypes that could have 
potential as contributing factors to prognosis (See Table 4 in Appendix IV for the 
complete multivariate results). This included the CD4:CD8 ratio, supporting the concept 
that ratio does contribute to prognosis, but to a lesser effect than the phenotypes 
described above (Table 3.4). CD4+CD57+PD-1+ and CD8+ EMRA CD57+HLA-DR+ were 
also shown to contribute to prognosis in a co-dependent manner.  
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Figure 3.29. Prognosis of CLL patients stratified based on CD8+ phenotype 
frequencies. Cells were collected using flow cytometry (FACS CantoII, BD FACSDiva) and 
analysed with FlowJo (v.9) using gating as described in Figure 3.1. Multivariate recursive 
partitioning was performed to establish significant ‘cut-off’ ratio values within the study group. 
Kaplan-Meier curves for progression-free survival of CLL patients stratified by: 
CD8+CD57+HLA-DR+ frequency of (A) 24.7% and (B) 26%; and by CD8+ EMRA 
CD57+HLA-DR+PD-1+ frequency of (C) 6.45% and (D) 6.86%. These were the most 
prognostically relevant thresholds based on the combined multivariate and univariate analyses. 
Multivariate analyses were performed by Dr. Robert Hills (Haematology Clinical Trials Unit, 
Cardiff University). Univariate analyses (Kaplan-Meier curves and survival statistics) were 
performed using GraphPad Prism. 
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Overall, results from the multivariate analysis further outline the complexity of the 
T-cell compartment in CLL and the impact it can have on prognosis. CD4:CD8 ratio was 
shown to be a contributing factor in prognosis confirming earlier work with a different 
patient cohort. However, ratio was shown to have a contributing effect alongside many 
other variables (Table 4, Appendix IV). The higher resolution analysis in this study 
revealed additional phenotypes that had a much stronger, significant effect on PFS. 
 
 
 Absolute  counts  3.8.
This study revealed several changes in phenotype frequency between healthy donors, 
the total CLL patient cohort and stratified CLLNR and CLLIR subgroups. However, this 
does not determine if the shift in frequency is due to an expansion of the T-cell 
subpopulation presenting the phenotype of interest or a reduction in the numbers of 
other T-cell sub-populations. To address these two possibilities, absolute counts were 
performed on 19 CLL patients, 8 of which had an inverted CD4:CD8 ratio.  
 
Absolute numbers of CD8+ T-cells were significantly higher in CLLIR versus CLLNR 
patients, implying that the inversion was caused by an expansion within the CD8+ T-cell 
population (p = 0.0073; Figure 3.30A). In addition, the absolute counts of the CD8+ 
EM and EMRA memory subsets were significantly higher in CLLIR patients (p = 0.0015 
and p = 0.0093, respectively), whereas there was no change in the number of CD8+ 
naïve subset (Figure 3.30B-D). This would suggest that the skewing in CD8+ T-cell 
memory distribution observed in Section 3.1 (Figure 3.3) is due to an increase within 
the more differentiated memory subsets rather than a reduction in the naïve population. 
Together, these results suggest that the CD4:CD8 inversion is due to a preferential 
expansion of CD8+ EM/EMRA T-cells, which is in line with previously published work 
(Nunes et al. 2012).  
 
This study also observed an absolute increase in CD8+ T-cells expressing CD57 
(p = 0.0093), HLA-DR (p = 0.0118) or PD-1 (p = 0.0118) in the CLLIR subgroup 
(Figure 3.31A). Therefore, the increase in frequency for these markers observed in CLLIR 
patients described in Sections 3.3.1 and 3.4.1 was due to an expansion of the cells 
expressing each marker (Figures 3.6, 3.7 and 3.16, respectively). The absolute count 
analyses were then applied to phenotypes combining multiple markers that had been 
shown to have the greatest prognostic potential by multivariate analyses (Section 
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3.7.2.). The CD8+ T-cell phenotypes that showed a significant effect on PFS were 
CD8+CD57+HLA-DR+ and CD8+ EMRA cells presenting CD57+HLA-DR+PD-1+. Earlier 
phenotypic analyses showed that the overall frequency of CD8+CD57+HLA-DR+ was 
significantly greater in CLLIR patients than CLLNR patients. This was also reflected in the 
absolute number of CD8+CD57+HLA-DR+ cells, which were significantly higher in CLLIR 
patients versus CLLNR (p = 0.0149; Figure 3.31B), demonstrating that the higher 
frequency of this phenotype within the CD8+ T-cell compartment was due to an 
expansion of said phenotype. The absolute count analysis also demonstrated an 
expansion of CD57+HLA-DR+PD-1+ in the CD8+ EMRA T-cell CLLIR population (Figure 
3.31C). Interestingly, this pattern was not reflected in the prior phenotypic analysis 
based on frequency.  This apparent discrepancy could be explained by the fact that 
although the CD57+HLA-DR+PD-1+ population is expanding within CLLIR patients, other 
CD8+ phenotypes in the inverted ratio patients may also have expanded in a similar 
fashion. Therefore, changes in the absolute number of these other phenotypes could 
lead to the lack of difference observed in the frequency of the triple positive phenotype 
between the patient subgroups. 
 
To summarise, the absolute counts support previous work that the CD4:CD8 inverted 
ratio was due to an expansion within the CD8+ T-cell compartment, specifically within 
the EM/EMRA memory subsets. Importantly, this analysis also demonstrated expansion 
of prognostically relevant T-cell phenotypes defined in the current study, such as 
CD8+CD57+HLA-DR+ and CD8+CD57+HLA-DR+PD-1+. It is not clear what is driving the 
expansion of these particular subsets.  
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Figure 3.30. Absolute counts of CD8+ T-cells in CLLNR (n = 11) and CLLIR 
(n = 8) patients. Cells and BD Trucount beads were collected using flow cytometry (FACS 
CantoII, BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 3.1. 
Patients were stratified based on CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). 
Patients with a ratio ≥1.0 were considered normal ratio patients (CLLNR). Memory subsets were 
defined using CCR7 and CD45RO memory markers: naïve (CCR7+CD45RO−), central memory 
(CM, CCR7+CD45RO+), effector memory (EM, CCR7−CD45RO+) and EMRA (CCR7−CD45RO−). 
Absolute counts for (A) overall CD8+, (B) CD8+ naïve, (C) CD8+ EM and (D) CD8+ EMRA 
between CLLNR and CLLIR patients are shown. Pairwise statistical analysis (CLLNR vs CLLIR) was 
performed using the non-parametric Mann-Whitney test. Significant results were included on the 
graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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Figure 3.31. Absolute counts of CD8+ T-cell phenotypes in CLLNR (n = 11) and 
CLLIR (n = 8) patients. Cells and BD Trucount beads were collected using flow cytometry 
(FACS CantoII, BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in 
Figure 3.1. Patients were stratified based on CD4:CD8 ratio: a ratio <1.0 was considered 
inverted (CLLIR). Patients with a ratio ≥1.0 were considered normal ratio patients (CLLNR). 
Memory subsets were defined using CCR7 and CD45RO memory markers: naïve 
(CCR7+CD45RO−), central memory (CM, CCR7+CD45RO+), effector memory (EM, 
CCR7−CD45RO+) and EMRA (CCR7−CD45RO−). Absolute counts for: (A) CD57+, HLA-DR+ or 
PD-1+ cells in the CD8+ compartment; (B) CD8+CD57+HLA-DR+ T-cells, and (C) 
CD57+HLA-DR+PD-1+ cells in the CD8+ EMRA subset. Pairwise statistical analysis (CLLNR vs 
CLLIR) was performed using the non-parametric Mann-Whitney test. Significant results were 
included on the graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
 
CD8+EMRA+CD57+HLA-DR+PD-1+
CL
L
NR
CL
L
IR
0
5
10
15
20 **
C
D
8+
EM
R
A
+ C
D
57
+ H
LA
-D
R
+ P
D
-1
+ 
co
un
t (
ce
lls
/µ
l)
CD8+CD57+HLA-DR+
CL
L
NR
CL
L
IR
0
10
20
30
40
50 **
C
D
8+
C
D
57
+ H
LA
-D
R
+ 
co
un
t (
ce
lls
/µ
l)
CD8+ Single Marker
CL
L
NR
CL
L
IR
CL
L
NR
CL
L
IR
CL
L
NR
CL
L
IR
0
100
200
300
400
CD57+ HLA-DR+ PD-1+
**
*
*
C
D
8+
M
ar
ke
r+
 
co
un
t (
ce
lls
/µ
l)
Absolute)counts)of)CD8+)phenotypes)in)CLL)cohort)
A)
B) C)
Chapter 3: Results 
116 
 Discuss ion  3.9.
The aim of this study was to further explore the phenotypic composition of the CD8+ 
T-cell compartment of CLL patients. More specifically, it set out to investigate potential 
phenotypic differences between CLL patients with an inverted CD4:CD8 ratio (CLLIR) 
and CLL patients presenting with a ‘normal’ T-cell ratio (CLLNR). Associations between 
T-cell ratio, disease pathology and prognosis have been reported previously, in both HIV 
infection and CLL (Buggert et al. 2014; Gonzalez-Rodriguez et al. 2010). CLLIR has been 
linked to poorer prognosis and shorter time to first treatment, compared with their 
‘normal’ ratio counterparts. Therefore, further analysis within the CLLIR subgroup may 
reveal more powerful prognostic markers. Previous work had shown that CD4:CD8 
T-cell ratio inversion in CLL patients was due to a significant expansion within the CD8+ 
T-cells (Nunes et al. 2012), therefore the CD8+ T-cell compartment was the focus of this 
study.  
 
For this study, the CD4:CD8 stratification point was based on the previous work within 
our group (Nunes et al. 2012) that demonstrated a ratio of 1.0 was the optimum 
prognostic cut-off point. Later multivariate and univariate analyses during this study 
also supported that a cut-off point of around 1.0 was prognostically relevant: splitting 
the cohort based on the patients with a ratio closest to 1.0 (0.99 and 1.01) yielded the 
strongest prognostic difference in CLL patients. Interestingly, stratifying patients above 
and below a CD4:CD8 ratio of 0.52 revealed that a more extreme inversion of the 
CD4:CD8 ratio that identified patients with an even worse prognosis. This result should 
be taken with caution as there were wide confidence intervals, probably due to the low 
patient numbers within the subgroup with a ratio of 0.52 and below (n = 7). 
However, it does lend support to the relevance of the CD4:CD8 ratio in identifying CLL 
patients with poorer prognosis and imply that the skewing in the CD4:CD8 ratio has 
functional consequences on the T-cell pool that adversely impact upon disease 
pathology. Certainly further studies in a larger cohort appear to be warranted. 
 
Primary analysis of the T-cell memory subset distributions showed significant 
differences between healthy donors and both the total and stratified CLL cohorts. A 
reduction in naïve and increase in the EM T-cell frequency was observed in both the 
CD8+ and CD4+ T-cell compartments of CLL; this shift was more dramatic within the 
CLLIR cohort. Adding to this, absolute counts of CD8+ T-cells in CLLIR patients, revealed 
an increase in the numbers of more differentiated CD8+ EM/EMRA cells but no 
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significant change in the numbers of naïve cells. This study, therefore supports previous 
evidence of a move to more differentiated CD8+ memory phenotypes in CLLIR patients 
(Nunes et al. 2012), and also expands on this to show that the skewing is due to an 
increase in the number of CD8+ EM and CD8+ EMRA T-cells. 
 
Similar shifts towards a more differentiated memory phenotype have been associated 
with chronic antigenic stimulation, particularly persistent viral infections (Champagne 
et al. 2001; Wherry and Ahmed 2004). This response has also been observed in tumour 
immunology (Klebanoff et al. 2006). The move toward a more differentiated memory 
phenotype in this study supports the presence of persistent antigenic stimulation. EMRA 
T-cells are thought to be ‘terminally’ differentiated whereas EM T-cells are thought to be 
more responsive to antigenic/cytokine stimulation (Geginat 2003). As this study 
primarily observed larger increases in the EM subset in the CLLIR cohort, it is possible 
that the expansion of CD8 T-cells in CLL may reflect the accumulation of T-cells 
responding to antigenic stimulation. 
 
The shift to more differentiated memory subsets was further analysed by observing 
changes in markers previously associated with highly differentiated and senescent cells. 
CD57 is a marker associated with T-cell senescence, and its expression is elevated on 
more differentiated, functionally incompetent memory cells (Focosi et al. 2010; Strioga 
et al. 2011). This study saw a marked increase in CD8+CD57+ T-cells in the CLL cohort 
compared to healthy donors. When stratified by ratio, higher CD57 was more associated 
with the CLLIR group CD8+ T-cells: the absolute counts infer this increased frequency is 
due to an absolute increase in the number of CD8+CD57+ T-cells themselves. This 
ratio-associated increase in CD57+ frequency was seen in the CD8+ EM population but 
not the CD8+ EMRAs.  
 
High frequencies of CD57+ T-cells have been observed in CLL patients in previous 
studies, originating within the CD8+ EM and EMRA subsets (Nunes et al. 2012). The 
current study aimed to provide a more detailed, clinically relevant phenotype for these 
T-cells. One novel finding was the demonstration of an increase in CD8+CD57+ EM cells 
and not EMRA cells within the CLLIR subgroup. Based on the previous studies an 
increase in CD8+CD57+ EMRA cells would be predicted, particularly as this subset is 
considered the more ‘terminally differentiated’. However, in this study, there was an 
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expansion of CD8+CD57+ EM cells in CLLIR patients, suggesting that this subset is 
associated with the development of the inverted ratio.  
 
Although the overall skewing observed in this study supports the previous work within 
our group (Nunes et al. 2012), there were some differences between the two studies. 
The previous report observed significantly higher CD8+ EMRA frequency within the 
CLLIR subgroup; this study did see a trend towards increasing frequency of CD8+ EMRAs 
between the CLL cohort and the healthy donors, and a stepwise trend from healthy 
donors to CLLNR to CLLIR, but the differences did not reach significance. Nunes et al. 
(2012) also demonstrated an increase in CD8+PD-1+ within the CLLIR cohort. Here an 
increase in CD8+PD-1+ T-cells was observed in the CLL cohort as a whole when 
compared to healthy donors, but no difference was seen between the CLLNR and CLLIR 
patients. Similar PD-1 results to this study were also observed in a parallel study carried 
out in our laboratory (Reiss Reid, PhD Thesis 2015). These differences may be due to 
inherent variation between the patients included in each study that led to differences in 
the clinical characteristics of the study group, such as age, gender and IGHV status. For 
example, the mean age of each cohort differed greatly between studies; the mean age of 
patients enrolled into this study was 63.3 years, whereas the previous study had a mean 
age of 73.5 years. As age is known to be related to T-cell memory and phenotype shifts 
(Koch et al. 2008), it is conceivable that some differences would be observed between 
the cohorts.  
 
Contrary to the phenotyping results, preliminary absolute counts demonstrated higher 
numbers of PD-1+ cells within the CD8+ T-cell compartment of the CLLIR patients. This 
may not be reflected in an increased frequency due to parallel increases in PD-1− cells 
within the expanded CD8+ compartment of the CLLIR subgroup. Taken together with the 
phenotyping frequencies, these results support PD-1 as a marker that distinguishes CLL 
patients from healthy donors, but not as a marker involved in the CD8+ T-cell expansion 
observed within the CLLIR subgroup. This is further corroborated when analysing the 
co-expression of CD57 and PD-1. The frequency of CD8+CD57+PD-1+ T-cells was higher 
in the CLL cohort than the healthy donors, but no difference was seen between ratio 
subgroups within CLL patients (CLLIR vs CLLNR).  
 
KLRG-1 was also included in this study to ascertain the senescence status of the CD8+ 
compartment. KLRG-1 has been shown to be expressed by more differentiated CD8+ 
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T-cells that possess poor proliferative capacity (Göthert et al. 2013; Ibegbu et al. 2005). 
A study of German CLL patients reported higher levels of KLRG-1 in the CD8+ 
compartment that was replicated in the naïve and EM memory subsets (Göthert et al. 
2013). The CD8+KLRG-1+ frequency of the total CLL cohort analysed in this study did 
not significantly differ from healthy donors, but elevated KLRG-1+ T-cell frequencies 
were observed in the EM subset. When stratified into the ratio subgroups, the CLLIR 
patients demonstrated an elevated CD8+KLRG-1+ T-cell frequency compared to CLLNR 
and HD patients. EM CD8+KLRG-1+ was higher in CLLIR patients versus healthy donors, 
but not CLLNR patients. CD57+KLRG-1+ frequency was also elevated in the CLL cohort’s 
CD8+ compartment and EM subset in the CLL cohort as a whole. As with single KLRG-1 
presentation, this was exacerbated in the CLLIR total CD8+ T-cells, but the CLLIR EM 
population did not differ from the CLLNR patients. Therefore, although KLRG-1 appears 
to be more prevalent within the CLLIR subgroup, it is not a phenotype rising from the 
EM subset. 
 
CD127 expression as part of a senescent profile was also investigated. CD127, or 
IL-7Rα, is a component of a T-cell surface ligand for the cytokine interleukin-7 (IL-7), 
and is usually found in higher levels on naïve T-cells and central memory (CM) T-cells 
(A. Ma et al. 2006). Lower CD127 expression on T-cells has been associated with a 
more differentiated state and reduced capacity to respond and divide (Golden-Mason et 
al. 2006; Bengsch et al. 2010). The frequency of CD8+CD127+ T-cells was markedly 
reduced in the CLLIR cohort compared to both the CLLNR and healthy donors. This 
appeared to be connected to the lower proportion of naïve T-cells – as naïve cells have 
high CD127+, lower naïve frequency within the CD8+ T-cell compartment would 
logically mean a decline in the frequency of CD127+ cells. This is supported by a 
retrospective correlation analysis of the phenotyping data that demonstrates significant 
correlation between CD8+ naïve and CD8+CD127+ frequencies (r = 0.5360, 
p <0.0001; Appendix V). 
 
Reduced CD127 frequency was also observed within the EM and EMRA subset of the 
CD8+ compartment of CLLIR patients. CD127 is usually used in tandem with KLRG-1 to 
help further differentiate between different subsets of antigen-experienced cells: 
CD127+KLRG-1− memory T-cells are found following resolution of acute viral infections, 
whereas CD127−KLRG-1+ memory cells are present in chronic infection. This study 
observed reduced frequency of the CD127+KLRG-1− phenotype and higher 
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CD127−KLRG-1+ in the CD8+ T-cells of CLL patients, which was exacerbated with the 
inverted ratio. This supports the increased presence of a senescent CD127−KLRG-1+ 
phenotype associated with chronic antigenic stimulation. Inverse expression of CD127 
with CD57 has been described in a similar capacity (Ibegbu et al. 2005; Bengsch et al. 
2007); in this study cohort CD127−CD57+ and CD127+CD57− frequencies followed the 
same patterns as CD127 with KLRG-1 (Appendix II), adding further weight to the 
presence of a chronically stimulated,  senescent CD8+ population in CLL that is 
exaggerated in CLLIR patients. An increase in the CD57+KLRG-1+CD127− phenotype also 
supports this shift. 
 
It is clear from this study that there is an increasing shift to a more differentiated 
phenotype presenting markers for exhaustion and senescence in the CLL cohort 
compared to healthy donors. This is exaggerated further in the CLLIR subgroup. For the 
most part the increase is driven from both the EM and EMRA subsets. However, in some 
cases significant increases in phenotypes were only observed in the whole CD8+ 
compartment with non-significant increases in the EM or EMRA subset, suggesting that 
neither the EM nor EMRA subsets were individually responsible for the phenotypic 
changes. Another observation is that when stratifying by ratio, the CLLIR subgroup data 
appears to be more heterogeneous than the CLLNR data: the CLLIR subgroup includes 
some patients who possess phenotypic frequencies similar to those in the CLLNR group, 
but other CLLIR patients display much higher frequencies. Perhaps this represents 
varying stages of T-cell senescence among inverted patients, and further stratification of 
CLLIR ‘high-expressing’ patients in a larger cohort may reveal more specific patient 
subgroups with potential clinical relevance. 
 
This study included HLA-DR and CD38 as markers for T-cell activation to more precisely 
define the T-cell subsets driving the CD8+ T-cell expansion in CLL. Overall, the CLL 
cohort had significantly higher frequencies of CD8+HLA-DR+ T-cells compared to 
healthy donors. This difference was exaggerated in the CLLIR subgroup: this was 
reflected predominantly in the EM subset, but also the EMRA subset. CD38 showed a 
similar pattern in the CLLIR CD8+ compartment: a higher frequency was seen both in the 
whole CD8+ fraction, and the CD8+ EM subset. Although an increase in T-cells with 
markers associated with senescence/exhaustion has previously been observed in CLL 
patients (Nunes et al. 2012; Göthert et al. 2013), this increase in activation markers 
suggest that a significant proportion of expanded T-cells in CLL are activated rather 
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than senescent/exhausted. Furthermore, the increase in absolute number of CD8+ 
T-cells with HLA-DR imply that the higher frequency of activated cells is due to higher 
number of these cells in CLLIR patients than the CLLNR patients. 
 
Although CD57 expression is associated with a senescent T-cell phenotype, some 
evidence shows that under certain conditions CD57+ T-cells are able to respond to 
stimuli, extensively proliferate and produce cytokines (Chong et al. 2008). Therefore 
CD57+ T-cells may not be truly senescent, but instead represent highly differentiated 
cells that require certain conditions to respond. This study looked at the presentation of 
senescent markers CD57 and KLRG-1 with activation markers HLA-DR and CD38. The 
phenotypes CD57+HLA-DR+, CD57+CD38+ and KLRG-1+CD38+ were markedly higher in 
the CD8+ T-cell compartment of CLLIR patients. This pattern of expression was reflected 
in both the EM and EMRA subsets. This demonstrates that there is a subgroup of CD8+ 
T-cells that, although are highly differentiated, are also activated and potentially 
responsive to stimulus. Furthermore, as demonstrated in the increased number of 
CD8+CD57+HLA-DR+ T-cells in CLLIR patients (Figure 3.41B), these cells are more 
prevalent in this patient subgroup. This could be due to an accumulation of these cells 
under chronic stimulation. Due to the constraints of the Panels, the relationship 
between KLRG-1 and HLA-DR could not be explored. However, the results obtained 
suggest activation and proliferation of highly differentiated CD8+ T-cells in CLLIR 
patients. It is not clear what antigenic stimulus (if any) is driving the expansion of these 
T-cells.  
 
PD-1 is usually referred to as a marker for exhaustion, but is upregulated during 
activation: previous studies have demonstrated higher expression of PD-1 during T-cell 
activation than on resting cells, and co-expression with activation markers HLA-DR and 
CD38 – the same markers used in this study (Sauce et al. 2007). CD8+PD-1+HLA-DR+ 
T-cells were higher in CLL patients, but frequency of this phenotype was not associated 
with inverted CD4:CD8 ratio. This adds further evidence that PD-1 is not a CLLIR related 
marker, and activated PD-1+ CD8+ T-cells are not the dominant population among the 
expanded T-cells in the CLLIR patients.  
 
Multivariate analyses were included in this study to identify which CD8+ T-cell 
phenotypes were considered the most important in terms of prognosis. CD4:CD8 ratio 
did not appear to have a strong effect on prognosis, although it did have a contributing 
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effect alongside some other T-cell phenotypes (Table 4, Appendix IV). Furthermore, 
CD8+ frequency had a significant association with prognosis, implying that the CD8+ 
expansion did have prognostic weight. The two CD8+ phenotypes that did appear to 
have an independent effect on the prognosis of CLL patients were CD57+HLA-DR+ and 
EMRA CD57+HLA-DR+PD-1+. Recursive partitioning helped to subdivide the whole CLL 
cohort by the most prognostically relevant frequencies of these phenotypes: overall, 
patients with higher frequencies of CD8+ T-cells with these markers had poorer 
prognosis. It is worth noting that there were potential cut-offs at even higher 
frequencies: these subgroups of ‘high-expressing’ patients had a much poorer prognosis. 
This further supports that the higher the frequency of these phenotypes, the poorer 
prognosis the patient may have, although low patient numbers and wide confidence 
intervals mean that these results should be taken with caution.  
 
Both of these phenotypes are characteristic of highly differentiated, but activated, 
T-cells. It is possible that the accumulation of these T-cells are potentially either 
contributing to, or are a result of, the CLL pathology. Furthermore this may be driven by 
antigenic stimulation from the CLL cells themselves. Both of these phenotypes were 
shown to be higher in absolute numbers within the CLLIR subgroup, which further 
supports the expansion and accumulation of these phenotypes from stimuli driven 
proliferation. The multivariate analyses demonstrated there are some CD8+ phenotypes 
identified from this study that have improved prognostic value over T-cell ratio; it may 
be that ratio is prognostically valuable due to the phenotypes that are driving the 
inversion. 
 
In the majority of cases, CLL diagnosis is in elderly patients. The CLL cohort used in this 
study had an average age of 63.3 years at diagnosis. The elderly have been shown to 
have a compromised immunophenotypic profile compared to their younger 
counterparts, including an age-associated decrease in the naïve CD8+ T-cell frequency 
and increase in CD8+ EMRA T-cell frequency (Koch et al. 2008). This study used 
age-matched healthy donors to ensure that differences in T-cell phenotypes observed 
between CLL patients and healthy donors were not age-related. The memory T-cell 
phenotype skewing observed in this study was more predominantly within the EM T-cell 
subset rather than the further differentiated EMRA subset, providing further evidence 
that the observed phenotypic changes were related to disease rather than age. 
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In addition to age, secondary diseases and infections are also known to affect the T-cell 
compartment. Cytomegalovirus (CMV) is a common herpes virus that the majority of 
people encounter during their lifetime; infection is usually asymptomatic in the 
immunocompetent. However, once infected, CMV persists in a latent form for the rest of 
an individual’s lifetime. This can lead to skewing of the T-cell compartment due to the 
presence of chronically stimulated CMV-specific T-cells (Vasto et al. 2007).  
 
Due to its prevalence and persistence, a majority of elderly patients are CMV-positive, 
and exhibit CMV driven phenotypic changes in their T-cells (Vasto et al. 2007; Pita-
Lopez et al. 2009). Accumulation of highly differentiated but responsive CMV-specific 
T-cells in CLL has been shown previously (Raa et al. 2014). The current study observed 
no association between CMV and the CD4:CD8 T-cell ratio of CLL patients. 
Furthermore, stratifying patients based on CMV seropositivity showed a skewing 
towards a CD8+ EMRA phenotype. This is in line with the CMV driven phenotypic 
skewing recorded in previous work. This is different from the memory phenotype effect 
observed in the CLLIR patients of this study, which is more biased towards the EM 
memory subset. Therefore, findings observed here within the CLLIR cohort are 
independent of a CMV driven T-cell response. This confirms the previous study from our 
laboratory that demonstrated that the inverted CD4:CD8 ratio in CLL is independent of 
CMV (Nunes et al. 2012). 
 
The number of available CMV− patients restricted the analysis of CMV further in this 
study: a total 4 CLLIR patients were CMV− and only 1 of those patients was subjected to 
the complete phenotypic analysis (3 were analysed for memory subsets only). This 
prevented a more in depth exploration of CMV seropositivity and potential correlations 
with marker expression. As previously mentioned, the majority of elderly patients have 
encountered CMV, so this will limit any study of CMV− individuals in a CLL cohort. 
However, the high prevalence of CMV+ patients in both CLLNR and CLLIR subgroups 
would in itself suggest that results observed in CLLIR patients is not CMV driven. 
Regardless, future studies with larger numbers of CLL patients are required in order to 
obtain sufficient numbers of CMV− patients and eliminate CMV as a confounding factor 
when comparing the CLL subgroups. 
 
This study clearly demonstrates that application of multiple markers in tandem is more 
beneficial than looking at a single marker independently. The phenotypic complexity of 
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T-cells within CLL was missed in earlier studies, and this has an impact on 
interpretation of the role of T-cells in disease, e.g. that CD8+PD-1+ T-cells may not 
necessarily be “exhausted” in CLL as they often co-express activation markers, such as 
HLA-DR. One limitation of this study, however, was in the segregation of markers on 
two different phenotypic panels. This was a constraint of the FACS Canto II machine 
because only 8 parameters could be measured in a single sample. This prevented some 
comparisons between markers that could have been relevant, such as PD-1 with CD38, 
as they were not on the same panel. Future work could include compiling markers onto 
one larger phenotyping panel, using a flow cytometer that can analyse more 
parameters, such as the FACS Aria (11-16 parameters). This could also include further 
markers that allow for a more precise definition of T-cell subsets, including additional 
memory defining markers to further accurately identify the EM and EMRA populations, 
as well as additional senescence/activation markers. Another potential direction would 
be to rationalise the markers into a more streamlined, relevant flow cytometry panel 
including the markers deemed more prognostically relevant. This is further explored in 
Chapter 6, where a panel was developed based on the results of this chapter to analyse 
treated patients. 
 
Although CD8+ T-cells were the primary focus of the study, CD4+ T-cell data was also 
collected and analysed in the multivariate analyses. CD4+PD-1+HLA-DR+ was revealed 
to be the phenotype that had the strongest independent effect on PFS in this study, 
stronger than any CD8+ phenotype. Therefore, phenotypic evaluation of the CD4+ 
T-cells would be important in furthering our understanding of T-cells in CLL patients, 
and this is the focus of the next chapter. 
 
To conclude, this study has observed a skewing towards a more differentiated memory 
phenotype in CLL patients with an inverted CD4:CD8 ratio. As may be expected with an 
increase in differentiated memory, the CLLIR patients also possessed a larger percentage 
of CD8+ T-cells that displayed phenotypes associated with senescence. However, 
elevated levels of activation phenotypes are also observed, including co-expression with 
the senescence markers, implying that a small proportion of the differentiated cells have 
a mixed phenotype. Preliminary absolute counts suggest that these elevated levels of 
these phenotypes are due to an increase in absolute number. Therefore, there appears 
to be an increase in senescent, but activated T-cell phenotypes that could be an 
accumulation of chronically stimulated CD8+ T-cells, perhaps driven by the CLL tumour 
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antigens. That these phenotypes are exacerbated in CLLIR patients, who have been 
proven to have poorer prognosis than their normal ratio counterparts, implies that 
accumulation of these cells could be linked to the CLL disease and prognosis, either as a 
factor driving the poorer prognosis and exacerbated disease, or as a resulting effect of 
other factors that are driving the prognostic disease. There are some phenotypes in this 
study that have been shown to have greater prognostic power than ratio; as these 
phenotypes are shown in greater frequency in the CLLIR subgroup, it could be that the 
ratio and phenotypes are linked, but it is the phenotype that is more relevant in CLL 
pathology. 
 
In any case, the CD4:CD8 ratio does appear to be a prognostic factor that can identify 
patients who are more ‘at risk’, but this study has uncovered more relevant CD8+ T-cell 
phenotypes with greater prognostic potential and therefore more clinical relevance. 
These new phenotypic markers now need to be validated in a prospective fashion in 
larger cohorts of CLL patients. 
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Chapter 4 
Immunophenotyping of CD4+ T-cells in CLL 
The original aim of this thesis was to explore the CD8+ T-cell compartment of CLL 
patients in order to further understand their potential role in disease. This was based on 
previous descriptions of a subgroup of patients with inferior prognosis who had a 
preferentially expanded CD8+ T-cell compartment resulting in an inverted CD4:CD8 
ratio (CLLIR). Phenotypic exploration of these CD8+ T-cells in Chapter 3 demonstrated 
great phenotypic complexity, with distinct differences between CLLNR and CLLIR patients. 
 
When multivariate analyses were performed to elucidate whether distinct CD8+ T-cell 
phenotypes were linked to poorer prognosis in the CLL cohort, the CD4+ phenotype 
HLA-DR+PD-1+ was also shown to be prognostically relevant. In fact, this phenotype 
had a greater effect on progression-free survival (PFS) than the CD8+ phenotypes 
identified in the analysis (Chapter 3, Table 3.4).  
 
Like their CD8+ counterparts, CD4+ T-cell abnormalities have also been reported 
previously in CLL (Görgün et al. 2005; Tinhofer et al. 2009; Monserrat et al. 2013). In 
addition to this, CD4+ helper T-cells have been shown to activate and maintain CLL cells 
both in vitro and in vivo (Os et al. 2013). It was therefore apparent that phenotypic 
exploration of CD4+ T-cells in CLL patients could reveal CD4+ subpopulations with 
potential relevance to CLL disease. Although we previously showed that preferential 
expansion of CD8+ T-cells was the major contributor to the CLLIR phenotype, a detailed 
analysis of the CD4+ subset could reveal phenotypes that are more prominent within the 
inverted ratio patients that could potentially exacerbate the disease. 
 
Therefore, this Chapter set out to characterise the CD4+ T-cells of CLL patients, with 
specific reference to the CLLNR and CLLIR subgroups. Focus was given to phenotypic 
markers that were identified in the previous chapter. 
Chapter 4: Results 
127 
 
 
Figure 4.1. Representative gating strategy used for phenotypic analysis of CD4+ 
T-cells. (A) Gating strategy for CD4+ T-cells and their respective memory subsets. Cells were 
collected using flow cytometry (FACS CantoII, BD FACSDiva) and analysed using FlowJo (v.9). 
Lymphocytes were gated based on forward and side scatter profile; single cells were gated by 
forward scatter area and height. CD4+ T-cells were identified by gating on CD3+ and then CD8− 
or CD4+ populations. Memory subsets were defined using CCR7 and CD45RO memory markers: 
naïve (CCR7+CD45RO−), central memory (CM, CCR7+CD45RO+), effector memory (EM, 
CCR7−CD45RO+) and EMRA (CCR7−CD45RO−). (B) Gating strategy for activation and 
senescence/exhaustion markers within the CD4+ T-cell compartments and memory subsets. 
Gating of positive populations was confirmed with fluorescence-minus-one (FMO) controls 
where necessary. 
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 Gat ing  for  CD4 + T-ce l l s :  use  o f  CD8− 4.1.
The gating strategy applied to the CD4+ analysis was similar to that applied to CD8+ 
T-cells (Figure 4.1). During the initial phases of analysis, restrictions on the numbers of 
markers in the antibody panels meant that it was not possible to include an antibody for 
CD4. Instead, primary analysis was performed on an Accuri C6 4-colour flow cytometer, 
and initial 8-colour analyses on the BD FACS Canto II included an additional marker, 
BCL-2 (see Chapter 2 for further Panel information). Subsequently, a CD4 antibody was 
substituted into one of the two FACS Canto II panels to positively identify this subset of 
T-cells.  
 
To assess whether gated CD8− T-cells from previous panels could be used in lieu of a 
defined CD4+ population, SPICE analysis was performed to compare memory subset 
distribution between the CD8− (when a CD4 antibody was not included) and CD4+ 
T-cell compartments (Figure 4.2, Table 4.1). No statistical difference was seen between 
the average memory subset distributions between these subsets for CLL patients as a 
whole (p = 0.39) or when subdivided in CLLNR and CLLIR subgroups (p = 0.67 and 
p = 0.66, respectively), suggesting that the CD8− gate in the earlier analyses was 
analogous to the CD4+ T-cell population. Therefore, the CD8− data was amalgamated 
with the CD4+ data and included in the phenotypic analysis. 
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Figure 4.2. Subset comparison of CD4+ and CD8− memory subsets in CLL. Cells 
were collected using flow cytometry (FACS CantoII, BD FACSDiva) and analysed with FlowJo 
(v.9) using gating as described in Figure 4.1. Pie charts and accompanying statistics comparing 
CD8− (n = 61) and CD4+ (n = 95) memory subsets were generated using SPICE software (v5.3). 
 
 
 
Table 4.1. Pie chart analysis of memory subsets in CLL patients (CD8− vs CD4+) 
Patient Group CD8− vs CD4+ 
Total CLL 0.3939 
CLLNR 0.6718 
CLLIR 0.6620 
 
T-cell: CD8- T-cell: CD4+
Total&CLL&
CLLNR&
Patient Type: NR
T-cell: CD8-
Patient Type: NR
T-cell: CD4+
Patient Type: IR
T-cell: CD8-
Patient Type: IR
T-cell: CD4+
CLLIR&
CD8−& CD4+&
Naïve&
CM&
EM&
EMRA&
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 CD4 + memory  subsets  in  CLL 4.2.
Skewing to a more differentiated memory T-cell phenotype has already been 
demonstrated within the CD8+ compartment of CLLIR patients in the previous chapter 
(Chapter 3). The same analysis was performed on the CD4+ compartment to see if CD4+ 
memory cells of CLL patients were also abnormal when compared to age-matched 
healthy donors.  
 
As Figure 4.3 demonstrates, CD4+ naïve T-cells were significantly reduced in the CLL 
cohort compared to healthy donors (p = 0.0034), as were the CM subset 
(p = 0.0082). Inversely, The CD4+ EM compartment was larger in CLL patients 
compared to healthy donors, with an approximately 2-fold increase in frequency from 
22.03% to 40.22% (p = 0.0009). Therefore, it would seem that like the CD8+ 
compartment, CD4+ T-cells also demonstrate a more differentiated memory EM 
phenotype in CLL patients when compared with healthy age-matched controls. 
 
This was exacerbated when patients were stratified according to CD4:CD8 ratio 
(Figure 4.4): CLLIR patients had a significantly reduced naïve compartment (p ≤0.001 
versus both CLLNR and HD) and increased EM compartment (p ≤0.01 versus CLLNR and 
p ≤0.001 versus HD). As was the case for CD8+ T-cells, CD4+ T-cells demonstrated a 
significant skewing to a more differentiated EM phenotype within the memory subsets 
in the CLLIR subgroup. In contrast, the CD4+ EMRA population showed no significant 
increase; a trend that was evident in the CD8+ T-cell compartment (Chapter 3, Figure 
3.2). However, the CD4+ EMRA population represented a relatively low proportion of 
the CD4+ compartment compared to the EMRA compartment of the CD8+ (16.6% 
versus 52.5%, p < 0.0001). Furthermore, it is interesting to note that although CD4+ 
T-cells showed a reduction in naïve T-cells, a greater proportion of the CD4+ 
compartment is naïve when compared with CD8+ T-cells. 
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Figure 4.3. CD4+ T-cell memory subsets in age-matched healthy donors (HD, 
n = 14) and CLL patients (n = 99). Cells were collected using flow cytometry (FACS 
CantoII, BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 4.1. 
Lymphocytes were gated based on forward and side scatter profile; forward scatter area and 
height were used for exclusion of doublet cells. CD4+ T-cells were identified by gating on CD3+ 
and then CD8−or CD4+ populations. Memory subsets were defined using CCR7 and CD45RO 
memory markers: naïve (CCR7+CD45RO−), central memory (CM, CCR7+CD45RO+), effector 
memory (EM, CCR7−CD45RO+) and EMRA (CCR7−CD45RO−). Pairwise statistical analysis (HD 
vs CLL) was performed using the non-parametric Mann-Whitney test. Significant results were 
included on the graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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Figure 4.4. CD4+ T-cell memory subsets in age-matched healthy donors (HD, 
n = 14) and CLL patients with a normal (CLLNR, n = 63) and inverted (CLLIR, 
n = 36) CD4:CD8 T-cell ratio. Cells were collected using flow cytometry (FACS CantoII, 
BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 4.1. CLL 
patients with a CD4:CD8 ratio <1.0 were considered inverted. Three-way ANOVA statistical 
analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data 
assessed using the Dunn’s post-test. Significant results were included on the graph 
(* = p ≤0.05; ** =  p ≤0.01; *** = p ≤0.001). 
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 Phenotyp ic  overv iew 4.3.
A graphical overview of the different phenotypes and statistical comparisons for the 
whole CD4+ compartment was generated using SPICE version 5.3 (Figure 4.5, Table 
4.2; see Appendix VI for complete statistics). As with the CD8+ compartment, the CD4+ 
subset manifested phenotypic complexity with many sub-populations of T-cells defined 
based on the expression of multiple markers. Statistical comparison of the pie charts 
showed significant phenotypic differences between the CD4+ profile of CLL patients 
when compared with age-matched healthy donors in Panel 1, but not Panel 2 (Table 
4.2). An increase in CD4+ T-cells expressing one or more of the Panel 1 markers was 
clearly apparent, particularly the increase in PD-1+ (p <0.0001) and PD-1+HLA-DR+ 
(p <0.0001) cells. Triple positive cells (CD57+HLA-DR+PD-1+) also constituted a 
greater proportion of the CD4+ compartment in CLL patients compared to age-matched 
healthy donors (p <0.0001).  
 
Overall phenotypic changes were also observed in the CLLIR cohort compared to CLLNR 
patients and healthy donors (Figure 4.6, Table 4.3). Panel 1 showed the most significant 
differences, particularly with the increase in CD4+ T-cells co-expressing two or three 
markers at once. For example, CLLIR had a higher proportion of PD-1+HLA-DR+ 
(p <0.0001) and CD57+HLA-DR+ (p = 0.0012) expressing cells in the CD4+ 
compartment compared to CLLNR, as well as an increase in triple positive cells 
(CD57+PD-1+HLA-DR+, p <0.0001). In Panel 2, the CLLIR CD4+ compartment showed 
reduced CD127+CD38+ expressing cells (p = 0.0085), but an increase in 
CD57+KLRG-1+CD38+ cells (p = 0.0187). Unlike Panel 1, there were no overall 
differences in panel 2 markers between the CLLNR subgroup and age-matched healthy 
donors (Table 4.3). 
 
This phenotypic overview shows the complexity of sub-populations within the CD4+ 
T-cell compartment, and lends further support to the idea that both CD4+ and CD8+ 
T-cells experience preferential phenotypic changes within CLL and the CLLIR patients.  
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Table 4.2. Overall CD4+ phenotypic pie chart analysis (age-matched HD vs CLL) 
Panel HD vs CLL 
Panel 1 <0.0001 
Panel 2 0.2110 
 
 
 
Table 4.3. Overall CD4+ phenotypic pie chart analysis (age-matched HD vs CLLNR 
vs CLLIR) 
Panel HD vs CLLNR HD vs CLLIR CLLNR vs CLLIR 
Panel 1 0.0005 <0.0001 0.0009 
Panel 2 0.3492 0.0044 0.0044 
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 Markers  assoc ia ted  with  senescence  and/or  exhaust ion   4.4.
 
 PD-1 and CD57 4.4.1.
It was clear that phenotypic changes also occurred within the CD4+ T-cell population of 
the CLL patients, and like the CD8+ T-cells there was an observed skewing to the EM 
memory subset. To determine whether CLL patients were driven to a more exhausted, 
or highly differentiated, CD4+ phenotype, frequencies of PD-1+ and CD57+ T-cells were 
assessed. 
 
Within the CD4+ compartment, there was evidence of significantly higher PD-1 
frequencies in CLL patients when compared with age-matched healthy donors 
(p <0.0001; Figure 4.7A). This increase in PD-1-expressing cells appeared to originate 
predominantly from the CD4+ EM T-cells (p <0.0001), but was also increased in the 
EMRA subset (p = 0.0101).  
 
Interestingly, when stratified by CD4: CD8 ratio, the CLL patients in the CLLIR subgroup 
showed significantly higher levels of CD4+PD-1+ EM T-cells than the CLLNR subgroup 
and age-matched healthy donors (p ≤0.05 and p ≤0.001, respectively; Figure 4.7B). 
These findings contrasted with the proportions of CD8+PD-1+ expressing T-cells 
observed in the previous chapter, where the percentage of PD-1+ T-cells were not 
significantly different between CLLNR and CLLIR patients. 
 
In line with previous results (Nunes et al. 2012), a higher CD4+CD57+ T-cell frequency 
was observed in CLL patients compared to the healthy donors (p = 0.0088; Figure 
4.8A). On subdividing into memory subsets, this higher frequency appeared to be 
attributable to the EM subset (p = 0.0049). This significant increase was reflected in 
both the EM and EMRA memory subsets of CLL patients versus healthy donors 
(p <0.0001 and 0.0127, respectively), although a greater proportion originated from 
the EM subset. The pattern of CD4+CD57+ expression was exacerbated in the CLLIR 
subgroup (Figure 4.8B), where higher frequencies of CD4+CD57+ T-cells were seen 
compared to both CLLNR patients and healthy donors, and again this seemed to be 
attributable to higher frequencies in the CD4+ EM memory subset (p ≤0.001 for both). 
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Figure 4.7. PD-1 frequency in CD4+ T-cell memory subsets of CLL patients and 
age-matched healthy donors. Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 4.1. (A) 
CD4+PD-1+ T-cells in the whole CD4+ T-cell compartment, CD4+ EM and CD4+ EMRA memory 
subsets of CLL patients (n = 74) and healthy donors (n = 14). Pairwise statistical analysis (HD 
vs CLL) was performed using the non-parametric Mann-Whitney test. Patients were stratified 
based on CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a ratio 
≥1.0 were considered normal ratio patients (CLLNR). (B) Frequency of CD4+PD-1+ T-cells in the 
whole CD4+ T-cell compartment, CD4+ EM and CD8+ EMRA memory subsets of CLLNR (n = 47), 
CLLIR (n = 27) and healthy donors (n = 14). Three-way ANOVA statistical analysis was 
performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data assessed using 
the Dunn’s post-test. Significant results were included on the graph (* = p ≤0.05; 
** = p ≤0.01; *** = p ≤0.001). 
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Figure 4.8. CD57 frequency in CD4+ T-cell memory subsets of CLL patients and 
age-matched healthy donors. Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 4.1. (A) 
CD4+CD57+ T-cells in the whole CD4+ T-cell compartment, CD4+ EM and CD4+ EMRA memory 
subsets of CLL patients (n = 74) and healthy donors (n = 14). Pairwise statistical analysis (HD 
vs CLL) was performed using the non-parametric Mann-Whitney test. Patients were stratified 
based on CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a ratio 
≥1.0 were considered normal ratio patients (CLLNR). (B) Frequency of CD4+CD57+ T-cells in the 
whole CD4+ T-cell compartment, CD4+ EM and CD8+ EMRA memory subsets of CLLNR (n = 47), 
CLLIR (n = 27) and healthy donors (n = 14). Three-way ANOVA statistical analysis was 
performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data assessed using 
the Dunn’s post-test. Significant results were included on the graph (* = p ≤0.05; 
** = p ≤0.01; *** = p ≤0.001). 
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Taking these markers together, the average CD57+PD-1+ T-cell frequency was more 
than 5-fold higher in the CD4+ T-cells of the CLL cohort than the healthy age-matched 
donors (11.56% versus 2.28% respectively; p <0.0001; Figure 4.9A). Again, this was 
exacerbated in the CLLIR subgroup which demonstrated significantly higher 
CD4+CD57+PD-1+ T-cells than both the CLLNR subgroup and the healthy donors 
(p ≤0.001 for both; Figure 4.9B), with average CD57+PD-1+ frequency of CLLIR 
patients more than 7-fold higher than healthy donors.  
 
Increased frequency of the CD57 and PD-1 markers, both individually and co-expressed, 
further support a skew to a more differentiated subset in the CD4+ T-cells, which was 
more marked in the CLLIR subgroup. Interestingly, the increase in PD-1+ and 
CD57+PD-1+ frequencies within the CD4+ compartment of CLLIR patients differed from 
the results seen with CD8+, where PD-1 expression was not associated with an inverted 
CD4:CD8 ratio (Chapter 3, Section 3.3.1, Figure 3.8).  
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Figure 4.9. CD57 and PD-1 co-expression in CD4+ T-cells of CLL patients and age-
matched healthy donors. Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 4.1. (A) 
CD4+CD57+PD-1+ T-cells in the whole CD4+ T-cell compartment, CD4+ EM and CD4+ EMRA 
memory subsets of CLL patients (n = 74) and healthy donors (n = 14). Pairwise statistical 
analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney test. Patients were 
stratified based on CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a 
ratio ≥1.0 were considered normal ratio patients (CLLNR). (B) Frequency of CD4+CD57+PD-1+ 
T-cells in the whole CD4+ T-cell compartment, CD4+ EM and CD8+ EMRA memory subsets of 
CLLNR (n = 47), CLLIR (n = 27) and healthy donors (n = 14). Three-way ANOVA statistical 
analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data 
assessed using the Dunn’s post-test. Significant results were included on the graph 
(* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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 Naïve  phenotypes  (CD127 and CD38)  4.4.2.
As described in Section 4.2, the CD4+ naïve population was significantly reduced in CLL 
patients, particularly in the CLLIR subgroup. This was also seen in CD8+ T-cell 
compartment in Chapter 3, and aligned with a reduction of CD127+ naïve cells. We 
therefore explored whether any of the activation or senescence phenotypic markers 
included in this study were associated with the reduction in CD4+ naïve cells. 
 
Like the CD8+ compartment, CD127+ frequencies were significantly lower in the CD4+ 
T-cell compartment of CLL patients compared to their healthy age-matched counterparts 
(p = 0.0061; Figure 4.10A). The activation marker CD38+ was also markedly reduced 
in the CD4+ naïve compartment of CLL patients (p = 0.0011). The reduction of 
CD127+ and CD38+ was more severe in CLLIR patients when compared to both CLLNR 
and healthy donors (p ≤0.01 and p ≤0.001, respectively; Figure 4.10B). The CLLIR 
cohort also demonstrated an extended decrease in naïve CD4+CD38+ T-cells compared 
to both CLLNR and healthy donors (p ≤0.05 and p ≤0.001, respectively).  
 
As both CD127 and CD38 followed the same pattern of reduction in the CD4+ naïve 
population of CLL patients, further analysis was performed to explore the co-expression 
of both markers within the CD4+ naïve subset of CLL patients. The frequency of 
CD4+CD38+CD127+ naïve T-cells was markedly reduced in the CLL cohort when 
compared to healthy donors (p = 0.0059; Figure 4.11A), and this was exacerbated in 
the CLLIR subgroup of patients, which demonstrated lower frequencies than both the 
CLLNR and healthy donor groups (p ≤0.01 and p ≤0.001, respectively; Figure 4.11B). 
Furthermore, subsequent correlation analysis of CD38 against CD127 revealed that 
there was a strong linear correlation between the two markers (r = 0.8461, 
p <0.0001; Figure 4.11C). Taken together this lends support to the notion that the 
naïve CD127+CD38+ phenotype is depleted within the CD4+ compartment of CLL 
patients, and this is particularly evident in those with an inverted CD4:CD8 ratio. 
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Figure 4.10. CD38 and CD127 frequency in CD4+ naïve T-cells of CLL patients 
and age-matched healthy donors. Cells were collected using flow cytometry (FACS CantoII, 
BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 4.1. (A) 
CD4+CD38+ and CD4+CD127+ T-cells in the CD4+ naïve memory subset of CLL patients 
(n = 74) and healthy donors (n = 14). Pairwise statistical analysis (HD vs CLL) was performed 
using the non-parametric Mann-Whitney test. Patients were stratified based on CD4:CD8 ratio: a 
ratio <1.0 was considered inverted (CLLIR). Patients with a ratio ≥1.0 were considered normal 
ratio patients (CLLNR). (B) Frequency of CD4+CD38+ and CD4+CD127+ T-cells in the CD4+ naïve 
memory subset of CLLNR (n = 47), CLLIR (n = 27) and healthy donors (n = 14). Three-way 
ANOVA statistical analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with 
all pairs of data assessed using the Dunn’s post-test.  Significant results were included on the 
graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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Figure 4.11. CD38 and CD127 co-expression in CD4+ T-cells of CLL patients and 
age-matched healthy donors. Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 4.1. (A) 
CD4+CD38+CD127+ T-cells in the CD4+ naïve memory compartment of CLL patients (n = 74) 
and healthy donors (n = 14). Pairwise statistical analysis (HD vs CLL) was performed using the 
non-parametric Mann-Whitney test. Patients were stratified based on CD4:CD8 ratio: a ratio 
<1.0 was considered inverted (CLLIR). Patients with a ratio ≥1.0 were considered normal ratio 
patients (CLLNR). (B) Frequency of CD4+CD38+CD127+ T-cells in the CD4+ naïve memory 
compartment of CLLNR (n = 47), CLLIR (n = 27) and healthy donors (n = 14). Three-way 
ANOVA statistical analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with 
all pairs of data assessed using the Dunn’s post-test. (C) Correlation analysis of CD38 versus 
CD127 in the CD4+ naive memory compartment of CLL patients. Pearson correlation analysis 
was performed to quantify the degree of correlation between the two parameters. Significant 
results were included on the graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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 Markers  assoc ia ted  with  act ivat ion  4.5.
 
 HLA-DR and CD38 4.5.1.
Alongside an increase to more differentiated phenotypes in CLL patients, Chapter 3 also 
showed an increase in CD8+ T-cells expressing markers associated with T-cell activation 
(HLA-DR and CD38). This was heightened in the CLLIR patients and implied that there 
was an expansion of activated T-cells within the CD8+ compartment. It is worthy of note 
that CD38 expression on T-cells has been previously identified as a potential prognostic 
marker in CLL (Tinhofer et al. 2006). As a skewing to a more differentiated phenotype 
was also seen in the CD4+ T-cell population, the expression of HLA-DR and CD38 were 
also explored within this compartment. 
 
When looking at the CLL cohort as a whole, there was no significant difference in the 
frequency of CD4+HLA-DR+ T-cells when compared to age-matched healthy donors. 
However, there was a significant difference between CLL patients and healthy donors in 
the CD4+EM subset (p = 0.0232, Figure 4.12A). Stratification of the cohort showed that 
the CLLIR subgroup had significantly higher CD4+HLA-DR+ T-cell frequencies compared 
to the CLLNR and healthy donors in the whole CD4+ compartment (Figure 4.12B, 
p ≤0.01 for both); again, this appeared to be driven by an increased frequency within 
the CD4+ EM T-cells (p ≤0.01 versus both CLLNR and CLLIR).  
 
In the CD4+ T-cell compartment as a whole, the frequency of CD38+ T-cells did not 
differ between CLL patients and healthy donors. However, the percentage of 
CD4+CD38+ T-cells was significantly higher within the CD4+ EM subset (p = 0.0029, 
Figure 4.13A). No difference was seen between CLLNR and CLLIR CD4+CD38+ 
frequencies in either the whole population, or the EM subset (Figure 4.13B). It was 
reported in the previous section that CD4+ naïve memory T-cells had a reduced 
frequency of naïve CD38+ cells (Section 4.4.2): this may have negated the rise in CD38+ 
EM frequency, resulting in the lack of frequency change in the entire CD4+ T-cell 
population as a whole. 
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Figure 4.12. HLA-DR frequency in CD4+ T-cell memory subsets of CLL patients 
and age-matched healthy donors. Cells were collected using flow cytometry (FACS CantoII, 
BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 4.1. (A) 
CD4+HLA-DR+ T-cells in the whole CD4+ T-cell compartment and CD4+ EM memory subset of 
CLL patients (n = 74) and healthy donors (n = 14). Pairwise statistical analysis (HD vs CLL) was 
performed using the non-parametric Mann-Whitney test. Patients were stratified based on 
CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a ratio ≥1.0 were 
considered normal ratio patients (CLLNR). (B) Frequency of CD4+HLA-DR+ T-cells in the whole 
CD4+ T-cell compartment, CD4+ EM and CD8+ EMRA memory subsets of CLLNR (n = 47), CLLIR 
(n = 27) and healthy donors (n = 14). Three-way ANOVA statistical analysis was performed 
using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data assessed using the Dunn’s 
post-test.  Significant results were included on the graph (* = p ≤0.05; ** = p ≤0.01; 
*** = p ≤0.001). 
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Figure 4.13. CD38 frequency in CD4+ EM T-cells of CLL patients and age-matched 
healthy donors. Cells were collected using flow cytometry (FACS CantoII, BD FACSDiva) and 
analysed with FlowJo (v.9) using gating as described in Figure 4.1. (A) CD4+CD38+ T-cells in 
the CD4+ EM memory subset of CLL patients (n = 74) and healthy donors (n = 14). Pairwise 
statistical analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney test. 
Patients were stratified based on CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). 
Patients with a ratio ≥1.0 were considered normal ratio patients (CLLNR). (B) Frequency of 
CD4+CD38+ T-cells in the CD4+ EM memory subset of CLLNR (n = 47), CLLIR (n = 27) and 
healthy donors (n = 14). Three-way ANOVA statistical analysis was performed using 
Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data assessed using the Dunn’s post-
test.  Significant results were included on the graph (* = p ≤0.05; ** = p ≤0.01; 
*** = p ≤0.001). 
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In summary, this section demonstrates that in addition to a skewed memory phenotype, 
CLL patients demonstrated higher proportions of activated CD4+ T-cells that largely 
originate from the EM subset. Interestingly, elevated levels of activated CD4+ T-cells 
were shown in the CLLIR patients, but this exacerbation was only seen with the 
CD4+HLA-DR+ phenotype, again driven by the CD4+ EM subset (Figure 4.12B). Overall, 
there was an increased frequency of more differentiated, potentially activated 
(HLA-DR+) T-cells linked with inversion of the CD4:CD8 ratio. 
 
 CD57,  PD-1  and HLA-DR 4.5.2.
As discussed in the previous chapter, although markers such as PD-1 and CD57 are 
considered exhaustion/senescent markers, there remains some controversy in using 
them in isolation as an identifier of exhausted or senescent cells, as they can be found 
on T-cells that are able to respond to certain stimuli, such as CD3 with IL-2 and AB 
serum (Chong et al. 2008). In support of this, we identified subsets of phenotypes in the 
CD8+ compartment that co-expressed PD-1 and/or CD57 with activation markers 
(PD-1+HLA-DR+, CD57+HLA-DR+, CD57+CD38+ and CD57+PD-1+HLA-DR+) that were 
markedly increased in CLL patients. Furthermore, CLLIR patients had a more marked 
increase in CD8+ T-cells that co-presented CD57 with either HLA-DR or PD-1. With the 
previous section demonstrating increased single frequencies of these markers, further 
phenotypic analysis was applied to identify any patterns of co-expression of 
senescent/exhaustion markers with activation markers on CD4+ T-cells of CLL patients. 
 
The CLL cohort displayed an increased frequency of CD57+HLA-DR+ T-cells compared 
to healthy donors in the CD4+ total compartment (p = 0.0020), as well as the CD4+ 
EM and EMRA memory subsets (p = 0.0013 and p = 0.0363, respectively; Figure 
4.14A). CD4+CD57+HLA-DR+ frequencies were amplified in the CLLIR subgroup 
compared to both CLLNR and age-matched healthy donors (Figure 4.14B): again, this 
was seen in the total CD4+compartment (p ≤0.001 for both), CD4+ EM (p ≤0.001 for 
both) and CD4+ EMRA memory subsets (p ≤0.05 versus CLLNR; p ≤0.01 versus HD). It 
is worth noting that a large proportion of this phenotype appeared to originate from the 
EM subset rather than the EMRA subset. 
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Figure 4.14. CD57 and HLA-DR co-expression in CD4+ T-cells of CLL patients and 
age-matched healthy donors. Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 4.1. (A) 
CD4+CD57+HLA-DR+ T-cells in the whole CD4+ T-cell compartment, CD4+ EM and CD4+ EMRA 
memory subsets of CLL patients (n = 74) and healthy donors (n = 14). Pairwise statistical 
analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney test. Patients were 
stratified based on CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a 
ratio ≥1.0 were considered normal ratio patients (CLLNR). (B) Frequency of 
CD4+CD57+HLA-DR+ T-cells in the whole CD4+ T-cell compartment, CD4+ EM and CD8+ EMRA 
memory subsets of CLLNR (n = 47), CLLIR (n = 27) and healthy donors (n = 14). Three-way 
ANOVA statistical analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with 
all pairs of data assessed using the Dunn’s post-test.  Significant results were included on the 
graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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Multivariate analyses of the CLL cohort performed in Chapter 3 (Section 3.7) showed 
that the phenotype from this study that had the strongest association with prognosis 
was CD4+HLA-DR+PD-1+ (further discussed in Section 4.6.1). Comparison between 
healthy donors and CLL patients revealed that CLL patients had a significantly higher 
proportion of HLA-DR+PD-1+ cells in the CD4+ T-cell compartment (Figure 4.15A, 
p = 0.0008). The CLL CD4+ EM (p <0.0001) and EMRA (p = 0.0073) subsets 
mirrored this increased frequency of HLA-DR+PD-1+, with the largest percentage of this 
phenotype found in the EM subset. 
 
When the CLL patients were stratified according to CD4:CD8 ratio in Figure 4.15B, 
CLLIR patients demonstrated a significantly higher frequency than both and CLLNR and 
healthy donor patients (p ≤0.01 and p ≤0.001, respectively). Again, this appeared to 
be predominantly driven by the EM subset rather than the EMRA subset, as the CD4+ 
EM T-cells of CLLIR patients had significantly higher frequency of HLA-DR+PD-1+ versus 
CLLNR and healthy donors (p ≤0.001 for both). 
 
It is clear, therefore, that although higher frequencies of T-cells expressing PD-1 were 
associated with the T-cell memory subset, a large proportion of these T-cells 
co-expressed activation markers.  
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Figure 4.15. HLA-DR and PD-1 co-expression in CD4+ T-cells of CLL patients and 
age-matched healthy donors. Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 4.1. (A) 
CD4+HLA-DR+PD-1+ T-cells in the whole CD4+ T-cell compartment, CD4+ EM and CD4+ EMRA 
memory subsets of CLL patients (n = 74) and healthy donors (n = 14). Pairwise statistical 
analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney test. Patients were 
stratified based on CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). Patients with a 
ratio ≥1.0 were considered normal ratio patients (CLLNR). (B) Frequency of CD4+HLA-DR+PD-1+ 
T-cells in whole CD4+ T-cell compartment, CD4+ EM and CD8+ EMRA memory subsets of CLLNR 
(n = 47), CLLIR (n = 27) and healthy donors (n = 14). Three-way ANOVA statistical analysis 
was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data assessed 
using the Dunn’s post-test. Significant results were included on the graph (* = p ≤0.05; 
** = p ≤0.01; *** = p ≤0.001). 
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 CD4 + T-ce l l  phenotypes  and cytomegalov irus  (CMV) in fect ion  4.6.
Cytomegalovirus (CMV) is a common persistent viral infection in the elderly population 
(Görgün et al. 2005; Vasto et al. 2007; Tinhofer et al. 2009; Pita-Lopez et al. 2009; 
Monserrat et al. 2013). Previous work has shown that both the CD4+ and CD8+ T-cell 
compartments in CMV+ patients are skewed towards the more differentiated memory 
subsets (Os et al. 2013; Pourgheysari et al. 2010; Khan et al. 2002). However, no 
association has been shown between CMV infection and clinical prognosis in CLL (Parry 
et al. 2016). The skewed phenotypes in CMV+ patients are thought to be due to 
expansions in chronically stimulated CMV-specific T-cells that are defined as senescent, 
although there is evidence that CMV-specific T-cells in CLL patients can act in a 
functional capacity (Raa et al. 2014). To assess whether CMV was a contributing factor 
for the unusual phenotypes that were observed in the CD4+ compartment, patient 
serum for a cohort of CLL patients was collected and serotyped by the Public Health 
Wales Microbiology Laboratory, UHW, Cardiff.  
 
The CMV serostatus was assessed in 63 of the CLL patients used in this study; of those 
tested, 43/63 (68%) were CMV seropositive. The previous chapter demonstrated that 
the CD4:CD8 ratio and the skewing to CD8+ EM T-cells in CLL were not driven by CMV 
infection (Chapter 3, Section 3.5). 
 
SPICE software analysis was used to compare the distribution of memory CD4+ T-cell 
subsets among CLL patients based on CMV serostatus using pie charts (Figure 4.16). No 
significant CD4+ subset changes were observed between CMV+ and CMV- CLL patients 
(p = 0.1667). As with the CD8+ CMV results, this suggests that the phenotypic 
abnormalities observed among the CD4+ memory T-cells are driven by CLL pathology 
rather than chronic CMV stimulation. 
 
Chapter 4: Results 
153 
 
 
 
 
 
 
Figure 4.16. CMV serostatus in CLL patients. Cells were collected using flow cytometry 
(FACS CantoII, BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in 
Figure 4.1. Plasma samples from CLL patients were serotyped for antibodies against CMV. 
Distribution of CD4+ memory subsets in CMV seropositive (n = 43) and CMV seronegative 
(n = 20) CLL patients. Flow cytometry data and CMV information were analysed and t-tests 
performed using SPICE software (v5.3).  
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 Prognost ic  s ign i f icance  o f  CD4 + T-ce l l  phenotypes  4.7.
To investigate whether the phenotypes in this study were associated with prognostic 
significance in CLL, multivariate analyses were performed on both the CD4+ and CD8+ 
compartments (full details of the multivariate process is outlined in Chapter 3, Section 
3.7). Interestingly, the cox proportional hazards regression model (with forward 
selection) revealed that the phenotype with the greatest effect on progression-free 
survival (PFS) in this study was CD4+HLA-DR+PD-1+. Full multivariate results, 
including simple statistics and correlation analyses with CD4:CD8 ratio, are included in 
Appendix IV. 
 
Additional multivariate analyses consisting of recursive partitioning followed by 
univariate analysis (Kaplan-Meier curves) were applied to identify the optimum 
CD4+HLA-DR+PD-1+ frequency cut-offs by which patients could be stratified into poor 
or good prognostic subgroups. The most prognostically relevant thresholds are included 
here; for the complete multivariate and univariate outputs see Appendix IV. 
 
The analysis revealed that patients with more than 14.4%-16.7% of 
CD4+HLA-DR+PD-1+ cells had significantly poorer prognosis, as measured by PFS 
(Figure 4.17A-B). The multivariate analyses also demonstrated that a 31.5% 
CD4+HLA-DR+PD-1+ threshold had an even greater prognostic effect (Figure 4.17C), 
potentially identifying a high-risk group with an exacerbated phenotype. A low cut-off 
value of 4.95% was also shown by the multivariate analysis to have an effect on 
prognosis. Interestingly, when univariate analysis was applied to this threshold, patients 
with a CD4+HLA-DR+PD-1+ population of ≤4.95% (21/74 patients [28.4%]) never 
experienced disease progression during the follow-up period (Figure 4.17D).  
 
Overall it appears that an initial cut-off of around 15% CD4+HLA-DR+PD-1+ T-cells 
identified patients at risk of poorer prognosis (based on the recursive partitioning cut-
off frequencies of 14.4% and 16.7%), whilst frequencies of 31.5% and above identified 
a high-risk population. Conversely, CLL patients with less than 5% of 
CD4+HLA-DR+PD-1+ cells (based on the 4.95% cut-off) demonstrated no risk of disease 
progression. Taken together these analyses support the concept that increasing 
frequency of CD4+HLA-DR+PD-1+ T-cells is linked to inferior prognosis. Section 4.5.2 
observed that on average CLLIR patients had higher proportions of this phenotype, 
further supporting the concept that the CD4:CD8 ratio is linked to prognosis. However, 
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in this study, higher resolution phenotyping has identified a T-cell signature with an 
even stronger association with disease progression.  
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Figure 4.17. Prognosis of CLL patients stratified based on CD4+HLA-DR+PD-1+ 
frequencies. Cells were collected using flow cytometry (FACS CantoII, BD FACSDiva) and 
analysed with FlowJo (v.9) using gating as described in Figure 4.1. Multivariate recursive 
partitioning was performed to establish significant ‘cut-off’ ratio values within the study group. 
Kaplan-Meier curves for progression-free survival of CLL patients stratified by a 
CD4+HLA-DR+PD-1+ frequency of (A) 14.4% (B) 16.7% (C) 31.5% and (D) 4.95% are shown. 
Multivariate analyses were performed by Professor Robert Hills (Haematology Clinical Trials 
Unit, Cardiff University). Univariate analyses (Kaplan-Meier curves and survival statistics) were 
performed using GraphPad Prism 5.0. 
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 Absolute  counts  4.8.
As rationalised in Chapter 3 (Section 3.8), preliminary absolute counts were obtained 
for 19 CLL patients to establish whether the changes in frequency of particular CD4+ 
subpopulations in CLLIR vs CLLNR patients reflected increases or decreases in absolute 
number.  
 
No change in the numbers of CD4+ T-cells was observed between the CLLNR and CLLIR 
patients (Figure 4.18A). This, combined with the expansion of CD8+ T-cell numbers 
described in Chapter 3, adds further evidence that the CD4:CD8 ratio is inverted due to 
an expansion in CD8+ T-cell numbers, rather than a reduction in the number of CD4+ 
T-cells. Similarly, no significant changes in absolute numbers of CD4+ cells were seen in 
the naïve, EM and EMRA populations (Figure 4.18B-D): however, there was a trend of 
reduced naïve and expanded EM T-cell numbers within the inverted ratio patients. This 
may suggest that the skewing towards a more differentiated phenotype within the CD4+ 
compartment could be due to a combined reduction in the number of naïve T-cells and 
an increase in the number of EM T-cells. 
 
Significantly higher frequencies of CD4+CD57+, CD4+HLA-DR+ and CD4+PD-1+ T-cells 
were detected in the CLLIR patients versus CLLNR patients in the phenotypic analysis. 
Although trends in increased numbers of these phenotypes were observed in the CD4+ 
compartment of CLLIR patients, none reached significance (Figure 4.19A). 
CD4+HLA-DR+PD-1+ was the phenotype shown to have greatest prognostic potential 
within this study and occurred at significantly higher frequency in CLLIR subgroup 
compared to CLLNR subgroup. By contrast, analysis of absolute cell counts did not reveal 
a significant difference in the numbers of CD4+HLA-DR+PD-1+ T-cells between CLLNR 
and CLLIR patients. However, there was more heterogeneity in the counts for the CLLIR 
subgroup, with 4/8 patients having counts above the average for CLLNR (Figure 4.19B). 
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Figure 4.18. Absolute counts of CD4+ T-cells in CLLNR (n = 11) and CLLIR 
(n = 8) patients. Cells and BD Trucount beads were collected using flow cytometry (FACS 
CantoII, BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 4.1. 
Patients were stratified based on CD4:CD8 ratio: a ratio <1.0 was considered inverted (CLLIR). 
Patients with a ratio ≥1.0 were considered normal ratio patients (CLLNR). Absolute counts for 
(A) overall CD4+, (B) CD4+ naïve, (C) CD4+ EM and (D) CD4+EMRA between CLLNR and CLLIR 
patients are shown. Pairwise statistical analysis (HD vs CLL) was performed using the 
non-parametric Mann-Whitney test. Significant results were included on the graph 
(* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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Figure 4.19. Absolute counts of CD4+ T-cell phenotypes in CLLNR (n = 11) and 
CLLIR (n = 8) patients. Cells and BD Trucount beads were collected using flow cytometry 
(FACS CantoII, BD FACSDiva) and analysed with FlowJo (v.9) using gating as described in 
Figure 4.1. Patients were stratified based on CD4:CD8 ratio: a ratio <1.0 was considered 
inverted (CLLIR). Patients with a ratio ≥1.0 were considered normal ratio patients (CLLNR). 
Absolute counts for: (A) CD57+, HLA-DR+ or PD-1+ cells in the CD4+ compartment; (B) 
CD4+HLA-DR+PD-1+ T-cells in the CD4+ compartment. Pairwise statistical analysis (HD vs CLL) 
was performed using the non-parametric Mann-Whitney test. Significant results were included 
on the graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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 Relat ionship  between CD4 + and CD8 + phenotypes  4.9.
It is clear from the phenotypic analysis of the CD4+ compartment that there are some 
similarities in the phenotypes present at higher frequencies in the CLL CD4+ and CD8+ 
compartments. The CD8+ phenotype with the strongest prognostic relevance described 
in Chapter 3 (determined by multivariate analyses) was a senescent/activated 
phenotype CD8+CD57+HLA-DR+, which was present at higher frequencies in the CLLIR 
subgroup. CD57+HLA-DR+ T-cell frequencies were also increased in the CD4+ T-cell 
compartment of CLL patients, and were exacerbated in the CLLIR subgroup. Correlation 
analyses were used to compare CD57+HLA-DR+ frequencies in the CD8+ and CD4+ 
compartments and determine any potential relationship. As shown in Figure 4.20A, 
there was a significant positive relationship between CD8+CD57+HLA-DR+ and 
CD4+CD57+HLA-DR+ (r = 0.7211, p <0.0001). 
 
As CD4+HLA-DR+PD-1+ was deemed the most prognostically relevant phenotype from 
the CD4+ T-cell compartment, correlation analysis was performed to compare any 
association with the prognostic CD8+ phenotype CD8+CD57+HLA-DR+. There was a 
strong, positive relationship between CD8+CD57+HLA-DR+ and CD4+HLA-DR+PD-1+ 
(r = 0.7684, p <0.0001; Figure 4.20B). The significant association of these 
phenotypes between the CD4+ and CD8+ compartments, together with their increased 
frequency in CLLIR patients, suggests a connection between certain CD4+ T-cell 
phenotypes with the expansion of the CD8+ T-cell compartment and the inversion of the 
CD4:CD8 ratio.  
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Figure 4.20. Correlation between CD4 phenotypes and CD8+CD57+HLA-DR+ in 
CLL patients (n = 74). Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed with FlowJo (v.9) using gating as described in Figure 4.1. Correlation 
of (A) CD8+CD57+HLA-DR+ versus CD4+CD57+HLA-DR+, and (B) CD8+CD57+HLA-DR+ versus 
CD4+HLA-DR+PD-1+. Linear regression and Spearman’s correlation coefficient were performed 
using GraphPad Prism 5.0. 
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 Discuss ion  4.10.
The aim of this chapter was to further explore the phenotypic composition of the CD4+ 
T-cell compartment of CLL patients. This included analysing phenotypic differences 
between CLL patients with an inverted CD4:CD8 ratio (CLLIR) and CLL patients 
presenting a ‘normal’ T-cell ratio (CLLNR). The original focus of this thesis was the CD8+ 
T-cell compartment, based on a previous study demonstrating inferior clinical prognosis 
in patients with expanded CD8+ T cell populations. However, multivariate analyses 
revealed that a CD4+ phenotype had a greater effect on prognosis in CLL patients. 
Previous studies have demonstrated an increase in absolute numbers and phenotypic 
alterations within the CD4+ T-cell compartment in CLL (Görgün et al. 2005; Monserrat 
et al. 2013; Os et al. 2013). Taken together, this suggested that phenotypic analysis of 
CD4+ T-cells in the current study was warranted.  
 
In line with previous work (Nunes et al. 2012), preliminary counts revealed that the 
number of CD4+ T-cells were not significantly different between the CLLIR and CLLNR 
patients, supporting that the inversion of ratio is due to a preferential expansion within 
the CD8+ T-cell compartment. However, it is clear from the phenotypic overview that 
although the numeric size of the CD4+ compartment did not change between CLLNR and 
CLLIR patients, there are significant phenotypic differences between the two subgroups 
and age-matched health donors. Therefore, this study identified differences within the 
CD4+ T-cell compartment that are CLL-specific and not due to immunological aging, 
including further phenotypic aberrations in the CLLIR subgroup. 
 
CD4+ T-cell memory subset distribution in CLL patients was skewed to a more 
differentiated phenotype, and showed significant differences between healthy donors 
and both the total and stratified CLL cohorts. A reduction in naïve and increase in the 
EM subsets was observed in both the CD8+ and CD4+ T-cell compartments of CLL; this 
shift was more dramatic within the CLLIR cohort. This showed that, as previously 
observed with CD8+ T-cells, CD4+ T-cell memory within the CLLIR group skewed 
towards a more differentiated effector memory phenotype compared to CLLNR patients 
and healthy donors. This also supports the previous work of Nunes et. al (2012) who 
reported a similar shift in memory subset compositions. There is a known age-associated 
skewing to more differentiated memory in CD4+, but this is normally characterised by a 
reduction in naïve and age-related increase in CD4+ EMRA T-cells (Koch et al. 2008). 
The skewing observed in this study differs in that it is the EM compartment that sees the 
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relative increase. Age related effects were controlled for by using age-matched healthy 
donors.  
 
Unlike CD8+ T-cells, little to no inflation of CMV-specific CD4+ T-cells has been 
observed within the CD4+ T-cell pool (Kim et al. 2015; Klenerman and Oxenius 2016); 
however, CMV-specific CD4+ T-cells do appear to accumulate with age and display a 
highly differentiated memory phenotype (Pourgheysari et al. 2007). Previous work has 
shown increased proportions of CMV-specific CD4+ T-cells in CLL compared to controls 
(11% versus 4.7%), with higher frequencies observed with advanced disease 
(Pourgheysari et al. 2010). Also, the CMV+ CLL patients had higher CD4+CD57+ T-cells 
compared to the CMV+ healthy donors (Pourgheysari et al. 2010): however, as this was 
observed in the CD4+ population as a whole, and not the CMV-specific CD4+ 
population, it cannot be explicitly asserted that this is CMV driven. This study saw no 
association between CMV and CD4:CD8 ratio (see previous Chapter), and no significant 
difference in the distribution of CD4+ memory T-cell subsets between CMV seropositive 
and CMV seronegative patients. Again similar to the CD8+ results in the previous 
Chapter, the CD4+ memory subset composition in this study skewed heavily to the EM 
population, rather than an EMRA skew that one would expect if the memory 
distribution was CMV-driven. This implies that the CD4+ memory skewing (and the 
phenotypes that accumulate within the CLLIR subgroup) is not caused by CMV 
persistence. This includes CD4+HLA-DR+PD-1+, as the accumulation of this prognostic 
phenotype appears to originate within the EM compartment. Unfortunately, the number 
of CMV− patients in this cohort was limited, and direct analysis of any association 
between CMV seropositivity and the CD4+HLA-DR+PD-1+ could not be performed. 
Future work with a larger cohort of CMV− individuals would help confirm that CMV 
seropositivity is not a confounding factor.  
 
CD4+ memory subset skewing has been associated with other prognostic factors of CLL. 
Patients stratified by IGHV mutational status revealed that CLL patients with unmutated 
IGHV (inferior prognosis group), had a reduction in CD4+ naïve T-cells and a significant 
increase in CM/EM T-cells (Tinhofer et al. 2009). In another study, Zap-70+ CLL 
patients also demonstrated this skewing from naïve to EM CD4+ T-cells compared to the 
Zap-70− CLL patients (Monserrat et al. 2013). It is clear therefore that the distribution 
of subsets within the CD4+ memory compartment is associated with prognosis. 
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Further supporting the shift to more differentiated CD4+ T-cells was the increase in the 
single CD57 and PD-1 frequencies within the CD4 compartment of CLL patients, as well 
as the increase in double positive CD57+PD-1+ cells. These phenotypes appeared to be 
predominantly derived from the CD4+ EM compartment and were further enriched in 
the CLLIR patients. This implies that there was an increased proportion of differentiated 
CD4+ T-cells in the patients with preferentially expanded CD8+ T-cell populations. 
These results were again in line with previous work from our research group that 
demonstrated higher CD4+CD57+CD27−CD28− EM cells in CLL patients, particularly 
CLLIR patients (Nunes et al. 2012). However, it is worth noting that in the previous 
study the average frequency of CD57+CD27−CD28− EM in CLLIR patients was much 
lower (approximately 5% for the total CLL cohort and 7% for CLLIR subgroup). The 
mean CD57+ EM frequencies observed in this study were 12.1% for total CLL cohort and 
18.9% for CLLIR subgroup. It is possible that this disparity in CD57+ expression is due to 
differences in the patient cohorts studied. Alternatively, it may be due to the different 
phenotypes defined in each study. It is possible that there are CD57 sub-phenotypes 
beyond the conventional replicative senescent phenotype: CD57+CD27−CD28−. Future 
work using expanded flow cytometry panels to include CD27 and CD28 would help 
confirm this hypothesis. 
 
As naïve T-cells are known to express CD127 (A. Ma et al. 2006; Mahnke et al. 2013), it 
would be expected that the reduction in the naïve subset would be synonymous with a 
reduction of CD4+CD127+ T-cells. This proved to be the case in this study and was 
associated with inverted ratio. Interestingly, this study also identified a novel reduction 
in naïve CD4+CD38+ frequency, particularly in the CLLIR subgroup. Moreover, we 
investigated whether presentation of these markers were linked and found that there 
was indeed a strong positive correlation between CD38 and CD127 within the naïve 
compartment of CLL patients, and CD4+CD38+CD127+ naïve T-cells were also greatly 
reduced compared to healthy donors, more so in CLLIR patients. Due to the inclusion of 
age-matched controls, this reduction appears to be independent of age. Additionally, 
previous work has shown that in older patients the reduction in naïve cells is 
accompanied by higher proportions of senescent naïve CD4+CD57+ and activated naïve 
CD4+HLA-DR+CD38+ phenotypes (Ferrando-Martínez et al. 2011). Due to antibody 
panel constraints CD38 and HLA-DR were on separate phenotyping panels, so 
co-expression could not be investigated, however, no change in CD4+ naive HLA-DR+ 
frequency was observed. Post-hoc correlation analysis showed that there was no 
Chapter 4: Results 
165 
relationship between CD38 and HLA-DR frequencies within the CD4+ naïve 
compartment (Appendix VII). Although the multivariate analyses did not demonstrate a 
significant prognostic effect of these phenotypes in the naïve compartment, overall 
CD4+CD127+ and CD4+CD38+CD127+ were shown to be contributing co-variables 
associated with PFS (Appendix IV). This suggests that the reduction in naïve 
CD4+CD38+CD127+ may be linked to CLL pathology. An additional factor to take into 
account is whether the naïve population represents a Treg population, as resting Tregs 
can present a similar CCR7+CD45RO− phenotype (Rosenblum et al. 2015). 
Furthermore, no significant difference in absolute numbers of naïve CD4+ T-cells 
between CLLNR and CLLIR patients could suggest that the reduced CD127+ population is 
actually due to a shift towards CD127− within the CD4+ naïve subset, a phenotype 
associated with Tregs (Banham 2006; Seddiki et al. 2006). However, it may be that the 
preliminary counts in this study were not powered enough to identify significant trends; 
expanded absolute count studies would address this. The inclusion of additional 
markers that characterise Treg cells such as CD25 and FoxP3 and would also help 
determine whether populations within the CCR7+CD45RO− are truly naïve. 
 
Following exploration of senescence/exhaustion markers, we then investigated 
activation in CLL CD4+ T-cells using CD38 and HLA-DR as markers for activation. 
HLA-DR was shown to be the activation marker with most relevance in the CLL cohort, 
particularly in the CLLIR patients: these patients had significantly higher frequencies that 
appeared to be driven from the EM subset. Furthermore, this study observed an 
increased co-expression of CD57+HLA-DR+, confirming the presence of a differentiated 
T cell phenotype that might be activated in response to unknown stimuli. 
 
The increase in PD-1+ within the CD4+ compartment of CLLIR patients is an interesting 
contrast to the CD8+ compartment (Chapter 3), where higher frequencies of CD8+PD-1+ 
and CD8+CD57+PD-1+ were only observed in the CLL cohort as a whole, with no 
difference between CLLNR and CLLIR patients. Lack of exacerbated CD8+PD-1+ in CLLIR 
patients would suggest that the CD8+PD-1+ subset is not associated with the expanded 
CD8+ T-cells. However, there is an increased frequency of PD-1+ T-cells in the CD4+ 
compartment of CLL patients that is associated with the inverted ratio.  
 
Interestingly, further exploration of PD-1 with the activation marker HLA-DR revealed 
that there was a significantly higher proportion of CD4+ T-cells co-expressing these 
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markers, particularly in CLLIR patients. No significant effect was observed in absolute 
counts, but there did appear to be a trend in higher CD4+HLA-DR+PD-1+ cell numbers 
in CLLIR patients. As the absolute counts were preliminary and only included a small 
cohort of patients, an expanded analysis using a larger cohort such as that used in the 
phenotyping study (74 patients) would be better powered to identify changes in the 
phenotype cell numbers. Additionally, absolute counts of age-matched healthy donors 
will help distinguish CLL-specific changes. 
 
The multivariate analyses performed on this CLL cohort determined that overall, 
CD4+HLA-DR+PD-1+ had the strongest effect on prognosis. Survival analyses showed 
that patients with more than 14.4% CD4+HLAD-DR+PD-1+ cells demonstrated much 
poorer prognosis. Furthermore, the patients in this cohort possessing the lowest 
CD4+HLA-DR+PD-1+ (around 5% or less) had no reduction in survival, further 
demonstrating that increased presence of this phenotype related to poorer prognosis in 
CLL. Supporting this, the age-matched healthy donors analysed in this study had an 
average of 3.4% CD4+HLA-DR+PD-1+ (ranging between 0.9-6.9%). Higher numbers of 
CD4+PD-1+ T-cells have previously been linked to poorer prognosis in newly diagnosed 
CLL patients (Rusak et al. 2015); the CD4+HLA-DR+PD-1+ phenotype identified in this 
study could be further characterisation of a prognostic phenotype within the CD4+PD-1+ 
population. CD4+PD-1+ in HIV patients in early (<6 months after infection) versus 
delayed (≥2 years after infection) treatment revealed that PD-1 levels increased in 
patients who delayed therapy, and PD-1 levels decreased to similar levels in both 
subgroups following one year of anti-retroviral treatment. Adding to this, CD4+PD-1+ 
was significantly associated with CD4+CD38+HLA-DR+ activation (Cockerham et al. 
2014). That this phenotype was also higher in CLLIR patients demonstrated that there is 
possibly some relationship between these CD4+ phenotypes and the changes in the 
CD8+ compartment relating to CD4:CD8 ratio. Previous studies in HIV identified 
significant correlation between CD4:CD8 ratio and an ‘early differentiated’ CD4+ EM 
population that expressed various markers, including HLA-DR and PD-1 (Buggert et al. 
2014).  
 
It has been previously documented that PD-1 is upregulated on activated T-cells and 
performs negative feedback to the cell after engagement with it’s ligand PD-L1 
(Chikuma 2016). Increased PD-1 with activation markers has been linked to chronic 
stimulation in HIV (Cockerham et al. 2014). A subset of CD4+PD-1high T-cells has been 
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identified in follicular lymphoma (Yang et al. 2015). These CD4+ T-cells were mainly 
located in the lymph node tumour microenvironment, with a follicular helper T-cell 
phenotype, and supported B-cell growth. It is possible that there is a similar situation in 
CLL where CD4+ T-cells may be responding to chronic antigenic stimulation within the 
tumour microenvironment and supporting the B-CLL cells, thereby helping to drive the 
disease. Previous work demonstrating CLL-specific Th cells that can be activated by CLL 
cells, and in turn directly interact with the CLL cells to drive CLL cell activation and 
proliferation, supports this (Os et al. 2013). PD-1 ligand (PD-1L) has been found in 
higher frequencies on both B- and T-cells of CLL patients, and CD4+PD-1+ cells have 
been found in close proximity to B-CLL cells within the lymph node (Brusa et al. 2013). 
Furthermore, in addition to T-B interactions between the CD4+ T-cells and CLL cells, 
CD4+ T-cell:CD8+ T-cell interaction may mean that CLL-specific CD4+ T-cells could also 
be promoting the CD8+ T-cell expansion, and vice versa. This is supported by the 
positive relationship identified between CD4+ and CD8+ T-cells with an ‘activated 
senescent’ phenotype CD57+HLA-DR+, as well as CD4+HLA-DR+PD-1+ with 
CD8+CD57+HLA-DR+, both of which have a link to CLL prognosis. Functional analyses 
to directly establish the proliferative capacity and responsiveness of 
CD4+HLA-DR+PD-1+ T-cells from CLL patients, with and without autologous B-CLL cells 
and CD8+ T-cells, would gain further insight into the interlinking relationship between 
these immune cells. Furthermore, it could be suggested that the CD8+ expansion is 
being suppressed, preventing a successful response against tumour cells. This 
immunosuppression could be directly from the CLL cells themselves, or possibly from 
Tregs, which are present in higher frequencies in CLL patients compared to healthy 
donors and are associated with other poor prognostic markers (Aref et al. 2014). 
 
As discussed in the previous chapter, the ability to look at the distribution of multiple 
markers in tandem was somewhat limited in this study, due to BD FACS Canto II 
restrictions that meant a maximum of 8 parameters could be applied. This could be 
viewed as being simplistic as several recent studies have demonstrated that the complex 
nature of T-cell memory subsets, with many new functionally and phenotypically 
distinct T-cell subsets being defined. Furthermore, CD4+ T-cells can be divided into 
various subtypes with different immunological functions, such as Tfh cells and Tregs. 
Future analyses performed on flow cytometers with capacity to analyse a greater 
number of parameters (up to 36 markers) (Bendall et al. 2012) would allow tandem 
analysis of multiple T-cell activation/senescence markers, more precise definition of 
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naïve/effector/memory subsets, and also the inclusion of markers that further classify 
CD4+ T-cell types. 
 
As with the CD8+ T-cell compartment in Chapter 3, the CD4+ compartment 
demonstrates a dramatic shift to more differentiated phenotypes in CLLIR. Initially this 
could be assumed to be a shift towards senescence/exhaustion; however, with a 
synonymous increase and co-expression with HLA-DR implies that this is potentially a 
shift towards a differentiated, activated phenotype mainly originating from the EM 
compartment. Of particular relevance is the identification of the prognostically relevant 
phenotype in CD4+HLA-DR+PD-1+, which has potential applications within the clinical 
setting to identify CLL patients who are more at risk of progressive disease or disease 
relapse. This phenotype needs to be further explored in additional CLL cohorts with 
patients of varying disease stage and treatment. The potential of CD4+HLA-DR+PD-1+ in 
treated patients is explored more in the following chapter. 
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Chapter 5 
Phenotypic analysis of treated CLL patients 
Abnormal T-cell profiles have been found to be of prognostic relevance in a range of 
diseases, including chronic viral diseases such as HIV and CMV (Buggert et al. 2014; 
Trautmann et al. 2006; Champagne et al. 2001; Pawelec and Gouttefangeas 2013), and 
cancers (L. Zhang et al. 2003; Sato et al. 2005; Woo et al. 2002; Nunes et al. 2012). 
Due to the heterogeneous nature of CLL, where patients can present with asymptomatic 
disease or progressive aggressive disease, being able to identify patients who are more 
at risk of disease progression may be useful for targeting patients who need more 
observation and earlier treatment. The usual method of treatment for newly diagnosed 
CLL patients is the ‘watch and wait’ approach, whereby treatment is only initiated upon 
disease progression (Zenz et al. 2010; Oscier et al. 2012). The ability to identify 
indolent patients from those with progressive disease could not only optimise treatment 
approaches, but also prevent the uncertainty faced by patients during the ‘watch and 
wait’ phase. Furthermore, it is possible that these prognostic factors could help predict 
responses to standard treatment, and identify patients who are more at risk of relapse. 
 
Previous studies have characterised an array of T-cell abnormalities within CLL that are 
associated with inferior prognosis, including: lymphocyte count and inversion of the 
CD4:CD8 ratio (Gonzalez-Rodriguez et al. 2010; Nunes et al. 2012); T-cell CD38 status 
(Tinhofer et al. 2006); increased expression of markers for senescence and 
immunosuppression, such as CD57 (Serrano et al. 1997), PD-1 (Tinhofer et al. 2006; 
Gonzalez-Rodriguez et al. 2010; Nunes et al. 2012; Serrano et al. 1997; Novák et al. 
2015). In addition to confirming the prognostic relevance of the CD4:CD8 ratio, this 
thesis highlights additional T-cell phenotypes that were strongly associated with inferior 
clinical prognosis in CLL, namely CD4+HLA-DR+PD-1+ and CD8+CD57+HLA-DR+ (See 
Chapters 3 and 4). 
 
The aim of this chapter was to analyse a new cohort of CLL patients who had undergone 
treatment, to investigate the impact of treatment on the CD4:CD8 ratio and on more 
complex T-cell phenotypes. These were compared to untreated CLL patients in a cross-
sectional analysis. An 8-colour flow cytometry panel was designed to focus on markers 
that were shown to have the most prognostic relevance in the preceding chapters 
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(Chapters 3 and 4: CD57, HLA-DR and PD-1 – see Chapter 2 for antibody panel). Where 
possible, longitudinal phenotypic assessment of individual patients was used to assess 
whether there were changes over time. 
 
 Immunophenotyp ing  o f  untreated  versus  t reated  pat ients  5.1.
The cohort analysed in this experiment included 19 treated and 23 untreated CLL 
patients. To give a more robust statistical analysis, phenotyping data from this ‘treated’ 
cohort was merged with the larger CLL cohort that was used in the phenotyping study 
from the earlier chapters (Chapters 3 and 4). If a patient was analysed more than once, 
any repeated analyses were removed, unless the patient’s treated status had changed 
between sample collections (i.e. the patient was untreated at the first analysis, but had 
received treatment prior to the second analysis). This gave final patient numbers of 33 
treated and 68 untreated patients.  
 
 CD4:CD8 rat io  in  t reated  CLL 5.1.1.
CLL patients with an inverted CD4:CD8 ratio (CD4:CD8 ratio <1.0) have previously 
been shown to have poorer prognosis (Buggert et al. 2014; Nunes et al. 2012; 
Trautmann et al. 2006; Champagne et al. 2001; Pawelec and Gouttefangeas 2013). This 
finding was confirmed by the present study, which also used recursive partition analysis 
to show that the prognostic effect of CD4:CD8 ratio was most powerful with a cut-off 
value of 1.0. This suggests the hypothesis that inversion of the CD4:CD8 ratio in CLL 
patients leads to a more aggressive disease. Given that treated patients have, by 
definition, a more aggressive form of the disease (L. Zhang et al. 2003; Hallek et al. 
2008; Sato et al. 2005; Woo et al. 2002; Nunes et al. 2012), it might be predicted that 
these patients would also have a lower CD4:CD8 ratio.  
 
To test this, CLL patients were stratified into untreated and treated cohorts and 
phenotyped to determine the number of events within the CD4+ and CD8+ T-cells gates. 
From this the CD4:CD8 ratio was calculated. As seen in Figure 5.1A, the treated CLL 
group had a significantly lower CD4:CD8 ratio when compared to the untreated group 
(p = 0.0002), with untreated patients having a mean ratio of 2.8 (95% CI 1.97-3.63) 
and treated patients with a mean ratio of 1.1 (95% CI 0.77-1.40). In keeping with these 
findings, when stratified by normal (CD4:CD8 ratio ≥1.0; CLLNR) and inverted ratio 
(CD4:CD8 ratio <1.0; CLLIR), there was an increased proportion of treated patients 
displaying a CD4:CD8 inversion, 60.6% (20/33) in the treated subgroup versus 27.9% 
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(19/68) in the untreated subgroup. The frequency of inverted CD4:CD8 ratio in the 
treated and untreated populations was significantly different (p = 0.0022; Figure 
5.1B).  
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Figure 5.1. CD4:CD8 T-cell ratio in untreated (n = 68) and treated (n = 33) 
patients. CLL samples were collected using flow cytometry (FACS CantoII, BD FACSDiva) and 
analysed using FlowJo (v. 9). Lymphocytes were gated based on forward and side scatter profile; 
forward scatter area and height were used for exclusion of doublet cells. T-cells populations were 
identified by gating first on CD3+ then either CD4+ or CD8+ cells. The number of events in CD4+ 
and CD8+ gates were used to calculate CD4:CD8 ratio. (A) CD4:CD8 ratio of CLL patients 
divided into untreated and treated subgroups. Mann-Whitney test was used to determine 
significance. (B) Patients were stratified further based on a normal (≥1.0, NR) and inverted 
(<1.0, IR) CD4:CD8 ratio to produce four subgroups: untreated NR (n = 49), treated NR 
(n = 13), untreated IR (n = 19) and treated IR (n = 20). Fisher’s exact test was used for 
analysis (* = p ≤0.05, ** = p ≤0.01, *** = p ≤0.001). 
NR IR
0
20
40
60
80
Untreated
Treated
**
N
o.
 o
f P
at
ie
nt
s
CD4:CD8 ratio in Untreated vs Treated CLL
Un
tre
ate
d
Tr
ea
ted
0
5
10
15
20
25 ***
C
D
4:
C
D
8 
R
at
io
A 
B 
Chapter 5: Results 
173 
 CD8 + memory  T-ce l l  phenotypes  in  t reated  CLL 5.1.2.
Work presented in the previous chapters showed a skewing of memory T-cell subsets in 
both the CD8+ and CD4+ T-cell compartments relative to age-matched controls. For the 
CD8+ T-cell compartment, there was a reduction in the percentage of naïve T-cells 
(p <0.0001) and an increase in the percentage of EM T-cells (p = 0.0087). The CD8+ 
T-cells were also analysed for the phenotypic markers that were identified in Chapter 3 
as having prognostic potential.  
 
Initially, immunophenotyping of the CD8+ T-cells was performed to analyse the 
distribution of T-cell memory subsets (Figure 5.2). When patients were divided based 
on treatment status, the treated subgroup had significantly reduced CD8+ naïve T-cell 
frequencies when compared to the untreated group (p <0.0001) alongside an 
expanded proportion of CD8+ EM T-cells (p = 0.0115). These results mirror those seen 
when comparing the untreated CLL patients with age-matched healthy donors (Chapter 
3), suggesting that treated patients exaggerate this skewed phenotype. However, no 
significant change in the CD8+ EMRA subset was observed (p = 0.2280), implying that 
treatment does not increase the proportion of highly differentiated EMRA T-cells that 
are associated with T-cell exhaustion and senescence. 
 
CD57, HLA-DR and PD-1 were identified in earlier chapters as T-cell markers that 
contribute to the prognosis of CLL patients (in Boolean combinations). Interestingly, 
CD57 and PD-1 single marker frequencies within the CD8+ compartment did not differ 
between untreated and treated patients (Figure 5.3A). The activation marker HLA-DR, 
however, was more prevalent on CD8+ T-cells within the treated subgroup 
(p = 0.0003), implying an increased proportion of activated CD8+ T-cells in CLL 
patients who have undergone treatment. 
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Figure 5.2. CD8+ T-cell memory subsets in untreated (n = 68) and treated 
(n = 33) CLL patients. Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed using FlowJo (v.9). Lymphocytes were gated based on forward and side 
scatter profile; forward scatter area and height were used for exclusion of doublet cells. CD8+ 
T-cells were identified by gating on CD3+ and then CD8+ cells. Memory subsets were defined 
using CCR7 and CD45RO memory markers: naïve (CCR7+CD45RO−), Central Memory (CM, 
CCR7+CD45RO+), Effector Memory (EM, CCR7−CD45RO+) and EMRA (CCR7−CD45RO−). 
Pairwise statistical analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney 
test. Significant results were included on the graph (* = p ≤0.05; ** = p ≤0.01; 
*** = p ≤0.001). 
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Figure 5.3. Frequency of CD8+ T-cell phenotypes in untreated (n = 68) and 
treated (n = 33) CLL patients. Cells were collected using flow cytometry (FACS CantoII, 
BD FACSDiva) and analysed using FlowJo (v.9). Lymphocytes were gated based on forward and 
side scatter profile; forward scatter area and height were used for exclusion of doublet cells. 
CD8+ T-cells were identified by gating first on CD3+ then CD8+ cells. (A) CD57+, HLA-DR+ and 
PD-1+ single frequencies within the CD8+ compartment of untreated and treated patients. (B) 
CD57+HLA-DR+ frequency of CD8+ T-cells was shown to be of prognostic relevance in Chapter 3, 
and so frequency of CD8+CD57+HLA-DR+ T-cells untreated and treated CLL patients is shown. 
Pairwise statistical analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney 
test. Significant results were included on the graph (* = p ≤0.05; ** = p ≤0.01; 
*** = p ≤0.001). 
 
CD8+CD57+HLA-DR+ T-cells in Untreated and Treated CLL
Un
tre
ate
d
Tr
ea
ted
0
20
40
60
80 *
%
 o
f C
D
8+
 c
el
ls
CD8+ T-cell markers in Untreated and Treated CLL
Un
tre
ate
d
Tr
ea
ted
Un
tre
ate
d
Tr
ea
ted
Un
tre
ate
d
Tr
ea
ted
0
20
40
60
80
100
CD57 HLA-DR PD-1
***
%
 o
f C
D
8+
 c
el
ls
A 
B 
Chapter 5: Results 
176 
Previous multivariate analysis gave CD8+CD57+HLA-DR+ as the CD8+ phenotype with 
the most prognostic potential from within the CD8+ compartment (Chapter 3). Here, 
CD8+CD57+HLA-DR+ T-cell frequencies were higher in the treated subgroup 
(p = 0.0211, Figure 5.3B). Additional multivariate and survival analyses performed in 
Chapter 3 identified an optimal prognostic cut-off for this variable of 25%. To identify 
whether this prognostic threshold had any link with treatment, patients were stratified 
based on CD8+CD57+HLA-DR+ frequency of <25% or ≥25% within the untreated or 
treated groups: 42.4% of the treated subgroup (14/33) were above this threshold, 
compared to 23.5% of untreated (16/68). Fisher’s exact revealed no significant 
difference (p = 0.0641) between the distributions of patients with <25% or ≥25% 
(Figure 5.4).  
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Figure 5.4. Distribution of untreated and treated patients and 
CD8+CD57+HLA-DR+ frequency. Multivariate analyses performed in this thesis (Chapter 3) 
demonstrated CD8+CD57+HLA-DR+ as the most prognostic CD8+ phenotype within the study. 
Further analyses suggested an optimum cut-off approximately 25%, with patients who have 25% 
or more CD8+CD57+HLA-DR+ having poorer prognosis. Untreated and treated patients were 
stratified based on this threshold to produce four subgroups: <25% untreated (n = 52), <25% 
treated (n = 19), ≥25% untreated (n = 16) and ≥25% treated (n = 14). Fisher’s exact test 
was used for analysis. Significant results were included on the graph (* = p ≤0.05; 
** = p ≤0.01; *** = p ≤0.001). 
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 CD4 + memory  T-ce l l  phenotypes  in  t reated  CLL pat ients  5.1.3.
Work in Chapter 4 demonstrated that the CD4+ T-cell compartment of CLL patients is 
significantly enriched with memory T-cells and identified phenotypic subsets with 
potential prognostic value. Therefore, the distribution of CD4+ memory subsets was also 
compared in the treated and untreated patient subgroups. 
 
Looking at the CD4+ T-cell memory subsets (Figure 5.5), a dramatic reduction (more 
than 4-fold) was observed in the CD4+ naïve frequency in previously treated CLL 
patients compared to the untreated patient subgroup (9.7% versus 40.8%, p <0.0001). 
Conversely, the treated subgroup had a significantly higher frequency of CD4+ EM 
compared to the untreated patients (p <0.0001). This was a similar pattern to that 
observed when comparing CD4+ T-cell subsets between untreated CLL patients and 
age-matched healthy donors, suggesting that treatment is associated with depletion in 
the proportion of naïve T-cells and a relative increase in the proportion of EM T-cells. 
This pattern was also seen in the CD8+ T-cell compartment in the previous section 
(5.1.2), suggesting that both the CD4+ and CD8+ T-cell compartments in CLL manifest 
similar changes in the distribution of T-cell subsets, which are more pronounced in the 
treated subgroup.   
 
The expression of CD57, HLA-DR and PD-1 markers in different combinations in the 
CD4+ compartment, were associated with the inverted CD4:CD8 ratio (Chapters 3 and 
4). The proportions of T-cells expressing these markers in the CD4+ T-cell compartment 
of treated CLL patients were all higher when compared to the untreated CLL patients 
(Figure 5.6A). There were significantly higher frequencies of CD57+, HLA-DR+ and 
PD-1+ T-cells in the CD4+ compartment of treated CLL patients (p = 0.0004, 
p <0.0001 and p <0.0001, respectively). 
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Figure 5.5. CD4+ T-cell memory subsets in untreated (n = 68) and treated 
(n = 33) CLL patients. Cells were collected using flow cytometry (FACS CantoII, BD 
FACSDiva) and analysed using FlowJo (v.9). Lymphocytes were gated based on forward and side 
scatter profile; forward scatter area and height were used for exclusion of doublet cells. CD4+ 
T-cells were identified by gating on CD3+ and then CD4+ cells. Memory subsets were defined 
using CCR7 and CD45RO memory markers: naïve (CCR7+CD45RO−), Central Memory (CM, 
CCR7+CD45RO+), Effector Memory (EM, CCR7−CD45RO+) and EMRA (CCR7−CD45RO−). 
Pairwise statistical analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney 
test. Significant results were included on the graph (* = p ≤0.05; ** = p ≤0.01; 
*** = p ≤0.001). 
 
 
CD4+ T-cell memory subsets in Untreated vs Treated CLL
Un
tre
ate
d
Tr
ea
ted
Un
tre
ate
d
Tr
ea
ted
Un
tre
ate
d
Tr
ea
ted
Un
tre
ate
d
Tr
ea
ted
0
20
40
60
80
100
Naive CM EM EMRA
***
***
%
 o
f C
D
4+
 c
el
ls
39.6% 
10.5% 
35.9% 
13.9% 
Untreated 
10% 
8% 
64% 
18% 
Treated 
Naïve 
CM 
EM 
EMRA 
Chapter 5: Results 
180 
The multivariate analyses described in Chapter 4 demonstrated that 
CD4+HLA-DR+PD-1+ was not only the most prognostically significant CD4+ phenotype 
in CLL patients, but was also the strongest phenotype of all the parameters analysed. 
This phenotype was therefore investigated in relation to treatment status (Figure 5.6B). 
The median CD4+HLA-DR+PD-1+ T-cell frequency was more than 2-fold higher in the 
treated subgroup when compared with the untreated subgroup (20.3% versus 7.9%, 
p = <0.0001). Using the optimal CD4+HLA-DR+PD-1+ prognostic cut-off of 15% 
(identified in Chapter 4), treated and untreated patients were stratified based on this 
indicator. 57.1% (19/33) of treated patients had ≥15% CD4+HLA-DR+PD-1+ T-cells, 
associated with an inferior prognosis, versus 16.2% (11/68) in the untreated group. 
Fisher’s exact test, based on this stratification, supported a significant bias of patients 
within the treated subgroup possessing ≥15% CD4+HLA-DR+PD-1+ (p <0.0001, Figure 
5.7).  
 
The multivariate analyses in Chapter 4 also revealed that patients who had <5% of 
HLA-DR+PD-1+ within the CD4+ compartment uniformly showed no disease 
progression: 47.1% (32/68) of untreated patients fell within this category, versus only 
18.2% (6/33) of treated patients (p = 0.0080, Figure 5.7B). Conversely, results from 
the multivariate suggested that the CLL patients with CD4+HLA-DR+PD-1+ frequencies 
above 31.5% had the poorest prognosis, although patient numbers within this cohort 
were relatively small. Only the treated population contained patients with 
CD4+HLA-DR+PD-1+ frequencies above the 31.5% threshold (9/33 treated patients; 
27.3%), suggesting significant skewing of CD4+HLA-DR+PD-1+ within the treated subset 
(p <0.0001, Figure 5.7C). Taken together, these results show that patients with higher 
levels of the prognostic CD4+HLA-DR+PD-1+ are disproportionately represented in the 
treated subgroup, suggesting a potential link between the CD4+HLA-DR+PD-1+ 
phenotype and patients who undergo treatment. 
 
These results give potential that the CD4+HLA-DR+PD-1+ phenotype bears some 
association with patients who are treated and untreated: more specifically, higher 
CD4+HLA-DR+PD-1+ frequencies that are congruent with poorer prognosis appear to be 
more prevalent in the treated subgroup. However, it is uncertain whether having 
increased frequencies of this phenotype is indicative of patients who have poorer 
prognosis and require treatment, or that the patients with poorer prognosis receive 
treatment that then results in the higher CD4+HLA-DR+PD-1+ frequencies. 
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Figure 5.6. Frequency of CD4+ T-cell phenotypes in untreated (n = 68) and 
treated (n = 33) CLL patients. Cells were collected using flow cytometry (FACS CantoII, 
BD FACSDiva) and analysed using FlowJo (v.9). Lymphocytes were gated based on forward and 
side scatter profile; forward scatter area and height were used for exclusion of doublet cells. 
CD4+ T-cells were identified by gating first on CD3+ then CD4+ cells. (A) CD57+, HLA-DR+ and 
PD-1+ single frequencies within the CD8+ compartment of untreated and treated patients. (B) 
HLA-DR+PD-1+ frequency of CD4+ T-cells was shown to be of prognostic relevance in Chapter 4 
and to be the strongest prognostic marker to arise from that study, and so frequency of 
CD4+HLA-DR+PD-1+ T-cells Untreated and Treated CLL patients is shown. Pairwise statistical 
analysis (HD vs CLL) was performed using the non-parametric Mann-Whitney test. Significant 
results were included on the graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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Figure 5.7. Distribution of untreated and treated patients and 
CD4+HLA-DR+PD-1+ frequency. Multivariate analyses performed in this thesis (Chapter 3) 
demonstrated CD4+HLA-DR+PD-1+ as the most prognostic CD4+ phenotype within the study, 
and the strongest prognostic variable overall: further analyses suggested optimum prognostic 
thresholds. Untreated and treated patients were stratified into four subgroups based on these 
thresholds. (A) Stratification based on a threshold of 15% CD4+HLA-DR+PD-1+ (<15% 
untreated [n = 57], <15% treated [n = 14], ≥15% untreated [n = 11] and ≥15% treated 
[n = 19]). (B) Stratification based on a threshold of 5% CD4+HLA-DR+PD-1+ (<5% untreated 
[n = 32], <5% treated [n = 6], ≥5% untreated [n = 36] and ≥5% treated [n = 27]). 
(A) Stratification based on a threshold of 31.5% CD4+HLA-DR+PD-1+ (<31.5% untreated 
[n = 68], <31.5% treated [n = 24], ≥31.5% untreated [n = 0] and ≥31.5% treated 
[n = 9]). Fisher’s exact test was used for analysis. Significant results were included on the 
graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001).  
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 Longi tudina l  observat ions  o f  t reated  and untreated  CLL pat ients  5.2.
During the immunophenotypic analysis of treated patients, where possible, repeat 
sampling was performed with the aim of determining: a) whether the prognostic 
phenotypes changed over time, including during/after treatment, b) whether the 
prognostic markers were unchanged after treatment and c) whether the prognostic 
phenotypes were transient and reverted upon disease relapse. Longitudinal samples 
obtained at several time points were obtained for 9 treated and 6 untreated patients 
(Figure 5.8 and Figure 5.9). If data had been collected from the same patients as part of 
the main immunophenotyping study (Chapters 3 and 4), they were also included as 
additional data points. Due to the limited patient numbers, varying treatment regimens 
and inconsistent time intervals, analyses of the total cohort was not performed. 
However, the data collected was examined on an individual patient basis to look for 
potential trends. Since CD4:CD8 ratio, CD4+HLA-DR+PD-1+ and CD8+CD57+HLA-DR+ 
were previously identified (Chapters 3 and 4) as having potential prognostic value, the 
analysis focussed on these phenotypes at the different time points, and where available, 
the specific treatment received by the patient recorded.  
 
CD4:CD8 ratio status changed in 2/9 treated patients: Patient 8 changed from inverted 
(0.86) to a normal ratio of 1.23 prior to treatment, whereas Patient 9 had an initial 
ratio of 4.84 that became inverted (0.54) 20 months after treatment. A decrease in 
CD4+HLA-DR+PD-1+ frequency was observed following treatment in five of the treated 
patients (Patients 1-3, 5 and 6) and remained consistent in three others (Patient 4, 7 
and 9). The frequency of CD8+CD57+HLA-DR+ also reduced following treatment 
(Patients 1, 3, 5, 6, 7 and 9) or remained constant (Patients 2 and 4). In Patient 8 both 
CD4+HLA-DR+PD-1+ and CD8+CD57+HLA-DR+ and ratio increase over a single month, 
prior to treatment initiation. 
 
CD4:CD8 ratio appeared consistent across the time points for 3/6 untreated patients 
(Patient 2, 3 and 6); 2 patients retained a normal ratio despite showing either an 
increase (Patient 5) or a decrease (Patient 1) over time. 1 patient observed a change in 
ratio status, from inverted (0.73) to normal (2.87 and 3.74). The frequency of 
CD4+HLA-DR+PD-1+ changed very little across the time points in most patients, and 
frequencies were below the poor prognosis threshold suggested in the previous chapters 
(<15%), except for Patient 4 who had 17.1% CD4+HLA-DR+PD-1+ at primary analysis 
that then reduced to 9.6% at the next sampling. CD8+CD57+HLA-DR+ was more 
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variable but overall appeared to decrease over time. Overall, the markers observed were 
more consistent in the untreated group, particularly CD4+HLA-DR+PD-1+, which 
supports this phenotype as having the strongest potential as a prognostic marker. 
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Figure 5.8. Change in the frequency of T-cell phenotypes at different time points 
in the treated patient subgroup. Cells were collected using flow cytometry (FACS CantoII, 
BD FACSDiva) and analysed using FlowJo (v.9). Lymphocytes were gated based on forward and 
side scatter profile; forward scatter area and height were used for exclusion of doublet cells. 
CD4+ and CD8+ T-cells were identified by gating first on CD3+ then CD4+ cells. The number of 
events in CD4+ and CD8+ gates were used to calculate CD4:CD8 ratio. Sampling was performed 
at various time points. (---- and green shading: treatment; ----: death; CLB: chlorambucil; OFA: 
ofatumumab; FC: fludarabine/cyclophosphamide; ALE: alemtuzumab; IBR: ibrutinib; RIT: 
rituximab; IDE: idelalisib; FCR; fludarabine/cyclophosphamide/rituximab) 
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Figure 5.9. Change in T-cell phenotypes at different time points in the treated 
patient subgroup. Cells were collected using flow cytometry (FACS CantoII, BD FACSDiva) 
and analysed using FlowJo (v.9). Lymphocytes were gated based on forward and side scatter 
profile; forward scatter area and height were used for exclusion of doublet cells. CD4+ and CD8+ 
T-cells were identified by gating first on CD3+ then CD4+ cells. The number of events in CD4+ 
and CD8+ gates were used to calculate CD4:CD8 ratio. Sampling was performed at various time 
points. 
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 Discuss ion  5.3.
Due to the heterogeneity of CLL, at early diagnosis CLL patients are subjected to a 
‘watch and wait’ approach until disease progression and subsequent need for treatment. 
The application of appropriate prognostic markers could aid in the stratification and 
identification of patients who will have progressive disease and/or relapse following 
treatment. The aim of this chapter was to investigate CD4:CD8 ratio in treated patients 
to further explore its prognostic value, with the hypothesis being that an inverted ratio 
would be more prevalent in the treated patient group. In addition, the relationship 
between the potential prognostic markers CD4+HLA-DR+PD-1+ and 
CD8+CD57+HLA-DR+ was explored. Another aim was to assess longitudinal change in 
CD4:CD8 ratio and the prognostic phenotypes over time, including following treatment. 
Whether alterations in the CD4:CD8 ratio or phenotype frequency could be used as a 
way of monitoring disease relapse/need for further treatment was also considered. 
Unfortunately, limitations on sample acquisition meant that only preliminary 
longitudinal assessment could be performed (discussed below in more detail). 
 
This study revealed that treated CLL patients overall have lower CD4:CD8 ratios than 
the untreated CLL, with a significant increase in the proportion of patients with inverted 
CD4:CD8 ratios in the treated subgroup. Stratification of treated and untreated patients 
based on normal and inverted ratio also suggested a potential association between 
inversion of the CD4:CD8 ratio and treatment. This supports the previous assessment 
that this ratio is associated with poorer prognosis (Zenz et al. 2010; Nunes et al. 2012; 
Oscier et al. 2012). However, this study did not account for the effect of additional 
clinical factors such as age and gender; future additional analyses should include these 
clinical factors to correct this. The preliminary assessment of patients at different time 
points, however, did not reveal any discernible pattern of ratio improvement either 
shortly after or during treatment; nor was there any apparent ratio inversion prior to 
the need for treatment. In most patients, ratio status did not change and appeared 
relatively consistent across the time points measured, regardless of treatment status. 
Some patients did have more variation in the ratio, but this again was observed in both 
treated and untreated patients.  
 
Due to limitations on time and sample acquisition, it was not possible to pursue a true 
longitudinal analysis. This assessment was therefore limited by inconsistent time-points 
between patients, varying from 1-30 months between sample collections. These 
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variations restricted the comparisons that can be made and the changes that could be 
observed throughout a patient’s timeline. A larger, prospective study with samples 
collected at standardised intervals would allow a more accurate assessment of the 
relationships between T-cell prognostic markers in treated CLL by allowing for more 
consistent monitoring of changes over time. Detailed patient follow-up would be needed 
to assess the prognostic potential of these markers in the prediction of untreated 
patients who need treatment, and in relation to relapse of previously treated patients 
with need for additional treatment. The additional investigation of absolute counts at 
each time point would also help in interpreting changes in the proportions or 
percentages of T-cell phenotypes in conjunction with disease. 
 
A distinct skewing towards the EM phenotype in the treated subgroup was associated 
with an inverted CD4:CD8 ratio. It is possible that the larger proportion of inverted ratio 
patients in the treated subgroup (60.6% compared to the 27.9% in untreated patients) 
is a confounding factor that contributes to the altered memory phenotype seen overall. 
Interestingly, the shift to EM was far more prominent in the CD4+ T-cell compartment. 
This, along with increased frequencies of CD57+ and PD-1+ in CD4+ and not the CD8+ 
T-cell population, would suggest that CD4+ T-cells have increased 
senescence/exhaustion within the treated compartment. However, both CD4+ and CD8+ 
T-cells displayed higher HLA-DR frequencies, implying that there is also increased T-cell 
activation in treated patients. Furthermore, the CD4+ compartment comprises of various 
functional subsets, including Tregs. Therefore, future work should include additional 
parameters to identify these populations. 
 
Previous work noted that PD-1 expression on CD4+ and CD8+ T-cells in CLL patients is 
particularly higher in patients who have relapsed or refractory disease, with the highest 
number of CD8+PD-1+ observed in patients with active disease and during relapse 
(Tinhofer et al. 2006; Novák et al. 2015; Gonzalez-Rodriguez et al. 2010; Nunes et al. 
2012; Serrano et al. 1997). Nunes et al. (2012) also associated CD8+PD-1+ with 
inverted CD4:CD8 ratio and disease progression. Similarly, a higher proportion of 
inverted ratios in the treated subgroup was observed in this chapter. However, this 
study observed no difference in CD8+PD-1+ frequency when comparing treated and 
untreated patient subgroups. This is in-line with the lack of differences observed 
between normal and inverted ratio patients in the previous chapters. Based on the 
available information, it was unclear whether the patients had active disease or relapsed 
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disease at time of sampling. This could be addressed with a longitudinal study over a 
longer time frame that recorded specific patient stages (active 
disease/remission/relapse etc.) at the point each sample was taken.  
 
Following multivariate and survival analyses, CD8+CD57+HLA-DR+ was shown to be the 
CD8+ phenotype with the strongest prognostic effect, whereas CD4+HLA-DR+PD-1+ was 
shown to be the strongest prognostic factor overall. Both phenotypes were considered to 
have stronger prognostic potential than CD4:CD8 ratio within that study, and so 
frequencies of these phenotypes were investigated. Both CD8+CD57+HLA-DR+ and 
CD4+HLA-DR+PD-1+ frequencies were significantly higher in treated CLL patients 
compared to untreated. The biggest, more significant increase was seen with the 
CD4+HLA-DR+PD-1+ phenotype (7.9% in untreated patients versus 20.3% in treated) 
than the CD8+CD57+HLA-DR+ (17.4% versus 26.2%, respectively). In addition, Fisher’s 
exact tests showed that the higher frequency CD4+HLA-DR+PD-1+ phenotypes 
significantly skewed to the treated subgroup. As stated previously for the CD4:CD8 
ratio, this test did not take other cofounding clinical factors into account; however, as 
treatment is initiated in CLL patients with progressive disease (Hallek et al. 2008), the 
presence of a phenotype associated with inferior prognosis within a treated cohort is not 
wholly unexpected.  
 
Some treated patients observed a decrease in the CD8+CD57+HLA-DR+ subset following 
treatment, but levels of this phenotype appeared sporadic in both treated and untreated 
patients. On the other hand, CD4+HLA-DR+PD-1+ demonstrated potential to remain 
more consistent within the untreated patients, with a decrease in frequency often 
observed following treatment. Furthermore, CD4+HLA-DR+PD-1+ began to increase in 
some patients in the treated cohort during periods without treatment, including one 
patient who died after their final sample collection. It is possible that there is an 
accumulation of this phenotype as disease progresses, which is then depleted either 
directly or indirectly following treatment. Taken together with the skewed 
CD4+HLA-DR+PD-1+ in the treated cohort, this suggests that the CD4+HLA-DR+PD-1+ 
phenotype may be a superior potential marker for not only patients at risk of more 
aggressive disease, but may also be a potential marker of disease progression/relapse 
and need for further treatment. Whether higher frequencies of CD4+HLA-DR+PD-1+ 
T-cells identifies poor prognosis patients that will eventually require treatment, or 
whether the treatment itself results in exacerbated CD4+HLA-DR+PD-1+ frequencies, 
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could not be fully determined here due to the study limitations described above. 
Furthermore, there is inherent difficulty in separating treatment from inferior prognosis, 
as the inferior prognosis patients are ones with progressive disease and who are 
undergoing treatment, or have received treatment prior to assessment. However, from 
the limited longitudinal patient data studied in this chapter, some treatment-naïve 
patients possessed high CD4+HLA-DR+PD-1+ frequencies (≥14.4%) that decreased after 
treatment was initiated, suggesting that high CD4+HLA-DR+PD-1+ is present prior to 
therapeutics. Further comprehensive longitudinal studies that follow larger patient 
cohorts from diagnosis through to disease progression and treatment are needed to 
allow further assessment and confirm the prognostic value of CD4+HLA-DR+PD-1+.  
 
In conclusion, this preliminary study of treated CLL patients demonstrates associations 
with the previously identified CD4:CD8 ratio as a prognostic marker, but also two 
phenotypic markers that have been identified in this thesis as having a strong prognostic 
effect in CLL. The presence of these phenotypes in higher frequencies in treated patients 
suggests that these T-cells have a role in disease, but their prognostic role is unknown 
without further investigation. CD4+HLA-DR+PD-1+ has demonstrated good potential to 
be used for prognostic assessment in identifying patients with poorer clinical outcome. 
It could also provide a means for monitoring disease relapse, but additional, more 
comprehensive longitudinal studies are needed to fully assess the usefulness of this 
phenotype. Assessment by flow cytometry, particularly if limited to a few selected 
markers on a small panel would be a relatively simple and cheaper technique compared 
to more expensive and labour-intensive assessments, such as genotyping for prognostic 
genetic aberrations (Orchard et al. 2004). Therefore, if further work established the 
prognostic use of CD4+HLA-DR+PD-1+, this could prove a valuable tool to guide the 
treatment of CLL patients. 
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Chapter 6 
Single telomere length analysis (STELA) of T-cell memory 
subsets in CLL 
Telomeres are repetitive nucleoside -TTAGGG- sequences that ‘cap’ the end of 
chromosomes to protect loss of the important chromosomal DNA (Buggert et al. 2014; 
Baird 2005; Trautmann et al. 2006; Champagne et al. 2001; Pawelec and Gouttefangeas 
2013): each time a cell division occurs the telomeres shorten (L. Zhang et al. 2003; 
Sanders and Newman 2013; Sato et al. 2005; Woo et al. 2002; Nunes et al. 2012). 
Telomeric length has therefore been recognised as a way to establish the replicative age 
and senescence of a cell population.  
 
Prior studies have shown links between telomere lengths of peripheral blood cells and 
the prognosis of solid tumours, including head, neck, breast and renal cancer, although 
studies are conflicting on whether poorer prognosis is associated with longer or shorter 
telomeres (Zenz et al. 2010; Wu et al. 2003; Oscier et al. 2012; Shao et al. 2007; 
Svenson et al. 2008; Svenson et al. 2013). Telomere shortening specifically within the 
T-cell compartment has been associated with worse clinical status in lung cancer and 
Alzheimer’s disease (Tinhofer et al. 2006; Qian et al. 2016; Gonzalez-Rodriguez et al. 
2010; Panossian et al. 2003; Nunes et al. 2012; Serrano et al. 1997; Novák et al. 2015). 
The telomere length of adoptively transferred T-cells can also influence clinical 
outcome; melanoma patients who received tumour-infiltrating lymphocytes (TIL) with 
longer telomeres demonstrated higher persistence of TIL and this was associated with 
clinical response (Zhou et al. 2005). Therefore, it is possible that telomere length of 
T-cells could be linked to immunological response to disease and disease progression. 
 
Research focusing on telomere length of malignant B-cells in CLL patients has 
demonstrated that critically short telomeres are associated with disease progression, 
genomic instability and poorer prognosis (Grabowski et al. 2005; T. T. Lin et al. 2010b; 
T. T. Lin et al. 2014). Naïve (CD45RA+) and memory (CD45RA−) T-cells in poor 
prognosis Zap-70+/CD38+ CLL patients have been shown to possess significantly shorter 
telomeres than Zap-70−/CD38− patients. However, telomere length distributions of the 
CD8+ T-cell memory compartment in CLL patients, and telomeric differences based on 
CD4:CD8 ratio, have not been fully explored.  
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Chapter 3 investigated phenotypic abnormalities in CLL patients based on previous 
research in our group, which identified a poor prognosis subgroup of CLL patients with 
an expanded CD8+ T-cell compartment skewed to a more differentiated memory 
phenotype (Nunes et al. 2012). As well as supporting the increased presence of more 
differentiated phenotypes in CLL, we also identified ‘active differentiated’ phenotypes 
that were more prevalent in CLL patients with inverted CD4:CD8 ratios, and this was 
linked to inferior prognosis.  
 
The underlying reasons for this expanded population of CD8+ T-cells are not yet 
understood. One possibility is that chronic antigenic stimulation has led to an 
accumulation of long-lived, highly differentiated mature T-cells that have undergone 
continual stimulation and proliferation; these T-cells would have shorter telomeres due 
to extensive cell division coupled with reduced variation in telomere length distribution 
due to clonal expansion. A second possibility is that the origin of the expansion is 
activation of T-cells from the naïve compartment that then skew towards more 
differentiated phenotypes in response to continual antigenic stimulation.  
 
This study aims to investigate the telomere length distributions of the CD8+ T-cells in 
CLL patients in order to establish the proliferative age of CD8+ memory subsets in CLLIR 
patients. In order to achieve this, we will employ single telomere length analysis 
(STELA) to determine whether there are telomeric length differences within the CD8+ 
T-cell population within CLLNR and CLLIR patients. This will allow assessment of the 
replicative history of the expanded CD8+ population of inverted ratio patients.  
 
STELA is a multistep process that provides high-resolution measurement of telomere 
lengths at a specific chromosome end (in this case, the XpYp chromosome)(Baird 2005). 
A brief outline of the experimental process can be seen in Figure 6.1. This study focused 
on the CD4+ and CD8+ T-cell compartment as a whole, and the CD8+ memory subsets; 
Figure 6.2 shows the gating strategy applied to isolate these populations via FACS. 
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Figure 6.1. Experimental outline of the sample acquisition and single telomere 
length analysis (STELA) of T-cell populations in CLL. Peripheral blood mononuclear 
cells (PBMCs) were isolated from CLL patient blood samples by density centrifugation. T-cell 
subsets of interest were isolated first via enrichment using autoMACS cell separation (negative 
selection using CD19+ magnetic beads) and then via fluorescence-activated cell sorting (FACS) 
using BD FACS Aria. DNA was extracted from samples of interest (Qiagen QIAamp DNA Micro 
Kit) and quantified. STELA was then performed: telomere-specific (XpYpE2) PCR was performed 
and resolved via gel electrophoresis. DNA was then transferred to a membrane using Southern 
blotting and visualised via radioactive DNA-labelling of the membrane. Telomere length and 
distribution was calculated using Phoretix software: mean telomere lengths were calculated 
using Excel. Figure is a composite of diagrams including diagrams from Miltenyi Biotech and 
Qiagen3 
                                                
3 Diagrams obtained from: 
Miltenyi Biotech: http://www.miltenyibiotec.com/en/products-and-services/macs-cell-separation/macs-
technology/whole-blood-microbeads.aspx 
Qiagen: https://www.qiagen.com/gb/resources/resourcedetail?id=085e6418-1ec0-45f2-89eb-
62705f86f963&lang=en 
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Figure 6.2. Representative gating strategy used for FACS of T-cell subsets for 
single telomere length analysis (STELA). Fluorescence-activated cell sorting (FACS) was 
performed (BD Aria, BD FACSDiva) on purified PBMC samples. Lymphocytes were gated based 
on forward and side scatter profile; single cells were gated by forward scatter area and height. 
T-cells were identified by gating first on CD3+ then either CD4+ or CD8+ populations. CD8+ 
memory subsets were defined within the CD8+ gate using CCR7 and CD45RO memory markers: 
naïve (N, CCR7+CD45RO−), Central Memory (CM, CCR7+CD45RO+), Effector Memory (EM, 
CCR7−CD45RO+) and EMRA (CCR7−CD45RO−). Circled (blue) are the T-cell populations that 
were FACS sorted and taken forward for STELA. Post-sorting analysis of T-cells was performed 
using FlowJo (v.9). 
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 Preservat ion  o f  T -ce l l  compartment  dur ing  enr ichment  6.1.
CLL is characterised by the lymphoproliferative expansion of CD5+CD19+ malignant 
B-CLL cells (Zenz et al. 2010). Therefore, when PBMCs are isolated from CLL patient 
blood samples, the majority of the sample is comprised of B-cells and the relative 
proportion of T-cells within the patient sample is much smaller. For example, the CLL 
cohort used in the previous phenotyping chapters of this thesis (Chapters 3 and 4) had a 
median of 6.25% CD3+ cells in isolated PBMCs. Attempting to isolate T-cell subsets via 
FACS directly from PBMC samples would therefore be time consuming, and carries a 
higher risk of sorting error and contamination of the T-cell fractions with B-cells. 
 
To optimise the isolation of T-cell populations the PBMCs were enriched for T-cells via 
magnetic-activated cell sorting (MACS). PBMCs were labelled with CD19+ magnetic 
beads and run through an autoMACS machine (Miltenyi Biotech) allowing the isolation 
of a CD19+ and CD19− fractions. As CD19+ is a well-documented marker for B-cells this 
process therefore separated CLL cells from the rest of the sample and the negative 
fraction contained T-cell enriched PBMCs.  The enrichment process is shown in Figure 
6.3, which highlights the CD3+ frequency of a patient before and after CD19+ isolation. 
AutoMACS enrichment resulted in much higher proportions of CD3+ cells in the samples 
that were taken forward to FACS. 
 
Adding the autoMACS step introduced additional treatment of cells that could pose a 
risk to delicate T-cell populations and it was important that the phenotypic composition 
of the T-cell compartment was preserved for STELA analysis. Therefore, the memory 
subset distribution was compared before and after the autoMACS process (Figure 6.4). 
Both the CD4+ and CD8+ T-cell compartments as a whole and the memory subsets were 
maintained pre- and post-T-cell enrichment. The autoMACS process was therefore a 
useful method to obtain samples for FACS sorting that were enriched for T-cells. 
Furthermore, the distribution of the T-cell populations appears to be retained following 
autoMACS sorting. 
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Figure 6.3. Representative CLL patient demonstrating T-cell enrichment using 
automagnetic-activated cell sorting (autoMACS, Miltenyi Biotech). T-cells were 
enriched from isolated PMBC samples via negative selection. PBMCs were labelled with CD19+ 
magnetic beads and then passed through magnetic columns to allow the positive isolation of 
B-cells (CLL cells). The CD19− negative fraction was enriched with T-cells and retained 
fluorescence activated cell sorting of T-cell subsets and single telomere length analysis (STELA). 
(A) CD3+ T-cell frequency in PBMC of an example CLL patient. (B) CD3+ T-cell frequency within 
the CD19− (T-cell enriched) fraction following CD19 autoMACS selection. 
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Figure 6.4. Representative CLL patient showing phenotypic composition of T-cells 
pre- and post- autoMACS selection. Gating was performed as described in Figure 6.2. (A) 
Percentage of CD4+ and CD8+ T-cells before and after T-cell enrichment with autoMACS. (B) 
Percentage of CD8+ T-cell memory subsets before and after T-cell enrichment with autoMACS. 
Pre-autoMACS phenotyping data was collected using BD Canto II and BD FACSDiva. 
Post-autoMACS phenotyping data was collected during fluorescence-activated cell sorting 
(FACS) of sample (BD Aria, BD FACSDiva). Post-sorting analysis was performed using FlowJo 
(v.9). 
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 T-ce l l  memory  subsets  o f  STELA cohort  6.2.
Flow cytometric data showing T-cell subsets composition was recorded during FACS for 
CD4+, CD8+ and CD8+ memory subsets fractions. This data was subsequently analysed 
to assess whether the distribution of CD8+ T-cell memory subsets of the CLL patients in 
the STELA cohort fairly represented the results observed in the phenotyping cohort 
(Chapter 3). 
 
As shown in Figure 5.5A, the STELA cohort of CLL patients demonstrated a significant 
reduction in the CD8+ naïve T-cells when compared to healthy donors (p = 0.0116). 
Both the CD8+ EM and CD8+ EMRA cohorts demonstrated a trend towards increase in 
frequency in the CLL patients of the STELA study when compared to healthy donors, 
although this was not statistically significant. The CD8+ T-cell memory subset 
composition within the CLL patients of the STELA cohort is therefore similar to that 
observed previously. 
 
Parallels were also observed between the cohort from the phenotyping study (Chapter 
3) and that of the STELA cohort when patients were stratified by CD4:CD8 ratio. The 
reduction of CD8+ naïve T-cells was exacerbated in the CLLIR subgroup when compared 
against both CLLNR patients and healthy donors (p ≤0.05 and p ≤0.01, respectively). 
There was also a trend towards increased frequency of the CD8+ EMRA subset of CLLIR 
patients versus CLLNR and healthy donors. Interestingly, the same pattern was not seen 
in the CD8+ EM compartment.  
 
Overall, the composition of CD8+ T-cell memory subsets in the STELA cohort reflects 
that observed in the phenotypic study in Chapter 3: a clear skewing from naïve to 
differentiated memory. 
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Figure 6.5. Frequency of CD8+ T-cell memory subsets in CLL patients (n = 25) 
versus healthy donors (n = 3). Fluorescence-activated cell sorting (FACS) was performed 
(BD Aria, BD FACSDiva) using gating as described in Figure 6.2. (A) Subset composition of CLL 
patients (n = 25) versus healthy donors (n = 3). Pairwise statistical analysis (HD vs CLL) was 
performed using the non-parametric Mann-Whitney test. Patients were stratified based on 
CD4:CD8 T-cell ratio: patients with a CD4:CD8 ratio <1.0 were considered inverted (CLLIR) and 
patients with a ratio ≥1.0 were considered ‘normal’ (CLLNR). (B) Subset frequencies of healthy 
donors versus CLLNR (n = 11) and CLLIR (n = 14) patients. Three-way ANOVA statistical analysis 
was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data assessed 
using the Dunn’s post-test.  Significant results were included on the graph (* = p ≤0.05; 
** = p ≤0.01; *** = p ≤0.001). 
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 CD4 + and CD8 + te lomere  lengths  6.3.
Initially, STELA was performed on the entire CD4+ and CD8+ T-cell populations to 
identify any overall change in telomere length within the T-cell compartments between 
healthy donors and CLL patients.  
 
Within the CLL cohort neither CD4+ nor CD8+ T-cell telomere lengths differed from the 
healthy donor counterparts (Figure 6.6A). However, due to the number of healthy 
donors analysed (n = 3), this puts limitations on the comparisons between healthy 
donors and CLL patients. Statistical analysis comparing the CLL CD4+ and CD8+ T-cell 
compartments against one another also showed that there was no significant difference 
in mean telomere lengths between the two T-cell populations. 
 
Further stratification within the CLL cohort based on CD4:CD8 ratio was performed 
(Figure 6.6B): patients with a ratio <1.0 were considered to have an inverted ratio. The 
CD8+ compartment of CLLIR patients demonstrated numerically longer telomeres on 
average, particularly compared to the CLLNR subgroup (4.17 kb versus 3.57 kb; versus 
3.84 kb for age-matched healthy donors): however, this did not reach significance. The 
same pattern was observed in the CD4+ T-cell compartment, with CD4+ T-cells in the 
CLLIR subgroup having longer telomeres than the CLLNR (4.44 kb versus 3.80 kb) and 
healthy donors (4.44 kb versus 3.97 kb); again, these differences were not deemed 
significant. Further to this, there was no change in telomere lengths when comparing 
CD4 against CD8 within the CLLNR or within the CLLIR patient groups. 
 
Overall, the CLL cohort used within this study demonstrated no discernible differences 
in telomere length between CD4+ and CD8+ T-cells. Furthermore, the telomere lengths 
in these populations did not appear to differ in CLL patients compared to their healthy 
counterparts, although there is a trend for inverted ratio patients to have longer 
telomeres. 
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Figure 6.6. Telomere length of CD8+ and CD4+ T-cells in CLL versus age-matched 
healthy donors. Fluorescence-activated cell sorting (FACS) was performed (BD Aria, BD 
FACSDiva) using gating as described in Figure 6.2. DNA was extracted from CD4+ and CD8+ 
T-cells isolated from PBMCs of CLL patients and XpYp specific STELA was performed. Telomere 
length and distribution was calculated using Phoretix software: mean telomere lengths were 
calculated using excel. (A) Telomere lengths of CD8+ and CD4+ T-cells in healthy donors 
(n = 3) and CLL patients (n = 17). Pairwise statistical analysis (HD vs CLL) was performed 
using the non-parametric Mann-Whitney test. Patients were stratified based on CD4:CD8 T-cell 
ratio: patients with a CD4:CD8 ratio <1.0 were considered inverted (CLLIR) and patients with a 
ratio ≥1.0 were considered ‘normal’ (CLLNR). (B) Telomere lengths of CD8+ and CD4+ T-cells in 
healthy donors (n = 3) versus CLLNR (n = 6) and CLLIR (n = 10). Three-way ANOVA 
statistical analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs 
of data assessed using the Dunn’s post-test.  Significant results were included on the graph 
(* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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 Analys i s  o f  te lomere  length  between CD8 + T-ce l l  subsets  6.4.
The expansion of CD8+ T-cells in CLLIR patients resulted in a skewing to a more 
differentiated memory phenotype (Chapter 3). Therefore, further analysis was 
performed within the CD8+ T-cell compartment to analyse telomere lengths of the 
memory subsets of CLL patients. Due to the relatively small patient sample size and the 
low frequency of central memory CD8+ T-cells, the CM population was not routinely 
analysed. 
 
A representative STELA blot of the telomere length distributions of CD8+ T-cell memory 
subsets is shown in Figure 6.7. In the CLL CD8+ compartment, mean telomere length 
appears to decrease as the T-cells become more differentiated: naïve T-cells have the 
longest telomeres on average, followed sequentially by the CM and EM compartment, 
with the EMRA population having the shortest telomeres.  
 
This reduction in telomere length is consistent with previous work (Weng et al. 1995), 
and the suggestion that the T-cell populations further down the memory/differentiation 
pathway have undergone further replication and are therefore more ‘aged’. In this 
representative patient, the EMRA cells also had the lowest standard deviation of all the 
memory subsets. This implies that the CD8+ EMRA subset is less heterogeneous in terms 
of telomere length and is potentially either more clonal than the other memory subsets, 
or that the T-cells are stimulated by a diverse antigen repertoire and driven to similar 
telomere lengths as they become highly differentiated. The mean telomere lengths 
within the CD8+ population as a whole are much lower than those observed in the 
naïve, CM and EM population, and are closer to the EMRA population. Therefore, it is 
possible that the EMRA population makes up a large proportion of the CD8+ T-cell 
compartment in this patient, therefore skewing the mean telomere length. 
 
These patterns in telomere lengths are carried through to the whole CLL cohort. 
Collectively CD8+ EM and EMRA populations possess significantly shorter telomeres 
than the CD8+ naïve population (Figure 6.8A, p ≤0.01 for both). The same pattern is 
observed when using standard deviation of the memory populations as a surrogate 
measure of clonality, as naïve T-cells demonstrated a significantly larger standard 
deviation than the EM and EMRA subsets (Figure 6.8B, p ≤0.01 versus EM and 
p ≤0.05 versus EMRA).  
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Reduced telomere length and reduced telomere standard deviation appears to occur 
within the same T-cell population; it could be that the two are proportionally linked, i.e. 
that as telomere length shortens, variability is also reduced. To address this correlation 
analyses were performed to assess whether telomere shortening was associated with the 
telomere variability of a CLL T-cell population (Figure 6.9). A strong relationship 
between the mean telomere length and telomere length variability was observed in both 
CD4+ (r2 = 0.5543, p = 0.0003; Figure 6.9A) and CD8+ T-cells (r2 = 0.7728, 
p = 0.0010; Figure 6.9B), with the CD8+ compartment having the stronger 
association. CD8+ memory subsets followed this pattern: CD8+ naïve T-cells 
demonstrated the widest range and variance in telomere lengths (Section 6.4, Figure 
6.8) and here they showed weakest relationship between telomere length and 
variability (r2 = 0.5836, p = 0.0038; Figure 6.9C). Both CD8+ EM and CD8+ EMRA 
T-cells showed strong links between the mean telomere lengths and variability 
(r2 = 0.7233, p <0.0001; r2 = 0.7996, p <0.0001). Overall, a reduction in telomere 
length appeared to be associated with reduced variability. 
 
Overall, this suggests that the naïve T-cell population has undergone less proliferation 
(less aged) and is more heterogeneous, whereas the more differentiated memory 
subsets have undergone more proliferation (aged) and have become more clonal in 
nature. Furthermore, increased replicative age (shortened telomeres) is correlated with 
reduced variance within the T-cell subsets, implying that CLL patients with shorter 
T-cell telomeres have reduced T-cell clonality. 
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Figure 6.7. Representative STELA profile of the CD8+ T-cell subsets of a CLL 
patient. Fluorescence activated cell-sorting (FACS) was performed (BD Aria, BD FACSDiva 
using gating as described in Figure 6.2. DNA was extracted from CD8+ T-cells isolated from 
PBMCs of CLL patients and XpYp specific STELA was performed. Telomere length and 
distribution was calculated using Phoretix software: mean telomere lengths were calculated 
using Excel.  
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Figure 6.8. Telomere length and variability of CD8+ T-cell subsets of CLL 
patients. Fluorescence-activated cell sorting (FACS) was performed (BD Aria, BD FACSDiva) 
using gating as described in Figure 6.2. DNA was extracted from CD8+ T-cells isolated from 
PBMCs of CLL patients and XpYp specific STELA was performed. Telomere length and 
distribution was calculated using Phoretix software: mean telomere lengths were calculated 
using excel. (A) Mean telomere lengths of CD8+ T-cells in the naïve (n = 16), EM (n = 21) and 
EMRA (n = 21) subsets of CLL patients. (B) Standard deviation (SD) of telomere lengths of 
CD8+ T-cells in the naïve EM and EMRA subsets of CLL patients. Three-way ANOVA statistical 
analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with all pairs of data 
assessed using the Dunn’s post-test.  Significant results were included on the graph 
(* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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Figure 6.9. Posit ive correlat ions 
between the telomere lengths  and 
telomere variabil ity of T-cell memory. 
Fluorescence activated cell-sorting (FACS) 
was performed (BD Aria, BD FACSDiva using 
gating as described in Figure 6.2. DNA was 
extracted from CD8+ T-cells isolated from 
PBMCs of CLL patients and XpYp specific 
STELA was performed. Telomere length and 
distribution was calculated using Phoretix 
software: mean telomere lengths were 
calculated using Excel. Correlation between 
mean telomere lengths and standard deviation of telomere lengths for (A) Total CD4+ 
T-cell compartment, (B) Total CD8+ T-cell compartment, (C) CD8+ naive T-cell subset, 
(D) CD8+ EM T-cell subset, and (E) CD8+ EMRA T-cell subset. Spearman’s correlation 
analyses were used to determine significance. 
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 Telomere  length  o f  CD8 + T-ce l l  memory  subsets  in  CLL  6.5.
Phenotyping analyses revealed that CLL patients were much more skewed to a 
differentiated CD8+ T-cell EM/EMRA phenotype when compared to age-matched 
healthy donors ((Nunes et al. 2012) and Chapter 3). STELA was employed to 
investigate whether the skewing to increased differentiation was linked to an 
accumulation of replicatively-aged cells, or a conversion of newly activated T-cells 
moving down the differentiation pathway.  
 
Although CLL patients showed a trend for longer telomeres, the mean telomere length 
of naïve, EM and EMRA subsets did not differ significantly between the total CLL cohort 
and healthy donors (Figure 6.10). These preliminary results could imply that overall the 
CD8+ T-cell subsets of CLL patients have not undergone additional proliferation 
compared to CD8+ T-cells in healthy donors, and therefore do not appear to be any 
more aged in CLL pathology.  
 
Previous results (Chapter 3) demonstrated that phenotypic skewing was exacerbated in 
patients with inverted CD4:CD8 ratio (CLLIR), and the inverted ratio was predominantly 
due to an expansion within the CD8+ T-cell compartment. The STELA CLL cohort was 
therefore stratified into CLLNR and CLLIR subgroups for further analysis. In contrast to 
the phenotyping results, this did not result in any significant differences in mean 
telomere lengths either between the two CLL subgroups (CLLIR vs CLLNR) or between 
these subgroups and the healthy donors (Figure 6.11).  
 
Overall, telomere length does not appear to be different in CLL patients when stratified 
by CD4:CD8 ratio. 
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Figure 6.10. Mean telomere lengths of CD8+ T-cell memory subsets in CLL 
patients and healthy donors (n = 3). Fluorescence-activated cell sorting (FACS) was 
performed (BD Aria, BD FACSDiva). Lymphocytes were gated based on forward and side scatter 
profile; single cells were gated by forward scatter area and height. T-cells were identified by 
gating first on CD3+ then either CD4+ or CD8+ populations. CD8+ memory subsets were defined 
within the CD8+ gate using CCR7 and CD45RO memory markers: naïve (CCR7+CD45RO−, 
n = 16), Central Memory (CM, CCR7+CD45RO+), Effector Memory (EM, CCR7−CD45RO+, 
n = 21) and EMRA (CCR7−CD45RO−, n = 21). DNA was extracted from CD8+ T-cells isolated 
from PBMCs of CLL patients and XpYp specific STELA was performed. Telomere length and 
distribution was calculated using Phoretix software: mean telomere lengths were calculated 
using Excel. Pairwise statistical analysis (HD vs CLL) was performed using the non-parametric 
Mann-Whitney test. Significant results were included on the graph (* = p ≤0.05; 
** = p ≤0.01; *** = p ≤0.001). 
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Figure 6.11. Mean telomere lengths of CD8+ T-cell memory subsets in CLLNR 
patients, CLLIR patients and healthy donors (n = 3). Fluorescence-activated cell sorting 
(FACS) was performed (BD Aria, BD FACSDiva) using gating as described in Figure 6.2. DNA 
was extracted from CD8+ T-cells isolated from PBMCs of CLL patients and XpYp specific STELA 
was performed. Telomere length and distribution was calculated using Phoretix software: mean 
telomere lengths were calculated using excel. (A) Telomere length of CD8+ naïve T-cells in 
healthy donor, CLLNR (n = 7) and CLLIR (n = 9) patients. (B) Telomere length of CD8+ EM 
T-cells in healthy donor, CLLNR (n = 9) and CLLIR (n = 12) patients. (C) Telomere length of 
CD8+ EMRA T-cells in healthy donor, CLLNR (n = 9) and CLLIR (n = 12) patients. Three-way 
ANOVA statistical analysis was performed using Kruskal-Wallis test (HD vs CLLNR vs CLLIR), with 
all pairs of data assessed using the Dunn’s post-test.  Significant results were included on the 
graph (* = p ≤0.05; ** = p ≤0.01; *** = p ≤0.001). 
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 CD8 + na ïve  populat ions  with  abnormal ly  short  te lomere  length  6.6.
In line with previous work (Weng et al. 1995), this study observed that CD8+ naïve 
T-cells in CLL patients possessed significantly longer telomeres than the more 
differentiated memory subsets (EM/EMRA; see Figure 6.8, Section 6.4). However, one 
interesting observation that arose from this analysis was the presence of a subgroup of 
CLL patients (6/16 patients) with abnormally short telomeres within the CD8+ naïve 
subset. This was first apparent when visualising the STELA blots as a clear telomere 
shortening could be observed for certain patients (see representative Figure 6.12).  This 
was confirmed when data was analysed in a scatter plot: there appeared to be a distinct 
division where the CLL patients appeared to cluster in either a long or short telomere 
length subgroup (Figure 6.10).  
 
When stratified into CD8+ naïve long- and short- telomere subgroups, the short-
telomere subgroup possessed an average telomere length of 3.95 kb within the naïve 
subset, versus 6.17 kb in the patients with longer telomeres. The abnormally short CD8+ 
naïve telomere length was similar to the average telomere lengths observed in the EM 
and EMRA subsets of the total CLL cohort (3.83 and 3.90, respectively), suggesting that 
the naïve population of these patients possess a replicative age similar to that of a more 
differentiated memory T-cell.  
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Figure 6.12. CD8+ naïve populations with longer and shorter telomere length, 
shown in representative CLL patients. Fluorescence-activated cell sorting (FACS) was 
performed (BD Aria, BD FACSDiva) using gating as described in Figure 6.2. DNA was extracted 
from CD8+ T-cells isolated from PBMCs of CLL patients and XpYp specific STELA was performed. 
Telomere length and distribution was calculated using Phoretix software: mean telomere lengths 
were calculated using excel. Presented in this figure a representative CLL patients of the long and 
short telomere length subgroups. 
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 CLL pat ient  subgroups  with  long or  short  te lomeres  6.7.
The more differentiated CD8+ memory subsets’ telomeres are shorter and possess less 
variation than their naïve counterparts (Section 6.4, Figure 6.8), but there is still some 
level of telomere length heterogeneity within these memory subsets and patient-to-
patient variability. 
 
Following the observation that some patients possessed particularly short telomeres 
within the naïve CD8+ population (see previous section), analysis was performed to 
investigate any potential trend between long and short telomere subgroups within the 
other memory subsets of the CLL patient cohort. Patient data was collated from patients 
where STELA data was available for any three out of the four CD8+ populations of 
interest: CD8+ as a whole, CD8+ naïve, CD8+ EM and CD8+ EMRA. If telomere lengths 
for a patient were consistently above (long telomere) or below average (short telomere) 
of the T-cell population, they were assigned a specific colour (within the red spectrum 
for long telomere; blue spectrum for short telomeres). Results are displayed in Figure 
6.13. 
 
Overall, it appeared that there were subgroups within the study cohort who had 
consistently longer than average telomeres in the CD8+ naïve, EM and EMRA subsets. 
Conversely, there was a subgroup of CLL patients who consistently demonstrated 
shorter than average telomeres in naïve, EM and EMRA CD8+ T-cell subsets.  
 
This interesting observation suggests that telomere length of CD8+ T-cells in CLL 
patients can have a consistent trend across subsets; therefore, replicative age between 
the T-cell subsets in an individual patient may be linked.  
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Figure 6.13. CLL patient comparison for long and short telomere length sub-
groups. Fluorescence-activated cell sorting (FACS) was performed (BD Aria, BD FACSDiva) 
using gating as described in Figure 6.2. DNA was extracted from CD8+ T-cells isolated from 
PBMCs of CLL patients and XpYp specific STELA was performed. Telomere length and 
distribution was calculated using Phoretix software: mean telomere lengths were calculated 
using excel. If a patient’s mean telomere length was consistently longer than average in multiple 
subsets, they were assigned a colour in the red spectrum. If a patient’s mean telomere length was 
consistently shorter than average in multiple subsets, they were assigned a colour in the blue 
spectrum. Black stars represent patients who do not fit within the ‘all long’ or ‘all short’ 
subgroups. 
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 Corre la t ion  between subset  te lomere  length  6.8.
Patient subgroups were identified with a pattern of ‘longer’ or ‘shorter’ telomere lengths 
in all memory subsets. To assess whether there was an association with telomeres of 
proportional length across the CD8+ memory subsets, correlation analyses were 
performed. 
 
Strong positive associations were found between telomere lengths of the whole CD8+ 
fraction and that of the CD8+ EM subset (r2 = 0.5927, p = 0.0012; Figure 6.14A). A 
similar relationship was observed between CD8+ whole fraction and the CD8+ EMRA 
subset (r2 = 0.7012, p = 0.0001; Figure 6.14B). These relationships are perhaps not 
that surprising: as CLL patients have demonstrated that a significant proportion of the 
CD8+ T-cell compartment consists of EM/EMRA cells, the telomere lengths of the whole 
CD8+ fraction would therefore be strongly influenced by the telomere lengths of the 
EM/EMRA memory subsets. The strongest relationship was found between the CD8+ 
EM and CD8+ EMRA T-cell subsets, which demonstrated a significant positive 
relationship (r2 = 0.7852, p <0.0001; Figure 6.14C). This strongly suggests that the 
replicative age of EM and EMRA subsets are linked. 
 
In summary: correlations between telomere lengths of the whole CD8+ compartment 
against the EM and EMRA subsets is consistent with the previously observed 
compartmental skew to these more differentiated phenotypes, and such strong 
associations between the EM and EMRA telomere length lends strength to a linked 
replicative history between the two subsets.  
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Figure 6.14. Positive correlations between the telomere lengths of CD8+ T-cell 
memory subsets. Fluorescence-activated cell sorting (FACS) was performed (BD Aria, BD 
FACSDiva) using gating as described in Figure 6.2. DNA was extracted from CD8+ T-cells 
isolated from PBMCs of CLL patients and XpYp specific STELA was performed. Telomere length 
and distribution was calculated using Phoretix software: mean telomere lengths were calculated 
using excel. Correlation between mean telomere lengths were analysed for (A) Total CD8+ 
compartment versus CD8+ EM subset, (B) Total CD8+ compartment versus CD8+ EMRA subset, 
and (C) CD8+ EM subset versus CD8+ EMRA subset. Spearman’s correlation analyses were used 
to determine significance. 
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 Discuss ion  6.9.
This Chapter aimed to explore the replicative history of the T-cells in CLL patients, with 
a focus on the CD8+ T-cell compartment. Specifically, to test the hypothesis that the 
expansion of CD8+ T-cells in patients with inverted CD4:CD8 ratio was a result of 
excessive cell division. A prediction of this hypothesis would be that CD8+ T-cells in the 
CLLIR cohort would have shorter telomeres than CD8+ T-cells in the CLLNR cohort.   
 
Due to the low frequency of T-cells usually observed in CLL PBMC fractions, further 
purification of T-cells was performed using CD19+ magnetic bead sorting. Preliminary 
analysis of CD4+ and CD8+ populations demonstrated no detrimental effect on the 
CD4+/CD8+ frequencies or the memory subsets. However, there were limitations on size 
of patient samples (<5mls of blood) that meant detailed phenotyping (2 antibody 
panels, Chapters 3 and 4) and STELA could not be performed on the same patient 
samples. Phenotypic comparison between this CLL STELA cohort and the larger CLL 
cohort analysed in previous phenotyping analyses (Chapter 3) demonstrated that the 
STELA cohort displayed similar CD8+ T-cell memory composition, i.e. CLL patients 
skewed to a more differentiated memory phenotype compared to healthy donors that 
was exacerbated in CLLIR patients. However, for the most part the trend was non-
significant and only the reduction in CD8+ naïve frequency reached significance in 
either the total or stratified CLL cohort. Furthermore, Chapter 3 observed increased 
frequencies of CD8+ EM T-cells in the CLLIR subgroup compared to the healthy donors: 
this was not reflected in the STELA cohort, but the lack of significance could be due to 
the smaller cohort size of the STELA study. Further analysis with a larger patient cohort 
would give greater strength and understanding to the results, particularly in 
comparisons between healthy donor and CLL patient groups. However, overall the 
STELA cohort followed the expected skewing of subset distributions and therefore could 
provide insight into the replicative history of CLL T-cells. 
 
The primary aims of this study were to compare whether the telomere lengths of CD8+ 
subsets could provide insight on the expanded CD8+ compartment of CLLIR patients. 
This study did not observe any differences in telomere length of CD8+ T-cells of CLL 
patients compared against healthy donors. This was the same within the CD8+ 
compartment as a whole as well as the naïve, EM and EMRA memory subsets. However, 
due to the limitation in sample sizes, particularly in the healthy donor group, these 
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results are preliminary. An expanded telomere length analysis in a larger cohort would 
address this limitation. 
 
Using telomere length as a sign for proliferative age and senescence of cells is well 
documented (Allsopp et al. 1992; Vaziri et al. 1994; J. Lin et al. 2010a; Sanders and 
Newman 2013), as is the association of shortened telomeres with poorer disease 
prognosis and mortality (Willeit et al. 2010; Wu et al. 2003; Han et al. 2009; Shao et al. 
2007). This study used STELA to assess telomere length to allow a high resolution 
analysis of the telomeres lengths of a specific chromosome (XpYp), in addition to a key 
advantage of being able to detect telomeres at much shorter lengths than other 
techniques (Britt-Compton et al. 2011; Baird 2005). As the inverted CD4:CD8 ratio in 
CLL patients results from an expanded CD8+ compartment (Nunes et al. 2012), it could 
be expected that there would be a marked shortening in telomeric length of CD8+ 
T-cells in the CLLIR population, particularly within the EM and EMRA subsets. However, 
overall this study observed no CD8+ telomere shortening in the CLLIR subgroup, 
suggesting that there was no proliferative expansion. Instead, telomere lengths of CD8+ 
T-cells did not appear to differ between CLLIR, CLLNR and healthy donor patients. 
Although we expected CLLIR patients to demonstrate telomere shortening to reflect 
CD8+ T-cell expansion, there was instead a trend towards longer telomeres in CLLIR 
patients, although this was not significant. 
 
Rather than a clonal expansion of chronically stimulated, highly differentiated ‘aged’ 
CD8+ T-cells, the CD8+ T-cell expansion in CLL could originate from newly 
differentiated EM/EMRA T-cells converted from the naïve T-cell compartment. Newly 
formed memory T-cells possess a longer telomere length profile, similar to that observed 
in the healthy donors and CLLNR patients, and would accumulate via continuous 
turnover from the naïve pool. Related to this, Svenson et al. (2013) observed 
correlations between longer peripheral blood T-cell telomeres and increased levels of 
regulatory T-cells in renal cell carcinoma patients with poorer prognosis. This could 
suggest that the CD8+ expansion might not arise from a clonal expansion of highly 
differentiated T-cells that have undergone multiple rounds of division, but is rather an 
accumulation of ‘younger’ T-cells that are chronically stimulated but are under active 
immunological suppression from factors such as Treg cells. Accumulation of regulatory 
CD4+ T-cells in CLL patients has been reported previously (Piper et al. 2011; Nunes et 
al. 2012), and it is possible CLL cells themselves play an immunoregulatory role, as CLL 
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B-cells have been previously shown to demonstrate immunosuppressive functions 
(DiLillo et al. 2013; Ramsay et al. 2008).  
 
Another consideration is the involvement of telomerase contributing to CD8+ telomere 
length maintenance, either by conserving telomeres and preventing telomere shortening 
during proliferation, or by lengthening telomeres that have already shortened during 
multiple rounds of division. Aberrant upregulation of telomerase is often identified in 
malignant cells, including CLL cells (Rampazzo et al. 2011; Damle 2002). However, 
telomerase activity has also been reported in non-malignant hematopoietic cells, 
including T-cells, with an increase in telomerase activity during T-cell activation 
(Broccoli et al. 1995; Weng et al. 1996; Bodnar et al. 1996). Studies have observed 
induced telomerase activity and preserved telomere lengths in clonally expanded virus-
specific CD8+ memory T-cell populations during acute infections (Hathcock et al. 2003; 
Plunkett et al. 2001; Maini et al. 1999). It could be possible that a similar situation is 
taking place in the expanded CD8+ T-cells of CLLIR patients, whereby the expanded 
EM/EMRA population are proliferating in response to antigen, but do not display a loss 
of telomere length due to the up-regulation of telomerase within these cells. However, 
T-cell telomerase activity has been shown to decrease over time, and it is unable to 
overcome telomere shortening during long-term stimulations (Valenzuela and Effros 
2002; Bodnar et al. 1996). Therefore, the accumulation of T-cells that already possess 
longer telomeres seems more likely, perhaps with short-term rather than long-term 
telomerase maintenance. Further work investigating the presence of telomerase within 
the CD8+ T-cell compartment of CLL would help further elucidate the origin of the 
CD8+ T-cell expansion in CLLIR patients. Furthermore, parallel analysis of CLL cell 
telomere lengths and telomerase activity in CLL patient samples could help identify 
links between T-cell and CLL cell relationships within the tumour microenvironment. 
 
Prior work analysing telomere lengths of human T-cell memory subsets have shown 
naïve T-cells have the longest telomeres, where EM/EMRA telomere lengths are much 
shorter by comparison (Rufer et al. 1998; Weng et al. 1995): this was also observed in 
CLL patients in this study. Adding to this, STELA also demonstrated that the EM and 
EMRA subsets were less heterogeneous and more clonal than the naïve population. This 
is to be somewhat expected, as the memory T-cell are longer-lived cells that will have 
undergone more division than naïve T-cells. 
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Some CLL patients exhibited much shorter telomeres than others within the naïve 
compartment. Aging can have an effect on immune capacity in patients, including 
skewing to a more differentiated phenotype, increased senescence and a significant 
reduction in telomeres (Koch et al. 2008; Weiskopf et al. 2009). These characteristics 
are not fixed; immunological factors continue to worsen with age, including within the 
naïve T-cell population (Ferrando-Martínez et al. 2011). CLL is a predominantly a 
disease of the elderly and it is possible that the patients identified with shorter naïve 
telomeres were the more elderly patients within the cohort. However, preliminary 
retrospective correlation analysis suggests that age and naïve telomere length were not 
linked within the STELA cohort (Appendix VIII). This was based on limited data and 
small patient numbers, however, so further research including associations with age and 
other clinical factors would be beneficial. 
 
Another interesting pattern identified was a subgroup of CLL patients who had shorter 
telomeres (based on the patient average) across the CD8+ subsets (i.e. shorter telomeres 
in naïve, EM and EMRA). Inversely, a subgroup of patients who had longer telomeres in 
naïve CD8+ T-cells also had longer telomeres in the EM/EMRA subset. This was 
particularly apparent with the EM/EMRA subsets and draws an interesting link across 
the CD8+ compartment. Telomere length in peripheral blood lymphocytes has been 
associated with prognosis for various cancers (Svenson et al. 2008; Svenson et al. 2013; 
Duggan et al. 2014; Qian et al. 2016). Furthermore, there was strong correlation 
between the telomere lengths of the CD8+ EM and EMRA subsets, suggesting a 
relationship between their replicative history driven by the same stimulatory 
environment and potentially are clonotypes at different stages of the T-cell memory 
pathway. Stratification of CLL patients into these ‘long’ and ‘short’ T-cell telomere 
subgroups could have potential prognostic value in CLL. This study also observed a 
direct relationship with mean telomere length and the telomere length distribution, 
suggesting that in CLL patients where T-cell populations have undergone more 
replication have, they have also become more clonal. Unfortunately, comparisons were 
limited as prognostic data for each subset was not available for each patient. Additional 
telomere analysis of the CD8+ T-cell compartment in a larger cohort of patients and 
healthy donors could be used to compare telomere length against clinical data such as 
PFS applying survival analyses and shed further light on the relationship of telomere 
lengths across the T-cell subsets and whether there is any role in CLL prognosis. 
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One of the biggest limitations within this study was the acquisition of appropriate 
samples. The majority of PBMCs from CLL patients are malignant B-CLL lymphocytes. 
Therefore, larger samples are required in order to obtain an appropriate amount of 
T-cells suitable for sorting and DNA extraction. This limited the number of appropriate 
samples available, and could have introduced bias to the study as it restricted sampling 
to patients with larger numbers of lymphocytes per ml of blood, which is usually a 
signifier for CLL patients with higher pathology (i.e. higher numbers of circulating CLL 
cells). This may account for why the STELA cohort skewed even more towards the CD8+ 
EMRA subset than the cohort analysed in Chapter 3 as previously mentioned. In future 
work, it would be desirable to obtain a larger sample of blood from patients, to allow a 
more representative cohort to be used for analysis and to reduce bias. A larger patient 
cohort may also be better powered for the phenotypic skewing and telomere length 
trends demonstrated here to show significant differences within CLL patients. 
Furthermore, if larger numbers of T-cells could be acquired, this could give the 
opportunity for expansive phenotypic analysis to tunnel further into the T-cell 
compartment and isolate additional, phenotypes alongside STELA analysis within the 
same patient. As an example, this study was only able to perform STELA on the CD4+ 
compartment as a whole, whereas additional sample could allow for telomere length 
analysis of the CD4+ memory subsets and subtypes (Tregs, Th1, Th17). Additional 
sample could also give an opportunity to isolate smaller T-cell populations, such as the 
phenotypes of prognostic interest identified in the previous chapters. Further STELA 
analysis acquiring larger blood samples and/or collecting samples over a longer period 
could give rise to a larger cohort and more opportunity for additional analyses, for 
example investigating the links to CLL prognosis. It could also allow for longitudinal 
analysis of CLL patients to observe changes in T-cell/CLL cell telomere length over time 
or as a consequence of treatment.  
 
This study has given novel insight into T-cell telomere length of CLL patients.  
Somewhat unexpectedly and contrary to our hypothesis, telomere lengths in CLLIR 
patients were similar to CLLNR patients and healthy donors, despite the presence of the 
expanded CD8+ population. Further work is needed to establish how telomere length of 
the CD8+ expansion is maintained, whether it is due to the expansion originating from 
newly converted memory T-cells, or telomere lengthening processes such as telomerase. 
Additionally, this study identified subgroups of CLL patients with short or long 
telomeres that could be used to stratify future CLL cohorts and investigate the relevance 
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of this discovery, if any, on CLL pathogenesis and prognosis. Regardless, no loss of 
telomere length in CLLIR patients supports the assessment that the expanded CD8+ 
T-cells have not reached a stage of irreversible replicative senescence or terminal 
differentiation. 
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Chapter 7 
Final discussion 
The primary overall objective of this thesis was to gain further insight into the CD8+ 
expansion observed in a subgroup of CLL patients that resulted in an inversion of the 
CD4:CD8 ratio (CLLIR, ratio <1.0). One of the major factors that drove interest into this 
subgroup was that CLLIR patients had significantly poorer prognosis than their normal 
ratio (CLLNR) counterparts. Nunes et al. (2012) established that CLLIR patients were 3.4 
times as likely to experience disease progression (PFS HR = 3.4, p = 0.005). The CLL 
cohort used for the phenotyping study of Chapters 3 and 4 demonstrated similar results 
(HR 5.5, 95% CI 2.25-13.62, p = 0.0002) and showed a potential increased risk in 
patients with a ratio of approximately 0.5 or lower, suggesting that the lower the ratio, 
the more inferior the prognosis. Thus it may be possible to stratify patients into those 
with higher and lower risk of progression based on CD4:CD8 ratio alone.  
 
Both the multivariate and univariate analyses applied in Chapter 3 confirmed that 
CD4:CD8 ratio does have some prognostic link to CLL; however, the analyses revealed 
additional T-cell phenotypes that conferred a much stronger effect on PFS. The 
strongest phenotype to derive from this analysis was CD4+HLA-DR+PD-1+, which was 
present at much higher frequencies in CLL (particularly within CLLIR patients). 
CD4+PD-1+ T-cells have previously been shown to be higher in CLL and associated with 
poorer prognosis (Novák et al. 2015; Rusak et al. 2015), but the CD4+HLA-DR+PD-1+ 
phenotype has not been previously reported in CLL.  
 
This phenotype has been described previously on TILs in melanoma for both the CD4+ 
and CD8+subsets, including tumour-antigen specific CD8+ T-cells (Ahmadzadeh et al. 
2009). In CLL we also reported increased frequencies of HLA-DR+PD-1+ in both CD4+ 
and CD8+ compartments, but it was the CD4+ phenotypes that showed the greatest 
prognostic potential. Like melanoma, the increase in this phenotype within CLL could be 
related to the tumour microenvironment and tumour-specific T-cells. The 
HLA-DR+PD-1+ markers could define primed/activated T-cells that have impaired 
function. They may be unable to respond effectively due to the immunosuppressive 
effects of CLL cells: dysfunction between the PD-1/PD-1L axis between T-cells and CLL 
cells has been reported previously (Brusa et al. 2013), as well as expansions of CD8+ 
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T-cells expressing PD-1 that have impaired cytotoxic activity but retain cytokine 
production (Riches et al. 2013). Blockade of PD-1 has demonstrated a reversion of 
T-cell function and prevention of CLL progression in murine models (McClanahan et al. 
2015), supporting an immunosuppressive role for this molecule. 
 
This prompts the immunotherapeutic potential of anti-PD-1 therapy, and at the time of 
writing there is an ongoing clinical trial investigating dual therapy of ibrutinib with 
anti-PD-1 monoclonal antibody (Freeman and Gribben 2016). The results obtained in 
this thesis reinforce the relevance of the immunosuppressive phenotypes within CLL but 
further work is needed to assess any functional or prognostic importance behind the co-
expression of HLA-DR. If indeed the PD-1+HLA-DR+ T-cells are reacting to tumour 
antigen, it is possible that PD-1 blockade treatment would be superior in patients with 
high frequencies of CD4+HLA-DR+PD-1+ T-cells, due to the prevalence of tumour 
specific T-cells. A suggested study to address this would be to compare anti-PD-1 
antibody treatment in HLA-DR+PD-1+ versus HLA-DR−PD-1+ CLL samples in vitro.  
 
CD8+ T-cell frequency was included second in the list of significant prognostic variables, 
suggesting that rather than an inverted CD4:CD8 ratio as the prognostic factor, the 
CD8+ expansion itself should be the focus, regardless of ratio i.e. regardless of CD4+ 
T-cell numbers. Confounding CLL patients with CD8+ expansions, but not CD4:CD8 
inversion and therefore characterised as CLLNR, may explain why significant changes in 
telomere lengths were not observed in Chapter 6. Furthermore, there appeared to be 
some overlap between the prognostic phenotypes (CD4+HLA-DR+PD-1+ and 
CD8+CD57+HLA-DR+) and CD4:CD8 ratio, as these phenotypes were exacerbated 
within the CLLIR subgroup. It is possible, therefore, that the T-cells expressing these 
markers contribute to the CD8+ expansion that can then cause CD4:CD8 ratio inversion; 
hence the phenotypes (and the CD8+ compartment as a whole) are more direct 
prognostic factors. Analysis of a CLL cohort stratified by CD8+ T-cell frequency (with a 
threshold of approximately 30% as suggested by the multivariate analyses) or absolute 
CD8+ T-cell numbers rather than CD4:CD8 ratio may yield more significant associations 
with prognosis.  
 
With regards to the CD4:CD8 ratio, what can be summarised from the phenotypic 
analysis of this study confirms the already reported increase in senescence within the 
CLLIR subgroup (Nunes et al. 2012) in the form of CD57+ and KLRG-1+ T-cells making 
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up a significant proportion of the CD8+ compartment, with approximately 50% of CD8+ 
T-cells expressing CD57+KLRG-1+. However, we also observed a similar proportion of 
CD8+ T-cells with an activated phenotype and CD8+ T-cell subtypes identified as 
presenting an ‘activated senescent’ CD57+HLA-DR+ phenotype that were more frequent 
in the patients with inverted CD4:CD8 ratio (CLLIR). Interestingly, the CD4+ 
compartment exhibited similar trends with exacerbated CD57+HLA-DR+ and 
HLA-DR+PD-1+ frequencies in CLLIR patients, although these phenotypes comprised a 
smaller proportion of the total CD4+ compartment. That all these phenotypes occur in 
CLLIR patients and are strongly related to one another (as demonstrated in Chapter 4) 
would imply interrelated T-cell activation and subsequent differentiation in response to 
antigen(s). Furthermore, with both CD4+HLA-DR+PD-1+ and (to a lesser effect) 
CD8+CD57+HLA-DR+ identified as significant prognostic phenotypes, their potential 
importance in CD4:CD8 ratio and CLL pathology. With regard to the latter, it would be 
useful to ascertain whether these phenotypes are solely prognostic markers for these 
conditions or whether they play a direct role in CLL pathology, i.e. if they are tumour 
promoting T-cell populations, or tumour-reactive T-cells that accumulate under chronic 
antigenic conditions but are unable to respond in the immunosuppressive tumour 
microenvironment. If the latter, these phenotypes could prove to be a good target for 
immunotherapy, whether that be as a monotherapy or as a combination therapy with 
other CLL treatments. Further work to address this would be to explore the functional 
capabilities of T-cells expressing these phenotypes, such as proliferation assays (using 
mitogens or CLL-specific stimulation) and cytokine assays. 
 
One major confounding factor when investigating the immune dysfunction of an elderly 
population is the persistence of common latent viral infections that have accumulated 
during ones lifetime and dominate the T-cell repertoire (Fülöp et al. 2013). As the 
majority of CLL diagnoses occur in the elderly, it could be speculated that T-cell 
dysfunction in CLL is due to virus-specific T-cell clonotypes forming the majority of the 
T-cell pool, which may contribute to an impaired immune response against the CLL cells 
themselves. CMV can be found in approximately 90% of the elderly population and has 
been shown to drive both CD4+ and CD8+ T-cells to a highly differentiated, 
immunosenescent phenotype (Vasto et al. 2007). Adding to this, CMV-specific T-cells 
have been reported to form 5-30% of the CD8+ T-cell pool (Klenerman and Oxenius 
2016). Through the CMV serotyping of CLL patients, this study determined that CMV 
was not associated with the CD4:CD8 ratio, nor T-cell memory skewing observed in 
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both the CD4+ and CD8+ T-cell pools. Furthermore, the prognostic phenotypes of 
interest within this study (CD4+HLA-DR+PD-1+ and CD8+CD57+HLA-DR+) were 
significantly more prevalent within the CLLIR subgroup and seemed to originate from 
the EM memory compartment; this suggests that these phenotypes are also not 
CMV-driven. 
 
A large cohort study (n = 347) did show that CMV+ CLL patients experienced poorer 
prognosis than their CMV− counterparts: however, when exposed to multivariate 
analysis and taking confounding clinical factors such as age into account, this prognostic 
difference was lost (Parry et al. 2016). This not only lends further strength to the 
prognostic phenotypes of this study being CMV-independent, but also reinforces the 
value of performing multivariate analyses to establish valuable prognostic markers, as 
was done for this thesis. Due to the limited number of CMV− individuals in the cohort, 
CMV seropositivity could not be included in the multivariate analyses, and chi-squared 
analysis of CD4+HLA-DR+PD-1+ and CD8+CD57+HLA-DR+ could not be performed. 
Therefore, future studies with larger cohorts are needed to fully rule out CMV as a 
confounding factor.  
 
EBV is another latent virus found in the majority of adults, residing in B-cells (Visco et 
al. 2015). In healthy individuals EBV latency is controlled by CTLs, but in cases of 
immune T-cell dysfunction there is a risk of EBV reactivation and replication. CLL is not 
normally considered an EBV associated disease; EBV has low detection rate in CLL 
patients, EBV markers are only detectible on certain CLL subpopulations, and 
immortalisation of a CLL cell line using EBV has proved challenging (Visco et al. 2015; 
Dolcetti and Carbone 2010), though perhaps not impossible (Hertlein et al. 2013). 
Interestingly, recent work investigating EBV in CLL reported significantly higher EBV 
DNA load in CLL patients versus healthy donors, but concluded no relationship between 
EBV-load and disease state (Visco et al. 2015). However, high EBV load was identified 
as an independent prognostic variable following multivariate analysis, raising the 
question of whether EBV could be associated with the T-cell dysfunction reported in this 
thesis. This is enhanced by the fact that EBV-specific T-cells typically present a EM 
phenotype that is less differentiated than with CMV (Fülöp et al. 2013).  
 
Interestingly, EBV-specific CD8+ cells in CLL are highly differentiated memory cells 
compared to healthy donors, and present markers associated with exhaustion, (Hofland 
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et al. 2015). Additionally, considering the high prevalence of EBV reported in other 
immunological malignancies, including B, T and NK cell lymphomas (Dolcetti and 
Carbone 2010), the lack of similar evidence for CLL argues that there is low 
involvement of EBV within the disease. Taken together, this suggests that EBV is less 
likely to be a driving factor of the T-cell abnormalities reported in this thesis. Further 
work is needed to eliminate viral persistence as the driver for the CD4+HLA-DR+PD-1+. 
However, the reporting of CD4+PD-1+HLA-DR+ in melanoma as discussed above 
(Ahmadzadeh et al. 2009) lends support to the CD4+HLA-DR+PD-1+ phenotype being 
tumour-driven, rather than the result of chronic viral stimulation. 
 
In most studies analysing the telomere lengths of T-cells in cancer, it is a shorter 
telomere length that ties with poor prognosis (Wu et al. 2003; Shao et al. 2007). 
Opposing results are reported here in CLL where no significant change in telomere 
length was observed in CLLIR patients, which is somewhat unexpected in light of the 
observed CD8+ T-cell expansion. Lack of change in CD8+ T-cell telomere lengths within 
the CLLIR cohort, particularly within the EM/EMRA cohort, could be attributed to 
continuous turnover from the naïve CD8+ T-cell pool. These could be continuously 
driven down the T-cell differentiation pathway where they accumulate as EM and 
EMRA cells. This in turn may cause the reduction in CD8+ naïve frequency and skewing 
to the more differentiated memory phenotype as observed in Chapter 3, supporting the 
theory that the expanded CD8+ T-cells in CLLIR patients is driven by CLL-specific T-cells. 
Furthermore, unlike the other cancer studies where shorter T-cell telomeres were 
associated with poorer prognosis, CLL cells are accumulated malignant B-cells, meaning 
that B-cell:T-cell interactions within CLL can result in the ‘accidental’ promotion of CLL 
cells by Th cells (Os et al. 2013), which in turn can exert immunosuppressive effects 
upon the effector functions of the activated T-cells, including the impairment of T-cell 
proliferation (Ramsay et al. 2008). This could therefore result in the continual T-cell 
accumulation of T-cells that do not proliferate and therefore do not experience 
telomeric shortening. If this conversion from the naïve pool is indeed the case observed 
here, a gradual reduction of naïve T-cell numbers would be expected; however, this was 
not the case after analysis of the preliminary counts of Chapter 3. Furthermore, this 
study identified patients with abnormally short telomeres in their CD8+ naïve T-cells 
with mean telomere lengths similar to those observed in more differentiated memory 
subsets (Chapter 6). T-cell memory stem cells (Tscms) are reported to display the naïve 
memory phenotype (Gattinoni et al. 2011), as do a recently identified memory T-cell 
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population, termed Tmnps (memory T-cells with a naïve phenotype)(Pulko et al. 2016). 
It is possible, therefore, that a reduction in naïve T-cells was not observed in this study 
due to the confounding presence of alternative CCR7+CD45RO+ populations. Inclusion 
of additional characterising markers within future phenotypic analyses would help 
identify the truly naïve T-cells and the changes that occur within this subset. 
 
The application of T-cell immunotherapy in CLL has growing interest, particularly the 
development of chimeric antigen receptor (CAR) T-cells – autologous T-cells that are 
harvested from patients and genetically modified to recognise tumour specific antigen, 
before being expanded and adoptively transferred back into the patient (Freeman and 
Gribben 2016). CD19-specific CAR T-cells have demonstrated immunotherapeutic 
potential in CLL patients (Porter et al. 2015; Porter et al. 2013; Brentjens et al. 2011), 
with increased efficacy observed in the generation of CAR T-cells following ibrutinib 
therapy (Fraietta et al. 2016). However, using CAR T-cells directed to CD19+ cells 
would also include targeting of ‘normal’ B-cells; B-cell aplasia has been reported in CLL 
patients treated with CD19-specific CAR T-cells (Davila and Brentjens 2013). Therefore, 
optimising adoptive T-cell therapy by engineering the T-cells to recognise additional 
tumour-specific antigens could be of further therapeutic benefit. Further analysis into 
the clonality and specificity of the expanded T-cell populations identified in this thesis 
could help identify novel CLL specific antigens and the TCR that recognise them. High 
affinity versions of those TCRs could then be engineered into T-cells from CLL patients 
for therapy.  
 
One aspect for future work in the phenotypic characterisation of CLL patients with 
regards to CD4:CD8 ratio would be rather than looking at CLLIR related phenotypes and 
their link to inferior prognosis/CLL progression, to instead consider focusing on CLLNR 
occurring phenotypes. It is possible that the CD8+ expansion and phenotypes within 
CLLIR patients actually relate to the ‘normal’ T-cell pathology in CLL, and that perhaps 
with a focus on T-cell patterns in CLLNR one could identify T-cell attributes within CLL 
pathology that directly confer superior prognosis. Alternatively, further stratification of 
the CLLIR subsets based on disease progression could be used to assess differences 
between these patients. The contribution of additional clinical characteristics upon 
patient prognosis must also be taken into account (age, gender, etc.) and considered in 
any future analyses in order to ascertain whether any prognostic association is indeed 
due to T-cells.  
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A limitation with the phenotypic analysis and STELA applied in this thesis is that 
although it can provide insight into T-cell subset distributions and their molecular age, 
it only provides a snapshot of the T cell population at the time the patient sample was 
acquired. There is potential for phenotypic data to be transient even in normal 
individuals, particularly when observing immunological cell types such as T-cells that 
could become activated and expand in number due to transient infections that patients 
may encounter. This is apparent in the preliminary study of Chapter 5 where even some 
untreated patients demonstrated phenotypic variability over time. It could be argued 
that CD4:CD8 ratio could be more prone to variability due to T-cell responses in acute 
infections, whereas disease-specific T-cell phenotypes may hold more stability and only 
incur changes due to disease pathology. It would therefore be prudent to argue that 
focusing on CD4+HLA-DR+PD-1+, for example, rather than CD4:CD8 ratio or CD8+ 
frequency/numbers, may provide a more successful, stable means of prognostic 
evaluation in CLL. This is supported by the observations in treated patients, where 
CD4+HLA-DR+PD-1+ appeared more stable among the majority of untreated patients, 
and large frequency changes between time points occurred more often in treated 
patients. Ideally, analysis of both phenotype and telomere length would be undertaken 
in expansive longitudinal analyses. Unfortunately, the ability to perform such 
longitudinal assessment for the thesis was limited due to time and sample restrictions. 
Longitudinal analysis of untreated CLL over an extended time period (e.g. minimum of 
two years with standardised time points) would also be beneficial to identify T-cell 
changes that occur due to disease progression or effect of treatment. Such analyses 
would also be of similar benefit in observing CD4:CD8 ratio fluctuations over longer 
time periods to investigate disease related changes versus ‘normal’ ratio variations, i.e. 
during acute infections. 
 
In conclusion, the thesis has confirmed that CD4:CD8 ratio inversion is linked to more 
aggressive clinical disease. The combination of high-resolution flow cytometry and 
multivariate analysis revealed that this ratio inversion is linked to a complex array of 
CD8+ and CD4+ T-cell subsets. Importantly, two T-cell subsets, CD8+CD57+HLA-DR+ 
and CD4+PD-1+HLA-DR+, were shown to be stronger predictors of poor prognosis than 
the CD4:CD8 ratio and would be suitable for testing on larger UK wide cohorts. Further 
functional and genetic characterisation of these novel T-cell subsets may give insight 
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into role of T-cells within CLL disease, but may also provide simpler and more specific 
prognostic markers that will benefit CLL patients. 
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Appendix  I .  S ta t i s t ica l  ana lyses  o f  CD8 + marker  d is t r ibut ions  us ing 
SPICE 
 
Table 1. T-test analyses comparing CD8+ markers in CLL versus healthy 
donors (HD). 
Phenotype HD vs CLL 
Panel 1 
CD57+HLA-DR+PD-1+ <0.0001 
CD57+HLA-DR+PD-1− 0.0012 
CD57+HLA-DR−PD-1+ 0.0003 
CD57+HLA-DR−PD-1− 0.3548 
CD57−HLA-DR+PD-1+ <0.0001 
CD57−HLA-DR+PD-1− 0.4538 
CD57−HLA-DR−PD-1+ 0.1002 
CD57−HLA-DR−PD-1− <0.0001 
Panel 2 
CD57+CD38+CD127+KLRG-1+ <0.0001 
CD57+CD38+CD127+KLRG-1− 0.0002 
CD57+CD38+CD127−KLRG-1+ 0.0012 
CD57+CD38+CD127−KLRG-1− 0.0049 
CD57+CD38−CD127+KLRG-1+ 0.0001 
CD57+CD38−CD127+KLRG-1− 0.3528 
CD57+CD38−CD127−KLRG-1+ 0.3258 
CD57+CD38−CD127−KLRG-1− 0.0646 
CD57−CD38+CD127+KLRG-1+ 0.3530 
CD57−CD38+CD127+KLRG-1− 0.7257 
CD57−CD38+CD127−KLRG-1+ 0.0098 
CD57−CD38+CD127−KLRG-1− 0.0910 
CD57−CD38−CD127+KLRG-1+ 0.2011 
CD57−CD38−CD127+KLRG-1− 0.0204 
CD57−CD38−CD127−KLRG-1+ 0.6178 
CD57−CD38−CD127−KLRG-1− 0.0086 
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Table 2. T-test analyses comparing CD8+ markers in CLLIR versus CLLNR 
and healthy donors (HD). 
 
 
 
Phenotype HD vs CLLIR CLLNR vs CLLIR 
Panel 1 
CD57+HLA-DR+PD-1+ <0.0001 0.2436 
CD57+HLA-DR+PD-1− <0.0001 0.0010 
CD57+HLA-DR−PD-1+ 0.0066 0.8927 
CD57−HLA-DR+PD-1+ 0.0032 0.9157 
CD57+HLA-DR−PD-1− 0.1581 0.2088 
CD57−HLA-DR+PD-1− 0.1255 0.0618 
CD57−HLA-DR−PD-1+ 0.5626 0.0029 
CD57−HLA-DR−PD-1− <0.0001 <0.0001 
Panel 2 
CD57+CD38+CD127+KLRG-1+ 0.0006 0.0550 
CD57+CD38+CD127+KLRG-1− 0.0019 0.1184 
CD57+CD38+CD127−KLRG-1+ 0.0002 0.0026 
CD57+CD38+CD127−KLRG-1+ 0.0672 0.3527 
CD57+CD38−CD127+KLRG-1+ 0.0049 0.7243 
CD57+CD38−CD127+KLRG-1− 0.5705 0.5897 
CD57+CD38−CD127−KLRG-1+ 0.1450 0.1691 
CD57+CD38−CD127−KLRG-1− 0.1076 0.4745 
CD57−CD38+CD127+KLRG-1+ 0.3258 0.5207 
CD57−CD38+CD127+KLRG-1− 0.2181 0.0750 
CD57−CD38+CD127−KLRG-1+ 0.0106 0.0366 
CD57−CD38+CD127−KLRG-1− 0.0142 0.0691 
CD57−CD38−CD127+KLRG-1+ 0.0338 0.0031 
CD57−CD38−CD127+KLRG-1− 0.0002 0.0001 
CD57−CD38−CD127−KLRG-1+ 0.8962 0.5739 
CD57−CD38−CD127−KLRG-1− 0.0031 0.0728 
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Appendix  I I .  Phenotyp ic  analyses  o f  CD8 + T-ce l l s  in  CLL:  addi t ional  
data  for  CD57,  KLRG-1 and CD127 
 
Figure 1: Co-expression of CD57 and CD127 in (A) Whole CD8+ T-cell 
compartment (B) CD8+ EM and (C) CD8+ EMRA memory subsets of CLL patients. 
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Figure 2: Co-expression of CD57 and CD127 in (A) Whole CD8+ T-cell 
compartment (B) CD8+ EM and (C) CD8+ EMRA memory subsets of CLLNR, CLLIR 
and healthy donors. 
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Figure 3: Expression of CD57, KLRG-1 and CD127 in CD8+ EM T-cell memory 
subsets of (A) CLL patients and age-matched healthy donors, and (B) CLLNR, CLLIR 
and healthy donors. 
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Figure 4: Expression of CD57, KLRG-1 and CD127 in CD8+ EMRA T-cell memory 
subsets of (A) CLL patients and age-matched healthy donors, and (B) CLLNR, CLLIR 
and healthy donors. 
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Appendix  I I I .  Phenotyp ic  analyses  o f  CD8 + T-ce l l s  in  CLL:  addi t ional  
data  for  CD57,  KLRG-1 and CD38 
 
Figure 1: KLRG-1 and CD38 co-expression in CD8+ T-cell memory subsets of (A) 
CLL patients and age-matched healthy donors, and (B) CLLNR, CLLIR and healthy 
donors. 
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Figure 2: Expression of CD57, KLRG-1 and CD38 in CD8+ T-cells of CLL patients 
and age-matched healthy donors. 
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Appendix  IV .  Outputs  f rom mult ivar ia te  analys i s  
 
Table 1. Simple statistics (mean, standard deviation, median, minimum 
and maximum) calculated during multivariate analysis. 
Variable Mean 
Std 
Dev Median Minimum Maximum 
CD4:CD8 RATIO 2.36 3.02 1.33 0.29 21.86 
CD3+ 9.83 14.33 5.26 0.60 83.50 
CD8+ 33.12 15.89 32.50 4.07 67.40 
CD8+Naïve+ 10.68 12.78 5.10 0.02 46.60 
CD8+CM+ 1.93 2.05 1.13 0.01 8.84 
CD8+EM+ 29.74 15.80 27.15 0.23 63.80 
CD8+EMRA+ 57.64 17.01 60.70 27.30 97.40 
CD4+ 46.56 18.81 43.35 10.20 88.90 
CD4+Naïve+ 32.28 22.57 33.05 0.01 80.70 
CD4+CM+ 10.18 7.40 8.14 0.06 37.90 
CD4+EM+ 41.04 22.85 35.65 0.65 95.60 
CD4+EMRA+ 16.50 13.49 13.70 2.03 76.60 
CD8+CD57+ 58.07 23.67 61.20 4.20 100.00 
CD8+HLA-DR+ 35.07 20.34 34.65 2.61 86.50 
CD8+PD-1+ 33.99 17.33 31.25 6.30 81.30 
CD8+EM+CD57+ 17.72 14.97 12.20 0.00 58.40 
CD8+EM+HLA-DR+ 13.30 11.51 9.23 0.00 54.00 
CD8+EM+PD-1+ 15.91 11.22 14.20 0.00 58.50 
CD8+EMRA+CD57+ 38.34 19.67 35.25 0.00 97.50 
CD8+EMRA+HLA-DR+ 19.48 13.35 17.80 0.00 48.80 
CD8+EMRA+PD-1+ 15.63 11.24 13.10 0.00 62.20 
CD4+CD57+ 18.94 15.05 16.80 0.48 58.90 
CD4+HLA-DR+ 21.43 17.28 16.40 2.59 77.00 
CD4+PD-1+ 39.34 20.60 34.90 6.99 81.20 
CD4+EM+CD57+ 12.05 11.83 7.26 0.25 57.70 
CD4+EM+HLA-DR+ 14.34 15.03 8.85 0.16 74.50 
CD4+EM+PD-1+ 26.72 17.11 21.50 0.61 72.80 
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Variable Mean 
Std 
Dev Median Minimum Maximum 
CD4+EMRA+CD57+ 5.89 8.95 2.16 0.00 41.60 
CD4+EMRA+HLA-DR+ 4.26 6.50 1.81 0.00 36.30 
CD4+EMRA+PD-1+ 6.87 9.80 4.11 0.00 61.10 
CD8+CD57+HLA-DR+ 24.10 16.80 21.90 1.81 72.40 
CD8+CD57+PD-1+ 20.38 13.94 16.65 3.09 60.70 
CD8+HLA-DR+PD-1+ 14.92 11.56 10.90 1.49 53.80 
CD8+CD57+HLA-DR+PD-1+ 9.42 8.49 6.90 0.30 40.20 
CD8+EM+CD57+HLA-DR+ 9.27 9.54 6.62 0.02 50.00 
CD8+EM+CD57+PD-1+ 9.84 8.95 7.50 0.18 40.10 
CD8+EM+HLA-DR+PD-1+ 7.67 7.40 5.67 0.00 46.00 
CD8+EM+CD57+HLA-
DR+PD-1+ 4.94 5.51 2.92 0.00 32.30 
CD8+EMRA+CD57+HLA-DR+ 14.31 10.68 11.85 0.30 47.50 
CD8+EMRA+CD57+PD-1+ 10.33 8.65 8.11 0.64 37.50 
CD8+EMRA+HLA-DR+PD-1+ 6.27 6.23 4.96 0.00 33.20 
CD8+EMRA+CD57+HLA-
DR+PD-1+ 3.14 3.35 2.30 0.00 19.00 
CD4+CD57+HLA-DR+ 9.29 9.08 6.41 0.17 39.80 
CD4+CD57+PD-1+ 11.56 9.89 9.08 0.29 46.70 
CD4+HLA-DR+PD-1+ 13.89 12.33 9.08 0.85 50.70 
CD4+CD57+HLA-DR+PD-1+ 6.06 6.02 3.95 0.11 25.90 
CD4+EM+CD57+HLA-DR+ 6.34 7.50 3.31 0.04 38.70 
CD4+EM+CD57+PD-1+ 8.30 7.69 5.79 0.17 30.40 
CD4+EM+HLA-DR+PD-1+ 10.24 10.67 6.22 0.16 46.50 
CD4+EM+CD57+HLA-
DR+PD-1+ 4.55 5.03 2.85 0.04 23.80 
CD8+CD38+ 21.50 18.53 15.25 1.51 75.80 
CD8+CD57+ 55.78 22.08 58.70 2.86 99.90 
CD8+CD127+ 38.10 20.36 33.20 6.08 86.50 
CD8+KLRG-1+ 63.98 23.22 69.10 12.90 99.60 
CD8+EM+CD38+ 7.71 9.64 3.97 0.01 59.30 
CD8+EM+CD57+ 16.89 12.91 14.05 0.11 64.00 
CD8+EM+CD127+ 14.97 10.28 13.15 0.06 53.20 
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Variable Mean 
Std 
Dev Median Minimum Maximum 
CD8+EM+KLRG-1+ 20.43 12.26 18.85 0.11 57.80 
CD8+EMRA+CD38+ 10.39 10.39 7.26 0.36 47.50 
CD8+EMRA+CD57+ 37.36 20.89 31.15 1.27 98.20 
CD8+EMRA+CD127+ 14.14 9.11 12.90 0.65 49.90 
CD8+EMRA+KLRG-1+ 40.15 22.08 38.40 4.38 96.90 
CD4+CD38+ 29.42 16.17 25.00 5.75 74.30 
CD4+CD57+ 23.09 17.00 20.75 0.60 75.50 
CD4+CD127+ 60.78 21.28 63.35 12.50 93.50 
CD4+KLRG-1+ 35.01 23.70 33.05 0.49 99.20 
CD4+EM+CD38+ 8.32 10.84 4.64 0.01 65.10 
CD4+EM+CD57+ 11.32 11.01 7.88 0.03 56.30 
CD4+EM+CD127+ 26.43 16.22 23.50 0.09 76.70 
CD4+EM+KLRG-1+ 16.17 16.04 9.95 0.12 61.20 
CD4+EMRA+CD38+ 5.89 6.72 2.89 0.44 30.40 
CD4+EMRA+CD57+ 7.34 8.90 3.89 0.12 47.10 
CD4+EMRA+CD127+ 7.93 9.36 5.07 0.33 61.70 
CD4+EMRA+KLRG-1+ 9.63 13.92 6.14 0.14 83.30 
CD8+CD38+KLRG-1+ 13.77 14.65 8.22 0.35 65.60 
CD8+CD38+CD57+ 13.31 13.52 9.59 0.00 65.50 
CD8+CD38+CD127+ 4.81 7.14 2.19 0.00 35.50 
CD8+CD57+KLRG-1+ 42.29 21.22 39.90 1.75 99.50 
CD8+CD57+CD127+ 9.37 7.91 8.06 0.12 53.40 
CD8+CD127+KLRG-1+ 19.56 11.65 18.25 3.42 58.20 
CD8+CD38+CD57+KLRG-1+ 9.76 11.04 5.63 0.00 50.00 
CD8+EM+CD38+KLRG-1+ 4.69 5.61 2.62 0.00 28.50 
CD8+EM+CD38+CD57+ 5.09 7.80 2.48 0.00 56.20 
CD8+EM+CD38+CD127+ 1.41 1.91 0.64 0.00 9.22 
CD8+EM+CD57+KLRG-1+ 11.30 8.48 9.30 0.00 33.30 
CD8+EM+CD57+CD127+ 3.95 3.51 3.44 0.00 21.30 
CD8+EM+CD127+KLRG-1+ 8.76 6.97 7.27 0.00 40.20 
CD8+EMRA+CD38+KLRG-1+ 7.68 9.73 3.45 0.00 44.30 
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Variable Mean 
Std 
Dev Median Minimum Maximum 
CD8+EMRA+CD38+CD57+ 7.45 8.46 3.98 0.00 41.00 
CD8+EMRA+CD38+CD127+ 1.30 2.22 0.48 0.00 11.20 
CD8+EMRA+CD57+KLRG-1+ 29.50 20.19 26.20 0.80 96.90 
CD8+EMRA+CD57+CD127+ 4.88 7.10 3.29 0.06 49.80 
CD8+EMRA+CD127+KLRG-
1+ 8.74 7.84 6.62 0.24 49.60 
CD4+CD38+KLRG-1+ 10.79 10.82 6.54 0.06 48.00 
CD4+CD38+CD57+ 6.34 7.38 4.04 0.23 33.50 
CD4+CD38+CD127+ 17.84 15.14 16.00 0.27 69.20 
CD4+CD57+KLRG-1+ 14.26 13.57 9.39 0.19 60.30 
CD4+CD57+CD127+ 7.77 6.97 6.29 0.23 30.70 
CD4+CD127+KLRG-1+ 20.97 17.34 15.80 0.30 72.80 
CD4+EM+CD38+KLRG-1+ 3.86 6.96 1.54 0.00 46.20 
CD4+EM+CD38+CD57+ 3.32 5.02 1.77 0.00 30.60 
CD4+EM+CD38+CD127+ 3.75 5.57 1.52 0.01 29.70 
CD4+EM+CD57+KLRG-1+ 7.66 9.38 3.61 0.02 44.80 
CD4+EM+CD57+CD127+ 5.43 5.98 3.06 0.02 30.60 
CD4+EM+CD127+KLRG-1+ 10.27 11.21 6.33 0.09 53.20 
CD4+EMRA+CD38+KLRG-1+ 2.63 4.56 0.96 0.01 20.80 
CD4+EMRA+CD38+CD57+ 1.93 3.68 0.81 0.02 22.90 
CD4+EMRA+CD38+CD127+ 2.68 4.26 0.87 0.01 22.50 
CD4+EMRA+CD57+KLRG-1+ 2.06 3.16 1.01 0.00 16.60 
CD4+EMRA+CD57+CD127+ 5.37 6.51 2.62 0.07 30.40 
CD4+EMRA+CD127+KLRG-
1+ 3.47 3.43 2.34 0.12 18.00 
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Table 2. Correlation of phenotypic variables against CD4:CD8 ratio 
Variable r p-value 
CD3+ 0.01182 0.9204 
CD8+ -0.85023 <0.0001 
CD8+Naïve+ 0.71172 <0.0001 
CD8+CM+ -0.0712 0.5466 
CD8+EM+ -0.34253 0.0028 
CD8+EMRA+ -0.09578 0.4169 
CD4+ 0.87022 <0.0001 
CD4+Naïve+ 0.57513 <0.0001 
CD4+CM+ 0.03129 0.7913 
CD4+EM+ -0.46058 <0.0001 
CD4+EMRA+ -0.09769 0.4077 
CD8+CD57+ -0.51858 <0.0001 
CD8+HLA-DR+ -0.38528 0.0007 
CD8+PD-1+ 0.10998 0.3509 
CD8+EM+CD57+ -0.48736 <0.0001 
CD8+EM+HLA-DR+ -0.44627 <0.0001 
CD8+EM+PD-1+ -0.06893 0.5595 
CD8+EMRA+CD57+ -0.21366 0.0676 
CD8+EMRA+HLA-DR+ -0.25504 0.0283 
CD8+EMRA+PD-1+ 0.1388 0.2383 
CD4+CD57+ -0.52054 <0.0001 
CD4+HLA-DR+ -0.54439 <0.0001 
CD4+PD-1+ -0.48144 <0.0001 
CD4+EM+CD57+ -0.57537 <0.0001 
CD4+EM+HLA-DR+ -0.54785 <0.0001 
CD4+EM+PD-1+ -0.45261 <0.0001 
CD4+EMRA+CD57+ -0.30921 0.0073 
CD4+EMRA+HLA-DR+ -0.38201 0.0008 
CD4+EMRA+PD-1+ -0.22333 0.0558 
CD8+CD57+HLA-DR+ -0.45455 <0.0001 
CD8+CD57+PD-1+ -0.11104 0.3462 
CD8+HLA-DR+PD-1+ -0.13432 0.2539 
CD8+CD57+HLA-DR+PD-1+ -0.19634 0.0936 
CD8+EM+CD57+HLA-DR+ -0.44996 <0.0001 
CD8+EM+CD57+PD-1+ -0.17731 0.1307 
CD8+EM+HLA-DR+PD-1+ -0.24554 0.035 
CD8+EM+CD57+HLA-DR+PD-1+ -0.30524 0.0082 
CD8+EMRA+CD57+HLA-DR+ -0.32098 0.0053 
CD8+EMRA+CD57+PD-1+ 0.01128 0.924 
CD8+EMRA+HLA-DR+PD-1+ -0.06482 0.5832 
CD8+EMRA+CD57+HLA-DR+PD-1+ -0.12214 0.2999 
CD4+CD57+HLA-DR+ -0.61185 <0.0001 
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Variable r p-value 
CD4+CD57+PD-1+ -0.60481 <0.0001 
CD4+HLA-DR+PD-1+ -0.55478 <0.0001 
CD4+CD57+HLA-DR+PD-1+ -0.5868 <0.0001 
CD4+EM+CD57+HLA-DR+ -0.634 <0.0001 
CD4+EM+CD57+PD-1+ -0.61579 <0.0001 
CD4+EM+HLA-DR+PD-1+ -0.5718 <0.0001 
CD4+EM+CD57+HLA-DR+PD-1+ -0.6013 <0.0001 
CD8+CD38+ -0.25587 0.0278 
CD8+CD57+ -0.47144 <0.0001 
CD8+CD127+ 0.43507 0.0001 
CD8+KLRG-1+ -0.33109 0.004 
CD8+EM+CD38+ -0.24609 0.0346 
CD8+EM+CD57+ -0.24472 0.0356 
CD8+EM+CD127+ 0.41851 0.0002 
CD8+EM+KLRG-1+ -0.06604 0.5762 
CD8+EMRA+CD38+ -0.26348 0.0233 
CD8+EMRA+CD57+ -0.27029 0.0199 
CD8+EMRA+CD127+ 0.29147 0.0117 
CD8+EMRA+KLRG-1+ -0.2355 0.0434 
CD4+CD38+ 0.18795 0.1088 
CD4+CD57+ -0.48414 <0.0001 
CD4+CD127+ 0.3234 0.0049 
CD4+KLRG-1+ -0.26241 0.0239 
CD4+EM+CD38+ -0.25102 0.031 
CD4+EM+CD57+ -0.36741 0.0013 
CD4+EM+CD127+ -0.04415 0.7088 
CD4+EM+KLRG-1+ -0.27273 0.0187 
CD4+EMRA+CD38+ 0.07578 0.521 
CD4+EMRA+CD57+ -0.29755 0.01 
CD4+EMRA+CD127+ 0.1539 0.1905 
CD4+EMRA+KLRG-1+ -0.17546 0.1348 
CD8+CD38+KLRG-1+ -0.43485 0.0001 
CD8+CD38+CD57+ -0.47965 <0.0001 
CD8+CD38+CD127+ 0.07399 0.531 
CD8+CD57+KLRG-1+ -0.41236 0.0003 
CD8+CD57+CD127+ -0.11734 0.3194 
CD8+CD127+KLRG-1+ 0.12842 0.2755 
CD8+CD38+CD57+KLRG-1+ -0.51862 <0.0001 
CD8+EM+CD38+KLRG-1+ -0.32938 0.0042 
CD8+EM+CD38+CD57+ -0.36299 0.0015 
CD8+EM+CD38+CD127+ -0.08357 0.479 
CD8+EM+CD57+KLRG-1+ -0.23681 0.0422 
CD8+EM+CD57+CD127+ -0.02168 0.8545 
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Variable r p-value 
CD8+EM+CD127+KLRG-1+ 0.3152 0.0062 
CD8+EMRA+CD38+KLRG-1+ -0.42402 0.0002 
CD8+EMRA+CD38+CD57+ -0.40365 0.0004 
CD8+EMRA+CD38+CD127+ 0.0808 0.4937 
CD8+EMRA+CD57+KLRG-1+ -0.28491 0.0139 
CD8+EMRA+CD57+CD127+ -0.09619 0.4149 
CD8+EMRA+CD127+KLRG-1+ 0.01231 0.9171 
CD4+CD38+KLRG-1+ -0.23216 0.0465 
CD4+CD38+CD57+ -0.51012 <0.0001 
CD4+CD38+CD127+ 0.28742 0.013 
CD4+CD57+KLRG-1+ -0.43188 0.0001 
CD4+CD57+CD127+ -0.39756 0.0005 
CD4+CD127+KLRG-1+ -0.14371 0.2219 
CD4+EM+CD38+KLRG-1+ -0.427 0.0001 
CD4+EM+CD38+CD57+ -0.4548 <0.0001 
CD4+EM+CD38+CD127+ -0.13151 0.264 
CD4+EM+CD57+KLRG-1+ -0.4066 0.0003 
CD4+EM+CD57+CD127+ -0.35631 0.0018 
CD4+EM+CD127+KLRG-1+ -0.18797 0.1088 
CD4+EMRA+CD38+KLRG-1+ -0.21077 0.0715 
CD4+EMRA+CD38+CD57+ -0.31009 0.0072 
CD4+EMRA+CD38+CD127+ 0.24082 0.0387 
CD4+EMRA+CD57+KLRG-1+ -0.14347 0.2226 
CD4+EMRA+CD57+CD127+ -0.26926 0.0203 
CD4+EMRA+CD127+KLRG-1+ 0.25809 0.0264 
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Table 3. Summary of Cox-proportional hazard regression model with forward 
selection (0.05 level entry)  
 
Variable Number in Chi-square p-value 
CD4+HLA-DR+PD-1+ 1 23.4347 <.0001 
CD8+ 2 5.5428 0.0186 
CD8+CD57+HLA-DR+ 3 4.7188 0.0298 
CD8+EMRA+CD57+HLA-DR+PD-1+ 4 5.2623 0.0218 
 
 
Table 4. Summary of Cox-proportional hazard regression model with forward 
selection (0.99 level entry)  
Variable Number in Chi-square p-value 
CD4+HLA-DR+PD-1+ 1 23.4347 <0.0001 
CD8+ 2 5.5428 0.0186 
CD8+CD57+HLA-DR+ 3 4.7188 0.0298 
CD8+EMRA+CD57+HLA-DR+PD-1+ 4 5.2623 0.0218 
CD4+CD57+PD-1+ 5 3.2936 0.0695 
CD8+EMRA+CD57+HLA-DR+ 6 3.4165 0.0645 
CD4+EMRA+CD38+KLRG-1+ 7 8.0052 0.0047 
CD4+CD127+ 8 6.6548 0.0099 
CD4:CD8 RATIO 9 31.6757 <0.0001 
CD4+EMRA+CD57+KLRG-1+ 10 11.8763 0.0006 
CD4+CD38+CD127+ 11 6.6349 0.0100 
CD8+EMRA+CD57+ 12 22.6099 <0.0001 
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Figure 1: Prognosis of CLL patients stratified based on median frequencies of 
prognostic markers determined by multivariate analysis: (A) CD4+HLA-DR+PD-1+ 
(B) CD8+ (C) CD8+CD57+HLA-DR+ and (D) CD8+ EMRA CD57+HLA-DR+PD-1+. 
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Table 5. CD4:CD8 ratio cut-offs determined by multivariate analysis.  
Ratio Number in 
Chi-
square p-value 
0.521 1 41.3074 <0.0001 
1.009 2 8.2603 0.0041 
0.951 3 24.1866 <0.0001 
0.995 4 9.8197 0.0017 
0.504 5 9.2847 0.0023 
0.804 5 6.538 0.0106 
 
Figure 2: Prognosis of CLL patients stratified by CD4:CD8 ratio using cut-offs 
determined by multivariate analyses (Table 5) 
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Table 6. CD4+HLA-DR+PD-1+ cut-offs determined by multivariate analysis.  
CD4+HLA-DR+PD-1+ (% of CD4) Number in Chi-square p 
47.4 1 35.2552 <0.0001 
31.5 2 27.076 <0.0001 
14.4 3 8.0021 0.0047 
16.7 4 13.6212 0.0002 
4.69 5 4.3964 0.036 
4.95 5 89.8294 <0.0001 
37.5 7 4.5554 0.0328 
46.4 8 10.5532 0.0012 
 
Figure 3: Prognosis of CLL patients stratified by CD4+HLA-DR+PD-1+ using cut-
offs determined by multivariate analyses (Table 6) 
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Table 7. CD8+ cut-offs determined by multivariate analysis.  
CD8 (%) Number in Chi-square p-value 
56.9 1 29.6995 <0.0001 
58.5 2 8.1732 0.0043 
31.0 3 7.9394 0.0048 
33.2 4 9.1904 0.0024 
65.1 5 5.9365 0.0148 
 
 
Figure 4: Prognosis of CLL patients stratified by CD8+ using cut-offs determined 
by multivariate analyses (Table 7) 
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Table 8. CD8+CD57+HLA-DR+ cut-offs determined by multivariate analysis.  
CD8 CD57+HLA-DR+ (% of CD8) Number in Chi-square p 
64.5 1 15.0336 0.0001 
24.7 2 4.8578 0.0275 
24.7 3 10.0683 0.0015 
26.2 4 4.1445 0.0418 
 
 
Figure 5: Prognosis of CLL patients stratified by CD8+CD57+HLA-DR+ using cut-
offs determined by multivariate analyses (Table 8) 
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Table 9. CD8+ EMRA CD57+HLA-DR+PD-1+ cut-offs determined by multivariate 
analysis. 
CD8 EMRA CD57+HLA-DR+PD-1+ (% of 
CD8) 
Number 
in 
Chi-
square p 
6.45 1 6.3376 0.0118 
6.86 2 4.4215 0.0355 
 
 
Figure 6: Prognosis of CLL patients stratified by CD8+CD57+HLA-DR+ using cut-
offs determined by multivariate analyses (Table 9) 
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Appendix  V .  Corre la t ion  analys i s  o f  CD8 + na ïve  T-ce l l s  and 
CD8 +CD127 + T-ce l l s .  
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Appendix  VI .  S ta t i s t ica l  ana lyses  o f  CD8 + marker  d is t r ibut ions  us ing  
SPICE 
 
Table 1. T-test analyses comparing CD4+ markers in CLL versus healthy 
donors (HD). 
 
 
 
Phenotype HD vs CLL 
Panel 1 !
CD57+HLA-DR+PD-1+ <0.0001%
CD57+HLA-DR+PD-1− 0.0026%
CD57+HLA-DR−PD-1+ <0.0001%
CD57+HLA-DR−PD-1− 0.1080%
CD57−HLA-DR+PD-1+ <0.0001%
CD57−HLA-DR+PD-1− 0.8249%
CD57−HLA-DR−PD-1+ <0.0001%
CD57−HLA-DR−PD-1− <0.0001%
Panel 2 !
CD57+CD38+CD127+KLRG-1+ 0.0004%
CD57+CD38+CD127+KLRG-1− 0.0007%
CD57+CD38+CD127−KLRG-1+ 0.0020%
CD57+CD38+CD127−KLRG-1+ 0.0009%
CD57+CD38−CD127+KLRG-1+ 0.0004%
CD57+CD38−CD127+KLRG-1− 0.0143%
CD57+CD38−CD127−KLRG-1+ 0.0449%
CD57+CD38−CD127−KLRG-1− 0.0003%
CD57−CD38+CD127+KLRG-1+ 0.0812%
CD57−CD38+CD127+KLRG-1− 0.7101%
CD57−CD38+CD127−KLRG-1+ 0.0068%
CD57−CD38+CD127−KLRG-1− 0.0088%
CD57−CD38−CD127+KLRG-1+ 0.0362%
CD57−CD38−CD127+KLRG-1− 0.4206%
CD57−CD38−CD127−KLRG-1+ 0.8258%
CD57−CD38−CD127−KLRG-1− 0.6961%
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Table 2. T-test analyses comparing CD4+ markers in CLLIR versus CLLNR 
and healthy donors (HD) 
Phenotype HD vs CLLIR CLLNR vs CLLIR 
 Panel 1%
CD57+HLA-DR+PD-1+ 0.0015% <0.0001%
CD57+HLA-DR+PD-1− 0.0090% 0.0012%
CD57+HLA-DR−PD-1+ 0.0208% <0.0001%
CD57+HLA-DR−PD-1− 0.3620% 0.1115%
CD57−HLA-DR+PD-1+ 0.0120% <0.0001%
CD57−HLA-DR+PD-1− 0.0274% 0.2205%
CD57−HLA-DR−PD-1+ 0.8160% <0.0001%
CD57−HLA-DR−PD-1− 0.0004% <0.0001%
 Panel 2%
CD57+CD38+CD127+KLRG-1+ 0.0021% 0.0099%
CD57+CD38+CD127+KLRG-1− 0.0144% 0.2567%
CD57+CD38+CD127−KLRG-1+ 0.0010% 0.0187%
CD57+CD38+CD127−KLRG-1+ 0.0125% 0.1604%
CD57+CD38−CD127+KLRG-1+ 0.0009% 0.4462%
CD57+CD38−CD127+KLRG-1− 0.0104% 0.4596%
CD57+CD38−CD127−KLRG-1+ 0.0422% 0.4340%
CD57+CD38−CD127−KLRG-1− 0.0077% 0.0420%
CD57−CD38+CD127+KLRG-1+ 0.4361% 0.5358%
CD57−CD38+CD127+KLRG-1− 0.0436% 0.0085%
CD57−CD38+CD127−KLRG-1+ 0.4337% 0.0811%
CD57−CD38+CD127−KLRG-1− 0.0018% 0.1485%
CD57−CD38−CD127+KLRG-1+ 0.0627% 0.9830%
CD57−CD38−CD127+KLRG-1− 0.0109% 0.0034%
CD57−CD38−CD127−KLRG-1+ 0.4813% 0.1433%
CD57−CD38−CD127−KLRG-1− 0.7562% 0.9659%
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Appendix  VI I .  Corre la t ion  analys i s  o f  CD38 and HLA-DR in  CD4 + na ïve  
T-ce l l s  o f  CLL  pat ients .  
 
 
Correlation between activation markers CD38 and 
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Appendix  VI I I .  Corre la t ion  analys i s  o f  CD8 + na ïve  T-ce l l  te lomere  
length  and pat ients  age .  
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Appendix  IX .  Pat ient  Character i s t ics .  
 
Table 1. Clinical characteristics of phenotyping cohort (Chapters 3 and 4) 
 
Characteristic! ! Total!cohort!(n!=!74)!
Age!(years)! Mean% 62.9%
Median% 64.5%
Range% 29.3686.6%
Binet!stage,!n!(%)! A% 62%(83.8%)%
B% 7%(9.5%)%
C% 4%(5.4%)%
Unknown% 1%(1.4%)%
CD38!status,!n!(%)! +%(>20%)% 20%(27.0%)%
−%(<20%)% 24%(32.4%)%
Unknown% 30%(40.5%)%
Lymphocyte!doubling!time!(LDT),!n!(%)! <12%months% 9%(12.2%)%
>12%months% 48%(64.9%)%
Unknown% 17%(23.0%)%
IGHV!status,!n!(%)! Unmutated% 18%(24.3%)%
Mutated% 5%(6.8%)%
Unknown% 51%(68.9%)%
TTFT!status,!n!(%)! Treated% 22%(29.7%)%
Untreated% 52%(70.3%)%
 
 
Table 2. Clinical characteristics of merged untreated/treated cohort 
(Chapter 5) 
 
! ! Total!cohort!
(n!=!42)!
Treated!
(n!=!19)!
Untreated!
(n!=!23)!
Age!(years)! Mean% 70.6% 69.2% 72%
Median% 71% 70% 74%
Range% 44690% 44687% 47690%
Binet!stage,!n!(%)! A% 32% 11% 21%
B% 3% 3% 0%
C% 3% 3% 0%
Unknown% 4% 2% 2%
CD38!status,!n!(%)! +%(>20%)% 5% 5% 0%
−%(<20%)% 17% 6% 11%
Unknown% 20% 8% 12%
LDT,!n!(%)! <12%months% 5% 3% 2%
>12%months% 22% 7% 15%
Unknown% 15% 9% 6%
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IGHV!status,!n!(%)! Unmutated% 2% 2% 0%
Mutated% 6% 4% 2%
Unknown% 34% 13% 21%
TTFT!status,!n!(%)! Treated% 19% 6% 6%
Untreated% 23% 6% 6%
 
 
 
Table 2. Treatment history of treated cohort (Chapter 5) 
 
Treated!
Patient! Treatment!history!
Longitudinal!patients%
1! CLB:%Apr%20136Aug%2013%
2! CLB:%Oct%20106Mar%2011%
Ofatumumab:%Apr%6Oct%2013%
3! CLB:%Feb%20076Sep%2007%
CLB:%2012%
4! FC:%Jan%20086Jun%2008%
5! CLB:%Nov%20146Oct%2015%
6! FC:%Jan%20106Feb%2010%
CLB:%Oct%20136Mar%2014%
CLB:%Oct%20156ongoing%
7! FCR:%Sep%20096Mar%2010%
Alemtuzumab:%Jan6Apr%2012%
Ofatumumab:%Feb%20136Jan%2014%
Ibrutinib:%Jan%20146ongoing%
8! CLB/Rituximab:%Apr%20066Sep%2016%
Idelalsisib:%Sep%2016%
9! FCR:%Sep%20136Mar%2014%
Other!treated!patients%
10! Idelalisib/Rituximab:%Jan%20166Apr%2016%
11! CLB/Obinutuzumab:%Aug%20106Sep%2010%
BR:%Oct%20116Feb%2012%
12! CLB:%Jul%20066Jan%2007%
CLB:%Jan%20096May%2009%
FCR:%Sep%20116Feb%2012%%
13! BR:%Feb%20086Apr%2008%%
RCHOP,%Alemtuzumab,%BR%again,%GS%4059%and%finally%
idelalsib/Rituximab:%dates%unknown%
14! Alemtuzumab:%Oct%20086Jan%2009%
Stem%cell%allograft:%Jul%2009%
Idelalisib:%May%20156Sep%2016%%
15! CLB:%May%19936Apr%1994%
CLB:%Aug%20106Feb%2011%
16! Ibrutinib/rituximab:%Aug%20156ongoing%
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17! BR:%Feb%20146Jul%2014%
18! CLB:%Jul%20096Feb%2010%
CLB:%Dec%20156Mar%2016%
19! CLB:%Jul%20136Apr%2014%
20! FC:%Jan6Jul%2004%
Alemtuzumab:%Sep6Dec%2008%
BR:%date%unknown.%%
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